{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2009-og-eldre/rapport-2008-reseptregisteretnorpd-2004-2007-pdf.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Prescription Database til andre form\u00e5l som er om 4 Rapport 2008 FolkehelseinstituttetRapport 2008 Folkehelseinstituttet 5Preface The use of drugs in the population is increasing. An important goal of the health policies regarding pharmaceuticals in Norway is rational drug use. In order to improve drug use, knowledge about which drugs are used, how they are used and who uses them is vital. In December 2002, the Parliament decided to establish a national prescription database in Norway (NorPD). The task of building up the register was given to the Norwegian Institute of Public Health (NIPH). Since 1st January 2004, the institute has received monthly data on prescriptions from all Norwegian pharmacies. This report is the first edition in a planned annual statistical report from NorPD. The purpose of the report is to present NorPD and selected data. The report has three parts. Part 1 contains general information about NorPD, prescribing of medicines and drug statistics. The second part includes some key figures and comments about selected topics and drug groups. Part 3 contains tables with information about the number of individuals who had prescriptions dispensed from pharmacies in Norway during the period 2004-2007. The information includes particular drug substances as well as drug groups. ATC (Anatomical Therapeutic Chemical) classification is used in the tables. For 2007, information about age, gender and costs are included in the tables. The ATC/DDD version of January 2008 has been used in the report, see also www.whocc.no NorPD also has a web page where one can find information about the number of individuals who had prescriptions dispensed (prevalence), split by gender, 10-year age groups and geography (county or health region). The website is: www.norpd.no (English version) or www.reseptregisteret.no (Norwegian version). Data is available from 2004 and the website is annu- ally updated in March for the previous year. It is also possible to apply for data from NorPD for rese - arch or for other purposes which are according to the objectives of NorPD. More information about this can be found in the introduction to the book's section 3, and at the website of the Norwegian Institute of Public Health (www.fhi.no ). Department of PharmacoepidemiologyNorwegian Institute of Public Health August 2008 6 Rapport 2008 FolkehelseinstituttetForord ....................................................................................................................................................................... 3 1. Generell innledning 1.6 Definert D\u00f8gndose (DDD) .................................................................................................................... 18 1.7 WHO Collaborating Centre for Drug Statistics Methodology ....................................................... 18 2. Kommentarer til utvalgte legemidler (ATC C og B01) ................................................................................. 25 2.4 Midler til diabetesbehandling (ATC gruppe A10) ............................................................................ 28 2.5 Antibakterielle midler Antiepileptika Midler ADHD (ATC gruppe N06BA) .................................................................................. 36 Midler mot demens (ATC gruppe N06D) .................................................................................. 36 Midler mot opioidavhengighet i 41 3.3 abell - ATC hovedgrupper ................................................................................................................. 43 3.4 T abell - ATC gruppe A - Ford\u00f8yelsesorganer og stoffskifte ........................................................ 44 3.5 T abell - ATC gruppe B - Blod og bloddannende organer ............................................................... 52 3.6 T abell - ATC gruppe C - Hjerte og kretsl\u00f8p ...................................................................................... 54 3.7 T abell - ATC gruppe D - Dermatologiske midler ............................................................................. 60 3.8 T abell - ATC gruppe G - Urogenitalsystem og kj\u00f8nnshormoner .................................................. 65InnholdRapport 2008 Folkehelseinstituttet 73.9 T Hormoner til systemisk bruk, ekskl. kj\u00f8nnshormoner og insuliner 69 3.10 J - Antiinfektiva til systemisk bruk ............................................................ 71 3.11 T abell gruppe L - Antineoplastiske og immunmodulerende midler ............................... 75 3.12 T abell - ATC gruppe M - Musk ler og skjelett .................................................................................. 77 3.13 T abell - ATC gruppe N - Nervesystemet ......................................................................................... 80 3.14 T abell - ATC gruppe midler, insekticider og insektmidler ......................... 87 3.15 T abell - ATC gruppe R - Respirasjonsorganer ............................................................................... 89 3.16 T abell - ATC gruppe S - Sanseorganer ............................................................................................ 92 3.17 T abell - ATC Contents 8 Rapport 2008 FolkehelseinstituttetPreface ................................................................................................................................................................................ 5 1. General introduction ....................................................................................................................................... 11 1.1 Establishing the Norwegian Prescription Database (NorPD) ....................................................... 11 1.2 The NorPD .............................................................................................................................................. 12 Data collection and variables in NorPD .................................................................................... 12 Data protection ............................................................................................................................. 13 Quality checks ............................................................................................................................... 14 1.3 Regular General Practitioner Scheme, pharmacy- and reimbursement systems ................... 15 1.4 The Norwegian Drug Wholesales Statistics ..................................................................................... 16 1.5 The Anatomical Therapeutic Chemical (ATC) classification system ........................................... 17 1.6 The Defined Daily Dose (DDD) ............................................................................................................ 18 1.7 The WHO Collaborating Centre for Drug Statistics Methodology ............................................... 18 2. Comments to selected topics and drug groups .......................................................................................... 20 2.1 Selected key figures from NorPD ...................................................................................................... 20 2.2 Drug use among the elderly (70 years) ........................................................................................... 23 2.3 Cardiovascular drugs (ATC group C and B01) .................................................................................. 25 2.4 Drugs used in diabetes (ATC group A10) .......................................................................................... 28 2.5 Antibacterials for systemic use (ATC group J01) ............................................................................ 32 2.6 Drugs affecting the nervous system (ATC group N) ...................................................................... 34 Analgesics (ATC group N02) ........................................................................................................ 34 Antidepressants (ATC N06A) ............................................................................................... 36 Anti-dementia drugs (ATC group N06D) .................................................................................. 36 Drugs for treatment of opioid dependence (ATC group N07BC) ......................................... 37 3. The Norwegian Prescription Database 2004-2007 - Main tables .......................................................... 38 3.1 Description of the tables .................................................................................................................... 38 NorPD website and access to data ............................................................................................ 40 Calculation of prevalence by 1000 inhabitants ...................................................................... 40 3.2 Drugs with the highest number of users in Norway (tables) ........................................................ 41 3.3 T able - ATC main groups ...................................................................................................................... 43 3.4 T able - ATC group A - Alimentary tract and metabolism ............................................................. 44 3.5 T able - ATC group B - Blood and bloodforming organs ................................................................. 52 3.6 T able - ATC group C - Cardiovascular system ................................................................................ 54 3.7 T able - ATC group D - Dermatologicals ............................................................................................ 60 3.8 T able - ATC group G - Genito urinary system and sex hormones ............................................... 65 3.9 T able - ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ....69ContentsRapport 2008 Folkehelseinstituttet 93.10 T able - ATC group J - Antiinfectives for systemic use ................................................................ 71 3.11 T able - ATC group L - Antineoplastic and immunomodulating agents ..................................... 75 3.12 T able - ATC group M - Musculo-skeletal system ........................................................................... 77 3.13 T able - ATC group N - Nervous system ........................................................................................... 80 3.14 T able - ATC group P - Antiparasitic products, insecticides and repellents .............................. 87 3.15 T able - ATC group R - Respiratory system ..................................................................................... 89 3.16 T able - ATC group S - Sensory organs ............................................................................................ 92 3.17 T able - ATC group V - Various ........................................................................................................... 95 Some abbreviations and definitions ................................................................................................................ 96 Population in Norway 2004-2007 ..................................................................................................................... 97 10 Rapport 2008 FolkehelseinstituttetRapport 2008 Folkehelseinstituttet 111. General introduction 1.1 Establishing the Norwegian Prescription Database (NorPD) Norway has a long tradition of publishing drug sta tistics using data from wholesalers. Since 1977, these figures have been published annually in a book contai ning information about all drug sales in Nor way (1). The wholesale statistics are described on page 16. Although very useful for monitoring long-term trends in drug use on an aggregated level, figures based on drug sales from whole salers to pharmacies and hospi- tals have some limita tions. No information about an individual\u00b4s drug use is available from the wholesale statistics. During the 1990s the lack of more detailed information on drug use in the Norwegian population was recognised and the need to establish a popula-tion-based prescription register in Norway was offi- cially discussed (2-6). The proposal for more detailed drug statistics came partly in response to changes in the drug market infrastructure, which began when Norway joined the European Economic Association (EEA) in 1995. In 2000, a project to establish a national register based on prescriptions electronically transfered from all phar - macies was initiated by the Ministry of Health and Social Affairs (7). In December 2002, the Norwegian Parliament (Stortinget) passed a resolution to establish a register based on prescriptions dispensed at all Norwegian pharmacies. The task of building up the NorPD as the first pseudonymous health register in Norway was given to the Norwegian Institute of Public Health (NIPH). Stortinget also decided to establish a unit for pharma- coepidemiological research linked to the register (8). Prior to this decision, the Norwegian government had decided to move the WHO Collaborating Centre for Drug Statistics Methodology, and the Norwegian Drug Wholesales Statistics Database from the Norwegian Medicinal Depot to the NIPH. The Department of Phar - macoepidemiology was established in autumn 2002. This department combines the two units from the Norwegian Medicinal Depot with the NorPD and the 1. Generell innledning 1.1 Etableringen da Norge ble medlem av E\u00d8S i 1995. I startet etablert 12 Rapport 2008 Folkehelseinstituttetpharmacoepidemiology research unit. The department is part of the Division of Epidemiology at the NIPH. The expertise in drug statistics and methodology of the staff at the WHO Collaborating Centre for Drug Statistics Methodology and the Norwegian Drug Wholesales Statistics Database was vital to the successful creation of the NorPD (9). 1.2 The NorPD Data collection and variables in NorPD New legislation in the Norwegian pharmacy sector came into force on March 1 st 2001. According to the new act, pharmacies were obliged to forward prescrip - tion data to a new national drug database. In October 2003, new, detailed regulations for the NorPD were approved (10). The objectives of the NorPD, as defined in authoritative regulations, are to collect and prepare data on drug use in individuals and animals in order to: 1. describe drug use patterns, highlighting changes over time 2. promote and form a basis for research and review of the safety and effectiveness of drug use 3. serve as a management tool for the authorities in order to assure prescribing quality in addition to general surveillance, control and planning 4. give the prescribing doctors a basis for internal control, as part of an audit method to improve the quality of prescribing practices All NorPD data use must be in accordance with these objectives. The regulation also determines what kind of data can be collected from the pharmacies and administrative registers. The NorPD contains the following variables: Patient Person-identifier (encrypted), month/year of birth, month/year of death, gender, place of residence (municipality & county)Prescriber Person-identifier (encrypted), month/year of birth, gender, profession, speciality Drug Nordic article number (unique product identifier stating brand name, strength, pharmaceutical form and pack size), number of packs, ATC code, number of Defined Daily Doses (DDD), prescrip - tion category, reimbursement code (from March 2008: ICD-10 or ICPC codes), intended use and prescribed dose (free-text as per pharmacy label), dispensing date, price (pharmacy retail price)h\u00f8sten 2002. Denne avdelingen farmas\u00f8ytisk kompetansen knyttet til WHO Colla- Centre Drug Methodology og den Grossistbasert legemiddelstatistikken var viktig apoteklov tr\u00e5dte kraft 1. mars 2001, og loven ble apotek utredning municipality and county The Nordic article number is linked to other registries providing detailed information about the dispensed drugs. The indication for prescribing is generally not recorded in the database. However, the code of reim- bursement is recorded and may, in some cases, act as a proxy of diagnosis. From March 2008, prescribers must use either the International Classification of Diseases version 10 (ICD-10) or the International Clas- sification of Primary Care Codes (ICPC) as the code of reimbursement on the prescriptions. This will be fully implemented from January 2009. Since 1 st January 2004, the NIPH has received monthly data on prescriptions from all Norwegian pharmacies (figure 1). Monthly electronic reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy. NorPD contains information about all drugs prescribed (reimbursed or not) and dispensed at pharmacies to individual patients living outside insti- tutions, i.e. ambulant care. Unlicensed drugs are also included, but drugs sold over-the-counter (OTC) are not recorded in NorPD (see also page 39). However, if the OTC drugs are prescribed by a physician and dispensed, then they will be recorded in the database. The main data in NorPD are based on prescriptions to individual humans, but also prescribed drugs by veter - inarians to animals and prescribing to a physician's own practice are collected in NorPD. For patients in nursing homes and hospitals, the register collects figures on drug use at the level of the institution or the department, i.e. on an aggregate level. Data protection As shown in figure 1, pharmacy records of dispensed drugs are electronically and automatically transferred via Statistics Norway before arrival at NIPH and inclu- sion in NorPD. Statistics Norway acts as a so-called \"trusted third party centre\" and is a part of the data protection to ensure confidentiality of personal infor - mation. Statistics Norway only has access to patient personal identification numbers, and prescribers\u00b4 health personnel number, replacing both with a pseu- donymised identifier. Statistics Norway cannot read any other prescription data because this is encrypted before the data is received. When Statistics Norway sends the data including the pseudonymised identi-fiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The term \"Pseudony - mous health data\" is defined in the Personal Health Data Filing System Act (in Norwegian: Helseregister - loven): \"personal health data in of fullt implemen-tert om for 14 Rapport 2008 Folkehelseinstituttetbeen encrypted or otherwise concealed, but nonetheless individualized so that it is possible to follow each person through the health system without his identity being revealed\" (11). This means that the identity of patients and prescribers has been encrypted according to Norwegian legislation, but still individualized, so that it is possible to follow individuals over time and perform record-linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries. Quality checks For quality assurance, a number of queries are carried out monthly or half-yearly to identify possible errors or inconsistencies. NIPH performs different routine checks on the data before they are transferred to the NorPD. During data transfer the Nordic article number is checked. In the NorPD, the Nordic article number is linked to the national register of medicinal products with validated ATC codes and DDD values (12). This register is updated monthly. NIPH also checks if the data deliveries from each pharmacy are of a reason- able size. The total number of prescription records and the total number of patients and prescribers are checked every month. Routine statistics for pharma- cies are run every half year. Unusual variations in size of data files from month to month are identified and any missing data is caught, such as missing special data type deliveries or empty data files caused by technical error at the pharmacy or at the trusted third party. The Personal Identification Number is checked in Statistics Norway against the Central Population Registry. If the Personal Identification Number is invalid or missing, Statistics Norway creates a special pseudonym, but it is not possible to track these indi-viduals or link them to other data sources. However, the reported total number of prescriptions and DDDs can be included statistics.tert NorwayDispensed prescriptionsencryptedPrescriptions with pseudo-nymised transform to pseudonyms *Trusted third partyNorwegian Institute of Public Health NorPDRapport 2008 Folkehelseinstituttet 151.3 Regular General Practitioner Scheme, pharmacy- and reimbursement systems Regular General Practitioner Scheme In June 2001, the Regular General Practitioner (RGP) Scheme was implemented in Norway to ensure regular access to a pre-defined local General Practi- tioner for all patients and hence improve continuity. The RGP scheme gives all Norwegian inhabitants the right to have a general practitioner (GP) as their regular doctor. Nearly 4000 RGPs are part of this contractual system based on their patient list. Pharmacies Primary care pharmacies in Norway operate private commercial businesses, while hospital pharmacies are publicly owned. The pharmacies employ about 6000 employees of which the majority are authorised healthcare providers. A new pharmacy legislation (March 2001) led to major structural changes, mainly regarding pharmacy ownership. Before the new legis- lation, all the pharmacies were owned by pharmacists (MScPharm). Most pharmacies are now owned by major pharmacy chains but only pharmacists can hold the licence to run a pharmacy. After deregula- tion, the number of pharmacies has increased greatly, especially in cities. As of June 4 th 2008, there were 624 pharmacies in Norway, of which 591 were primary care pharmacies and 33 were publicly owned hospital pharmacies. Reimbursement system The reimbursement scheme is a key tool to achieve political health goals for social security and welfare for the population. One of these goals is that everyone should have access to necessary medicines, regard- less of their ability to pay. Membership in the National Insurance programme is mandatory for all Norwegian citizens. Nearly 67% of the costs for prescription-only medicine are covered by the Norwegian National Insurance Administration (13). To be included in the list, the disease/condition should be serious and chronic with a need for \"long-term treatment\" . This treatment is defined as for more than 3 months per year. Drugs on the list must have a Marketing Authorisa- tion (MA). Reimbursement is only granted for indica- tions approved for the drug in the Summary of Product Characteristics (SPC), and the holder of the MA has to apply for inclusion in the reimbursement scheme. The Norwegian Medicines Agency decides whether an application for inclusion in the scheme should be granted (14). nummeret kontrolleres 4000 basert er autorisert som helsepersonell. Den p\u00e5 m\u00e5 ha markedsf\u00f8ringstillatelse (MA). Refusjon 16 Rapport 2008 FolkehelseinstituttetThe reimbursement scheme is based on a list of diseases that has developed over time. Each of the diseases/conditions has defined criteria for reim- bursement and a corresponding list of reimbursable drugs (15). The disease list is part of the Norwegian legislation and can only be changed by the Ministry of Health and Care Services. The levels of the diseases vary from specific (e.g., diabetes mellitus) to very broad (e.g., cardiovascular diseases) categories, reflecting the way the list has evolved over the years. As of March 2008, the reimbursement list of diseases has been changed to a list of ICD-10 or ICPC codes with prescription conditions connected to each medicinal product. This new system will be fully imple - mented from January 1 st 2009. As well as the general reimbursement scheme, patients can apply for reimbursement on an individual basis for diseases/conditions and drugs not included in the list, according to set criteria. In 2007, these individual reim- bursements accounted for about 10 % of the total costs. 1.4 The Norwegian Drug Wholesales Statistics Statistics based on total sales of drugs from whole - salers to pharmacies and hospitals/nursing homes has been available in Norway since the 1970s. The Norwe - gian Drug Wholesales Statistics database includes total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes and non-pharmacy outlets and others with permission to sell medicines. Total sales of prescription and non-prescription human and veterinary medicines are included in the statistics. The statistics give an overview of developments in drug consumption over time, both at county and country level. The statistics, however, contain no information about the individual drug user. Drug Consumption in Norway - published annually Data from the Norwegian Drug Wholesales Statis-tics Database have been published annually in Drug Consumption in Norway (1) since 1977. Each issue includes total sales data for 5 year periods for both prescription- and non-pre - scription drugs in Norway. The book is available from the website www.drugcon- sumption.no. Further infor - mation on the Norwegian Drug Wholesales Statistics gis for indikasjoner godkjent for substansen over sykdommer en del av lovgivning og Rapport 2008 Folkehelseinstituttet 17database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no. 1.5 The Anatomical Therapeutic Chemical (ATC) classification system In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with one phar - macological/ therapeutic sub-group (2nd level). The 3rd and 4th levels are chemical/pharmacological/ therapeutic sub-groups and the 5th level is the chem- ical substance. The ATC code A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system: C Cardiovascular system (1st level, anatomical main group) 03 Diuretics (2nd level, therapeutic sub-group). D Potassium-sparing agents (4th level, pharmaco- logical sub-group)01 Spironolactone (5th level, chemical substance) All medicinal products containing plain spironolac - tone (Aldactone \u00aeand Spirix \u00ae) are thus assigned the code C03DA01. The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all preparations classified in main group C - Cardiovas - cular system (1st level), figures for the various sub-groups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient. The ATC code for all pharmaceuticals on the Norwegian market can be retrieved from the pharmacy medicinal product register and in the monographs of the national drug catalogue \"Felleskatalogen\". The yellow section of the latter, entitled The Anatomical Therapeutic Chemical Medicines Register, lists all medicinal products belonging to each of the ATC 5th level codes.legemiddelstatistikken niv\u00e5), tall for de ulike under - gruppene (2., 3. og 4. niv\u00e5) og ned til tall som viser 18 Rapport 2008 Folkehelseinstituttet1.6 The Defined Daily Dose (DDD) In some tables in the book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as the assumed average maintenance dose per day for a drug used on its main indication in adults. The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should there - fore be regarded as a technical measuring unit. Drugs used for more than one indication may cause particular problems. For example, for neuroleptics (ATC N05A) the doses used in psychoses, and not the lower doses used to treat neuroses, are chosen when assigning DDDs. With the exception of specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their administration route will have more than one DDD, each inked to a specific dosage form. For medi- cations where a booster dose is followed by a smaller maintenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance. When this is impossible, as is the case with combination preparations and some liquid prepara- tions, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.). In some ATC groups, DDDs are only assigned for some drugs (e.g. ATC group D, dermatologicals) and tables including DDDs will only cover the medications where a DDD has been assigned. The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evaluating the data. 1.7 The WHO Collaborating Centre for Drug Statistics Methodology The WHO Collaborating Centre for Drug Statistics Meth- odology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Pharmacoepidemiology at the NIPH. Further information about the ATC/DDD 1.6 D\u00f8gndose om de nasjonale terapitradisjonene kan variere fra land til et annet doseringsanbefalinger). har man valgt psykosedoser preparater hvor DDD inkludert omfatter - ning n\u00e5r tallene vurderes. 1.7 WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del 19system is given in the publication Guidelines for ATC classification and DDD assignment (16). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (17). Both publica- tions are available in English, Spanish or German. The website for the Centre is www.whocc.no. ATC and DDD changes are published annually and are applied by the end of the year. ATC/DDD version from January 2008 have been used in the book. Interested parties can order the ATC/DDD publications from the WHO Collaborating Centre for Drug Statistics Methodology.kasjonen Guidelines for ATC classification and DDD assignment (16). ATC Index with DDDs, som inne - holder en liste over alle kan bestille publikasjonene fra WHO Collaborating Centre for Drug Statistics Methodology. Referanser/References 1. R\u00f8nning M (Ed). Drug Consumption in Norway 2003-2007. [Legemiddelforbruket i Norge 2003-2007] Oslo: Norwegian Institute of Public helsedepartementet, 1996. 3. Norwegian Official Report No 6 1997. Prerequisites for the sale of medications: \"Cost-effective medications\" [In Norwegian]. Oslo NOU 1997:6. 4. Norwegian Official Report No 7 1997. Pills, priorities and politics: What kind of reimbursement system is needed for patients and society? [In Norwegian]. Oslo NOU antibiotikaresistens (2000-2004). The Norwegian Plan of Action to Combat Resistance to Antibiotics (In Norwegian). The Ministry of Health and Social Affairs. Oslo, Norway, March 2000. 7. Furu K. Drug utilisation in a public health perspective: establishing a national prescription register in Norway. Nor J Epidemiol 2001;11(1):55-60. 8. Lov av 18.mai 2001 12. R\u00f8nning M, Litleskare I, Addis A et al. Recommendations for national registers of medicinal products with validated ATC codes and DDD values. Italian J Public Health 2006;3(1):30-35. 13. Apotek og legemidler. Oslo: Apotekforeningen, Norway. 2007 14. Haga A, Sverre JM. Pricing and reimbursement of pharmaceuticals in Norway. Eur J Health Econ 2002;3:215-220. 15. Forskrift om 12-04-2007. 16. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2008. 11th edition. Oslo, 2007. 17. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2008. Oslo 2007. 20 Rapport 2008 Folkehelseinstituttet2. Comments to selected topics and drug groups 2. 1 Selected key figures from NorPD In 2007, 93 % of DDDs dispensed at Norwegian phar - macies were distributed as prescribed drugs to indi- viduals in ambulatory care. Deliveries to institutions (hospitals/nursing homes) made up 6 % of total DDDs and nearly 1 % of DDDs were for use in the physician's practice. During 2007, 33 000 different prescribers prescribed at least one prescription dispensed and collected by a patient at a pharmacy in Norway. Of these, there were 26 000 physicians, 4 800 dentists and 1 300 nurses / midwifes. Half of the prescribers had prescribed less than 100 prescriptions, while 4600 physicians had prescribed 2000 prescriptions in 2007. Overall, during the four year period (2004-2007) over 4.2 million unique individuals have been recorded in NorPD with at least one prescription medication dispensed from a pharmacy. In each year about two- thirds of the entire Norwegian population had at least one prescription dispensed, 75 % of the women and 61 % of the men (table 1). The regulation stating that the patient's personal identification number must be included on the prescription was introduced as late as 1 st October 2003. In the beginning of 2004, the first operational year of NorPD, the proportion of prescrip - tions having invalid or missing personal identification 2. Kommentarer til utvalgte tema og legemiddelgrupper 2.1 Utvalgte n\u00f8kkeltall fra ble 93 % av den totale mengde legemidler (i DDD) fra av totalt utlevert DDD, og i underkant av 1 % av total DDD ble levert til bruk i forskrivers egen apotek i Norge. Av disse forskriverne var det vel 26 000 leger, 4 800 %. Women n (%)Men n (%)Both gender n (%) 2004 1 685 636 (72.8) 1 331 140 (58.5) 3 016 776 (65.7) 2005 1 730 324 (74.3) 1 381 385 (60.2) 3 111 709 (67.3) 2006 1 756 444 (74.8) 1 412 436 (61.0) 3 168 880 (68.0) 2007 1 774 710 (75.0) 1 440 136 (61.5) 3 214 846 (68.3)Table 1: Number of individuals and one-year prevalence (% ) who had at least one prescription dispensed from Norwegian pharmacies 2004-2007. Rapport 2008 Folkehelseinstituttet 21number reached 6 %. Therefore, the prevalence figures from 2004 will be too low, and the real number of individuals receiving at least one prescription during the year should be higher this year. The proportion of prescriptions with an invalid personal identification number has declined further to about 2 % in 2007. The age-specific one year prevalence in 2007 was lowest in both genders at about 10-14 years of age (figure 1). About 90 % of individuals aged 70 years and older received prescription medications. Excluding women who received no other prescribed drugs than hormonal contraception for systemic use (ATC code G03A), the prevalence of drug use was reduced by about 10-15 % in women aged 15-29, although the proportion of drug users among women over 15 years of age was still higher than in men.Dette medf\u00f8rer at prevalensen av legemiddelbruk l\u00f8pet av \u00e5rene og var i 2007 p\u00e5 om lag 2 %. Ett\u00e5rsprevalensen i 2007 var lavest begge kj\u00f8nn i -34 35 -39 40 -44 45 -49 55 -59 60 -64 65 -69 70 -74 75+ 0 - 4 5 - 9 Men WomenAgeProportion (%) of the population 0102030405060708090100 WomenFigure 1: Age- and sex-specific one-year prevalence (%) of the entire Norwegian population who had at least one prescription of medication dispensed in 2007. 0102030405060708090100 <1 1 2 3 4 5 6 8 7 910 11 12 13 14 15 16 17Men Women AgeProportion (%) of the population Figure 2: One-year prevalence (%) of individuals 0-17 years who had at least one prescription of medication dispensed in 2007. 22 Rapport 2008 FolkehelseinstituttetAmong those 0-17 years, 477 071 individuals (45 %) had one or more prescriptions issued in 2007. About 30 % of girls and 38 % of boys had a prescription issued before they were one year old. The proportion of boys receiving at least one drug is slightly higher than in girls until the early teens (figure 2). From the age of 14 the proportion of girls receiving drugs is increasing steeply, while the boys remain quite stable. This is mainly due to use of hormonal contraception (ATC code G03A), but also use of more prescribed anal- gesics among girls. Table 2 shows the one-year prevalence of the entire population who received at least one prescription in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC code J), drugs acting on the nervous system (ATC code N) and drugs acting on the respiratory system (ATC code R). Blant barn 0-17 \u00e5r i 2007. Ca % av guttene fikk i luftveiene (ATC-kode R). ATC Women Men % % A Alimentary tract and metabolism 14.9 11.0 B Blood and blood forming organs 11.0 11.2 C Cardiovascular system 19.6 17.9 D Dermatologicals 13.6 11.2 G Genito urinary system and sex hormones 24.1 4.6 H Systemic hormonal preparations, excl.sex hormones and insulins 9.8 4.7 J Antiinfectives for systemic use 30.9 21.6 L Anti-neoplastic and immunomodulating agents 1.5 1.3 M Musculo-skeletal system 22.3 16.5 N Nervous system 29.8 20.3 P Antiparasitic products, insecticides and repellents 2.4 1.3 R Respiratory system 27.4 21.6 S Sensory organs 14.0 10.8 V Various 0.2 0.2Table 2: One-year prevalence (% of total Norwegian population) with at least one prescription dispensed in the main ATC groups at a pharmacy in 2007. Rapport 2008 Folkehelseinstituttet 232.2 Drug use in the elderly (70 years) Use of medicines in the population increases with age. Medicine use in hospitals and nursing homes is not included at the individual level in the NorPD. This often provides too low figures for the number of drug users, particularly in the oldest age groups. Neverthe - less, the figures from NorPD show that in the age group 70 years, 91% of the population had at least one drug dispensed on prescription in 2007 (fig 1). 2.2 Legemiddelbruk hos eldre (70 i 2007 de aller eldste legemiddel p\u00e5 resept i 2007. Figure 1: One-year prevalence (%) of dispensed prescriptions in 2007 for men and women aged 70 years and older0102030405060708090100 Men Women 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90+Proportion (%) of the population Age80 70 60 50 40 30 20 10 0 90 100 Table 1: Number of individuals having a prescription dispensed in the major ATC groups and the corresponding sales in total number of DDDs. Proportion (%) in the age group 70 years and older is given in brackets. ATC group Number of individuals (% 70 years or older)Million DDDs (% 70 years or older ) A Alimentary tract and metabolism 610 568 (30) 182 (34) B Blood and blood-forming organs 522 863 (49) 83 (51) C Cardiovascular system 882 923 (40) 766 (44) G Genito-urinary system and sex hormones 678 836 (12) 148 (11) H Systemic hormonal preparations, excl. sex hormones and insulins 342 396 (27) 59 (29) J Anti-infectives for systemic use 1 236 036 (15) 27 (24) M Musculoskeletal system 915 101 (17) 82 (32) N Nervous system 1 181 319 (23) 302 (26) R Respiratory system 1 152 808 (13) 230 (20) Total 3 214 846 (15) 1 982 (35) 24 Rapport 2008 FolkehelseinstituttetThe percentage is lower in the older age groups but this would be due to patients in institutions not being included. In the total population, the prevalence of drug use is 68% in 2007. The proportion of drug users is high in the oldest age groups, and this group also uses more drugs and a higher quantity of the medicines in terms of defined daily doses (DDDs). In 2007, the 70 years or older) group constituted a share of 15% of all drug users and 35% of the total number of defined daily doses (DDDs) dispensed on prescriptions (table1) Figure 2 shows the percentage distribution of the total number of individuals according to the number of drugs (defined as different ATC 5th levels) that were given during 2007 for drug users 70 years or older, compared to the rest of the population (0-69 years). 58% of the drug users in the age group 70 years and older use more than five drugs, while for those under 70 years, the share is 20%. Evidence-based guidelines often recommend several drugs for the treatment or prevention of disease. If an individual is treated for several illnesses, he or she will often use many drugs. Polypharmacy has been in high focus in medical lite - rature, but there is no general definition of the term (1). The figures from NorPD show that many elderly people will need to handle many drugs which may increase the risk of misuse (figure 2). To assess whether these numbers indicate overuse, underuse or misuse requires in-depth analysis and often more detailed information about the diagnoses. Prescriptions of drugs in ATC main groups B and C are used by the largest proportion of elderly (table 1). Andelen legemiddelbrukere er st\u00f8rst de under 70 \u00e5r var st\u00f8rste andelen eldre (tabell 1)05101520253070 years and older0-69 years Proportion (%) of users Number of drugs (ATC codes)1 2 3 4 5 6 7 8 9 10 >10 Figure 2: Proportion (%) of total drug users according to number of drugs dispensed (ATC-codes) in 2007 in the age groups 0-69 and 70 years and older Referanse/Reference: 1. Viktil K, Blix H, Reikvam 147-152Rapport groups C and B01) Overall, 882 923 individuals had at least one prescrip - tion dispensed for a cardiovascular drug (ATC group C) in 2007. This corresponds to a one-year prevalence in the population of 18.7 %. The one-year prevalence was 19.5 % for women and 18.0 % for men (not age adjusted). The one-year prevalence based on age and gender is shown in Figure 1. The prevalence increases with age among both women and men, while men 40 years or older have a higher prevalence than women. In the 14-39 year age group the prevalence is slightly higher among women than men which may be due to some women using drugs within this group, for example to treat hypertension in pregnancy. Overall, 40 % of the total number of individuals in the cardiovascular group are 70 years or older and 85 % are over 50 years. The number of individuals who had at least one cardiovascular prescription dispensed has increased gradually from 2004-2007, an annual increase of around 4 % (3 % increase when adjusted for the population growth) Many patients are using many cardiovascular drugs. On average, each individual had 2.2 different cardiovascular drugs (counted as ATC 5 th levels) dispensed in 2007. Introduction of new price and reimbursement regula- tions for some of the cardiovascular drugs has resulted in reduced costs in the latest 5 year period (1). When simvastatin became the drug of choice in June 2005, 2.3 Hjerte/kar legemidler (ATC gruppe hjerte/kar midler 70 \u00e5r eller eldre og % bytte til simvastatin, Figure 1: One-year prevalence (%) of cardiovascular prescriptions (ATC group C) in 2007 in Norway according to age and 26 Rapport 2008 Folkehelseinstituttetmany atorvastatin users had to be switched to simvastatin, resulting in reduced costs. Other statins should only be prescribed based on solid medical grounds. Figures from NorPD show that 39 % of atorvastatin users were switched to simvastatin in the 13-month period after introduction of this new regulation (2-3). There has been a sharp increase in the number of individuals using simvastatin, while the numbers of atorvastatin and pravastatin users has reduced from 2005 to 2006. In July 2007, the lowest tablet strengths (10 mg and 20 mg) of atorvastatin were removed from the general reimbursement scheme, further increasing the switch from atorvas-tatin to simvastatin in 2007. Norway has a high use of statins compared to other European countries. Overall, 395 238 individuals (9 % of the population) had at least one statin prescription dersom viser at 39 juli 2007 ble de laveste tablettstyrkene (10 mg og 20 tatt ut dette One-year prevalence (%) of statin prescriptions (C10AA) in Norway according to gender for the period 2004- 2007 Figure 3: One-year prevalence (%) of diuretics prescriptions (ATC group C03) in 2007 in Norway according to age and gender012345678910Men Women 2004 2005 2006 2007 AgeProportion (%) of the population Men Women 0510152025303540 Proportion (%) totalt 62 000 nye brukere av statiner i 2007 og over 90 % av disse fikk simvastatin. Nye fikk ekspedert en statinresept 2006. 85 % av de individene som fikk ekspedert en statinre - sept kan antall brukere av doxazosin i 2007. Andre alfablokkere er godkjent til behandling av BPH er ved behandling var en stor \u00f8kning i antall fra tromboseforebyggende legemidler er h\u00f8yere hos menn enn hos kvinner.dispensed in 2007, an increase of 35 000 individuals from 2006. Figure 2 shows the one-year prevalence of statin use for men and women in the period 2004-2007. The prevalence is higher among men than women in all age groups, while the prevalence increases with age in both genders. Data from NorPD show that over 70 % of the statin users also use other cardiovascular drugs (ATC group C). There were 62 000 new users of statins in 2007 and more than 90 % of these used simvastatin. New users were defined as individuals who had no statin pres- criptions dispensed in 2006, receiving a statin for the first time in 2007. 85% of individuals who used statins in 2004 also had a statin prescription dispensed in 2007. Adverse events could be one reason why some individuals stop statin treatment, but the figure is not adjusted for indivi- duals who died or emigrated during this period. The number of individuals using alpha blockers (e.g. doxazosin, C02CA04) dropped when doxazosin was removed from the reimbursement scheme in January 2004 (it was reintroduced in 2008). Alpha blockers are also used to treat benign prostatic hypertrophy (BPH), reflected by the fact that 70 % of the total number of users of doxazosin in 2007 were men. Other alpha blockers that are only approved for the treatment of BPH are classified in the ATC group G04CA, and the number of men who use these agents has increased by 50 % from 2004-2007. The number of individuals using diuretics (C03) has increased gradually from 2004-2007. The increase in sales over recent years could be because thiazides were introduced as the drugs of choice for uncom- plicated hypertension in March 2004. Figure 3 shows the one-year prevalence of diuretic use according to age and gender in 2007. The prevalence is higher in women than men in all age groups. The numbers of individuals using beta-blocking agents (C07), calcium channel blockers (C08) and ACE-inhibitors (C09A/C09B) have increased slightly during the period 2004- 2007. The largest increase in the number of individuals is seen for the angiotensin II antagonists (C09C/C09D). ATC group B includes drugs that are used to prevent thromboses (B01). Aspirin (B01AC06) is the most used drug in individuals 70 years or older. Overall, 344 947 individuals had a prescription dispensed for aspirin in 2007 with the elderly accounting for 52 % of the users. Other important medicines in this group are warfarin (B01AA03) and clopidogrel (B01AC04). In autumn 2004, clopidogrel was included in the reimbursement 28 Rapport 2008 Folkehelseinstituttetscheme under specific criteria which explains the large increase in the number of users from 2004 to 2005. The one-year prevalence for anti-thrombotic agent use is higher among men than among women. Heparins (B01AB) are used primarily in connection with surgery or treatment/prevention of deep venous thromboembolism and the age distribution differs in this group. Since prescribing to patients in institutions is excluded, the number of individuals given for ATC group B01AB in the tables would underestimate the total number of users. 2.4 Drugs used in diabetes (ATC group A10) The term diabetes mellitus includes type 1 diabetes, an insulin deficiency disease, and type 2 diabetes which is characterized by decreased insulin sensiti- vity and reduced insulin secretion. The prevalence of type 1 and type 2 diabetes is growing worldwide. The increase in the prevalence is explained by the fact that patients are living longer, and that there is an increase in the number of new cases reported. In Norway, the sale of drugs to treat diabetes mellitus, in terms of defined daily doses, has more than doubled over the last decade. The annual growth in sales of drugs used in diabetes has been relatively stable in the last five-years (5 % increase in doses in 2007). In 2007, pharmacy retail price sales amounted to more than 440 million NOK (1). Increased incidence (new cases) of type 2 diabetes, which is most prevalent, and more intensive treatment are the main reasons for the growth in turnover. Data from the Norwegian Prescription Database (NorPD) show that 132 000 individuals (2.8 % of Legemidler i heparingruppen (ATC group A10) Diabetes mellitus er en fellesbetegnelse for type 1- diabetes, en insulinmangelsykdom, og type kjennetegnes ved nedsatt insulinsensitivitet 2007). Omset - ningen i 2007 var p\u00e5 440 (utsalgs-pris apotek) (1). 2007. Dette er en \u00f8kning 000 individer i 2004 (se tabell s.48). Referanser/References : 1 R\u00f8nning M (Ed). Drug Consumption in Norway 2003-2007. [Legemiddelforbruket i Norge 2003-2007] Oslo: Norwegian Institute of Public 2008 2. Sakshaug S, Furu K, Karlstad \u00d8, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br J Clin Pharmacol. 2007;64(4):476-81. 3. 2006.Rapport 2008 Folkehelseinstituttet 29the population) received drugs for the treatment of diabetes dispensed at a pharmacy in 2007. This is an increase from 110 000 individuals in 2004 (see table p. 48). The one-year prevalence of drug-treated diabetes during the period 2004-2007 increased from 2.6 % to 3.1% in men and from 2.2 % to 2.6 % among women (Figure 1). NorPD cannot give exact preva- lence rates of type 1 diabetes and drug-treated type 2 diabetes, because insulin is used to treat both diabetes forms. In 2007, nearly 50 000 patients received insulin (A10A) and 99 000 patients were treated with tablets (A10B). Figure 2 and Figure 3 show one-year preva- lence per age group for the use of insulin and tablets in 2007, respectively. Nearly 33 000 patients received insulin only; more than 16 000 patients were pres- cribed both tablets and insulin, and 83 000 patients had only tablets dispensed. Figure 2 shows that the prevalence of insulin use in men is higher than for women in all age groups, with the exception of 0-14 years. The Norwegian Diabetes Association estimates that about 25 000 Norwegians have type 1 diabetes. From this information and figures from the NorPD, we can estimate that 25 000 patients with type 2 diabetes use insulin alone or in combination with tablets. The incidence of type 1 diabetes in children is a major concern in Norway and the other Nordic countries (2, 3). A Norwegian nationwide registry for type 1 diabetes in children under 15 years was created in 1989. Incidence rates for the period 1989-2003 have been published, and the results show an increase, despite stable incidence in the period 1989-1998 (4, 5). The incidence rate for the period 2001-2003 was nearly 29 per 100 000 person-years at risk (5). By Ett\u00e5rsprevalensen for medikamentelt behandlet diabetes i 2007 fikk n\u00e6r 50 000 pasienter mens 99 000 pasienter ble behandlet med tabletter (A10B). Figur 2 og viser per aldersgruppe for bruk av henholdsvis 33 000 pasienter fikk kun 000 pasi- b\u00e5de og insulin, og 83 tabletter. Figur 2 viser at denne informasjonen Reseptregisteret, beregne at i underkant av 25 000 med 1-diabetes hos barn er urovek - kende i Norge og de andre nordiske land (2,3). Et landsdekkende diabetesregister for type 1-diabetes for barn under \u00e5r opprettet i per 100 sammenlikning viser en ny finsk av type 1-diabetes, og i 2005 var den Figure 1: One-year prevalence (%) of antidiabetic prescriptions (A10) in Norway in men and women for the period 2004-2007 2004 2005 2006 2007 Year Proportion (%) of the populationMen Women 00.51.01.52.02.53.03.5 30 Rapport 2008 Folkehelseinstituttetcomparison, a new study shows that the incidence of type 1 diabetes in Finnish children is increasing at an even faster rate than previously (6). Since the 1950s, Finland has had the world's highest incidence of type 1 diabetes, and in 2005 it had 64 per 100 000 person- years at risk for children aged under 15 years. Indivi- duals under 15 years of age who uses insulin are most likely to be type 1 diabetes patients. Data from the NorPD show there were 1 726 insulin users in this age group in 2007, corresponding to a one-year preva- lence of 2.0 per 1000 inhabitants. The incidence rate in the age group under 15 years, calculated from the number of new users in 2007, was about 35 per 100 000 person-years at risk. In the period 2005-2007 the estimated incidence rate for diabetes in children and young people under 15 years has been stable, based on data from the NorPD, but higher than previously published figures (5). The use of drugs for the treatment of diabetes mellitus can be considered as a good surrogate endpoint for the prevalence of diabetes. The NorPD is therefore a new source of reliable prevalence and incidence estimates of drug-treated diabetes in Norway (7). The reason for this lies in the processing of prescriptions in the pharmacy. All patients with chronic diseases who are treated outside an institution have to visit a pharmacy in the course of a year (7). The NorPD only provides prevalence estimates for diabetes mellitus being treated with drugs. Many people with type 2 diabetes control their disease with diet, physical activity and weight loss only. The Norwegian Diabetes Association estimates that about 70% of people with type 2 diabetes need medical treatment. In addition, there are many undiagnosed cases (8). p\u00e5 64 per 100 000 person\u00e5r i aldersgruppen under 15 \u00e5r. Individer under 1-diabetes. ut fra antall nye brukere i 2007, var ca. 35 per 100 000 person\u00e5r. I perioden 2005-2007 har beregnet insidensrate med data fra Reseptregis- teret hos og unge stabil, kan surrogatendepunkt utbredelse 2: One-year prevalence (per 1000) of insulin prescriptions (A10A) in 2007 in Norway according to age and gender Proportion (per 1000) of the population the Norwegian Wholesales Statistics show that the total consumption of insulin is steadily increa- sing. The sales of insulin, measured in doses, increased by 2.8 % in 2007 (1). The trend over the past five years is a growth in the sales of rapid-insulin analogues which are often used in insulin pumps for continuous admi- nistration of insulin to patients with type 1 diabetes. Data from the NorPD suggest that there is a transi-tion from fast-acting human insulin to rapid-insulin analogues. The relatively new insulins, insulin glargine and insulin determir, are reimbursed for patients with frequent hypoglycaemic episodes only (on a named patient basis). The NorPD shows an increasing propor - tion of patients being treated with these long-acting insulin-analogues. Oral drugs are used mainly by patients with type 2 diabetes. A small number of patients have MODY (maturity onset diabetes of the young), and in addi- tion, some young women with the diagnosis poly - cystic ovary syndrome are treated with metformin or thiazolidindioner (insulin sensitizers). The sales measured in doses of tablets with blood glucose- lowering effect increased by 7 % in 2007. Metformin (A10BA02) and glimepiride (A10BB12) accounted for 47 % and 41 %, respectively, of the total sales of oral anti-diabetics in 2007, measured in doses (1). The NorPD shows that about 80 000 individuals received metformin, while roughly 45 000 had sulfonamides (see table p. 48). The use of tiazolidinediones (\"glita- zones, \" A10BG) is relatively low, but the number of individuals who receive the new, fixed combinations containing glitazones is increasing rapidly. Figure 3 shows the prevalence of antidiabetic tablet pres- criptions in 2007 according to age and gender. Up to 40-years of age, the proportion of women treated with oral antidiabetics was higher than men, while in the older age group, it was the opposite. Figure 3: One-year prevalence (%) of oral antidiabetic prescriptions (A10B) in 2007 in Norway according to age and gender 80+ 70 - 79 60 - 69 50 - 59 40 - 49 30 - 39 20 - 29 15 - 19 0 - 140123456789Men Women Proportion (%) of the population Agemed type1-diabetes. Tall fra Reseptregisteret antyder pasienter har MODY (maturity onset glimepirid utgjorde henholdsvis 47 % og % av totalsalget av perorale midler i 2007 m\u00e5lt i av perorale antidiabetika fikk statiner i 2006 (10). 32 Rapport 2008 Folkehelseinstituttet Type 2 diabetes patients have an increased risk of cardiovascular disease. International guidelines recommend the use of statins for this group of patients (9). Data from the NorPD shows that 54% of long-term users of oral blood glucose-lowering drugs also received statins in 2006 (10). The NorPD contains information from prescriptions dispensed from Norwegian pharmacies to individual patients living outside institutions. As a consequence, the number of individuals is underestimated, particu- larly in the oldest age groups. In 2007, the proportion of the total number of doses of drugs used in diabetes delivered to institutions was 4 %. 2.5 Antibacterials for systemic use (ATC group J01) In 2007, a quarter of the Norwegian population received antibiotics on prescription at least once. 29% of women and 21% of men in the total population received antibiotics. The prevalence of antibiotic use differed greatly between age groups. In the youngest and the oldest age groups antibiotics were most widely used. The decline in prevalence in the popula- tion 85 years old can be explained by the fact that the majority were resident in institutions. Adjusting for this, the prevalence of antibiotic use in the elderly I Reseptregisteret er diabetesmidlene % av mennene i Norge fikk aldersgruppen Norway 2003-2007. [Legemiddelforbruket i Norge 2003-2007] Oslo: Norwegian Institute of Public Health, 2008 2. EURODIAB ACE Study Group. Variation and trends in incidence of childhood diabetes in Europe. Lancet 2000; 355: 873-876. 3. Karvonen M, Viik-Kajander M, Moltchanova E et al. Incidence of childhood type 1 diabetes worldwide: Diabetes Moni- dale (DiaMond) Project Group. Diabetes 1516-1526. 4. Joner G, Stene LC, S\u00f8vik O. Nationwide, Prospective Registration of Type 1 Diabetes in Children Aged <15 Years in Norway 1989-1998. Diabetes al. Spatiotemporal Trends and Age-Period-Cohort Modeling of the Incidence of Type 1 Diabetes Among Children Aged <15 Years in Norway 1973-1982 and 1989-2003. Diabetes 884-9. 6. Harjutsalo V, Sj\u00f6berg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008; 371: 1777-82. 7. on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007; 28:88-136. 10. Str\u00f8m H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. Nor % % for aldersgruppene 75-79, 80-84 og 85 hver med en \u00e5r. living at home increased rather than decreased. The estimated prevalence was 34 %, 35 % and 37 % for the age groups 75-79, 80-84 and 85 years, respectively. The use of antibiotics was quite similar for young boys and girls, but from the age of 15-16 years, women used more antibiotics than men, with the greatest difference in the prevalence being found at the age of 20 (Figure 1). Phenoxymethylpenicillin was most commonly used by women and men; 10.6 % of the women and 9 % of the men used this. During 2007, phenoxymethylpenicillin was the drug that was given to most patients in Norway. It also tops the list of drugs that were most commonly given to individuals under 15 years of age (see table page 42). This list also includes two other antibacterial agents, erythromycin and amoxicillin, which, like phenoxymethylpenicillin, are widely used to treat respiratory infections in chil- dren. These three agents also represent (are classified in) the three groups of antibiotics with the greatest proportion of users in the total population; narrow spectrum penicillins with a share of 10 %, macrolides and penicillins with an extended spectrum, respecti- vely, each with a share of about 6 % in 2007. For women phenoxymethylpenicillin was followed by pivmecillinam (5.8 %), erythromycin (3.9 %) and trime - thoprim (3.5 %), while the use of phenoxymethylpeni-cillin in men was followed by erythromycin (2.8 %), doxycycline (2.6 %) and amoxicillin (2.1%). Pivmecillinam and trimethoprim are used for urinary tract infections, so more frequent treatment of such infections among women may explain some of the difference in antibiotic use between the sexes. This difference was greatest in the age group 20-40 years. Proportion (%) of of antibacterial prescriptions (J01) in 2007 in Norway according to age and gender 34 Rapport 2008 FolkehelseinstituttetFor b\u00e5de kvinner ble brukt av henholdsvis 15 % og 9 av av midler (ATC gruppe gruppe N02 m\u00e5 med av legemidler i del 3 i denne boken. I 2007 fikk mer enn 396 disse kodeinholdige The use of azithromycin was also high in this age group for men and women; this agent is often used to treat Chlamydia infections that commonly affect young adults. For women over 75 years of age, penicillin with an extended spectrum (J01CA), and sulfonamides and trimethoprim (J01E) were the largest groups of anti- biotics. Both of these groups of drugs are commonly used to treat urinary tract infections and were used by 15 % and 9 % of the women in this age group, respec - tively. For men, the use of narrow spectrum penicillins (J01CE) remained high and, similarly to penicillins with extended spectrum, they were used by almost 10% of the male population over 75 years. In the population as a whole, narrow spectrum penicil- lins were most commonly used by both women and men, followed by macrolides and tetracyclines for men and extended spectrum penicillin and macrolides for women. 2.6 Drugs affecting the nervous system Between 2004 to 2007, drugs affecting the nervous system were one of the ATC groups with most drugs dispensed from pharmacies. In 2007, a total of over 1.1 million individuals received a drug from this group, see table 43. The group includes a number of different drugs, (N05C), antidepressants some other mental health disor - ders (N05A), and drugs to treat addictive disorders (N07B). Analgesics (ATC group N02) Prescription of analgesics in the ATC group of N02 must be viewed together with the prescribing of drugs in the ATC group M01A Anti-inflammatory and anti-rheumatic products, non-steroids, and other drugs within the ATC group M03B, the muscle relaxants. These drugs have overlapping indications. The ATC groups M and N also include the most widely used non-prescription (OTC - over the counter) anal- gesics (paracetamol and ibuprofen). OTC sales are not included in the prescription statistics, please refer to footnotes in the tables in part 3 of this book. In 2007, more than 396 000 individuals received a combination of codeine and paracetamol (ATC code N02AA59, Paralgin forte \u00ae, Pinex forte \u00ae). These drugs are third on the list of most commonly dispensed drugs in Norway, see p. 41. In addition to the codeine-Rapport 2008 Folkehelseinstituttet 35legemidlene utleveres Sannsynligvis representerer mye av dette bruk av melatonin som containing drugs, plain paracetamol preparations were the most widely prescribed drug. Close to 223 000 individuals had at least one paracetamol pres-cription dispensed. The sharp increase in the number of paracetamol prescriptions in the period 2004 to 2007 can be seen in the use of the drug group \"coxibs\" (M01AH). After reports of serious adverse drug reactions most of these drugs were withdrawn from the market in 2004-2006. Paracetamol was one of the recommended options for this patient group. In addition to what is stated in the prescription statistics, a substantial amount of paracetamol is sold OTC. The wholesale drug statistics show that the prescription sales of paracetamol in 2007 accounted for 61% of the total paracetamol sales in doses. Anti-epileptics (ATC-group N03) A number of drugs used in epilepsy also have other uses, such as neuropathic pains (carbamazepine, valproic (valproic acid, lamotrigine, carbamazepine and gabapentin). These alternative indications reflect a significant and growing number of drug users in the group. Anxiolytics (ATC group N05B) Figures from the statistics show that 285 000 indivi- duals had dispensed at least one anxiolytic in 2007, of which women accounted for 65%. Mainly, benzo - diazepines were used. In addition to the drugs in the group, clonazepam (N03AE01) is increasingly used as an anxiolytic. Hypnotics and sedatives (ATC group N05C) In 2007, nearly 386 000 individuals had at least one hypnotic dispensed. In this group, women account for 66%. In the age group 80-89 years almost 35% of women received at least one hypnotic. The actual proportion of the elderly is even higher because pati- ents admitted in hospitals or other health institutions are not included in the statistics. The group is dominated by the total, 88 % of individuals who had had a hypnotic dispensed received one of these drugs. The Z-hypnotics have a slightly different chemical struc - ture to benzodiazepines, but probably have similar wanted and unwanted effects to the benzodiazepines (1). The biggest change in the period was observed for young people under the age of 20 in the dispensing of melatonin (N05CH01). This number doubled in the observation period, from 2 800 to 5 600 individuals. 36 Rapport 2008 FolkehelseinstituttetThis is probably due to an increasing use of this drug as a hypnotic for patients receiving therapy for ADHD (Attention-deficit hyperactivity disorder). Antidepressants (ATC group N06A ) The statistics shows that 283 000 individuals, or about 6 % of the population, were dispensed at least one antidepressant in 2007. In the last three years this figure has remained relatively constant. Women accounted for 66 % of those who were dispensed an antidepressant in 2007 (2). The biggest sub-group was the selective serotonin re-uptake inhibitors (SSRI). Dispensing to young individuals, under 15 years, was dominated by the two-SSRIs sertraline (Sertraline \u00ae, Zoloft (Fluoxetin \u00ae, Fontex \u00ae), which is the best documented antidepressant for this age group (3). Newer drugs that are still patent-protected, in parti- cular escitalopram (Cipralex \u00ae), have had a considerable increase in prescribing, representing a significant proportion of those who were dispensed drugs from this group. ADHD drugs (ATC group N06BA) I 2007 more than 22 000 individuals had at least one psychostimulant dispensed primarily for use in ADHD. Boys/men accounted for 69 % of these individuals. The statistics also show an increasing use among adults. The figures are consistent with previous observations (4). Anti-dementia drugs (ATC group N06D) Figures from NorPD shows that nearly 13 500 indivi- duals had been dispensed at least one anti-dementia drug in 2007, slightly fewer than the previous year. Women accounted for 62 %. The statistics do not include individuals who receive their medication in an sovemiddel hos pasienter som behandles med midler mot ADHD Hyperactivity Disorder). Antidepressiva gruppe N06A) Reseptregisteret (ATC gruppe 2007 enn (ATC gruppe i institusjoner (5). Figure 1: One year prevalence (%) of hypnotic prescriptions (ATC group N05C) in 2007 in Norway according to age I 2007 var 542 rapport fra LAR- programmet inkludert i slike behandlingsopplegg (6). institution, where a relatively widespread use of these drugs is documented (5). Drugs for the treatment of opioid dependence (ATC group N07BC) This group includes drugs such as methadone, Subutex \u00ae and opioid antagonist) used to treat opioid dependence. The number of patients who receive these drugs as a part of drug-assisted rehabilita- tion programs cannot be read from the tables. Some patients in these programs have their drugs dispensed from the pharmacies, while others will have them dispensed through an institution, or possibly a combina- tion of the two. This difference between the number of patients in the drug-assisted rehabilitation programs, and the number seen in statistics will be greatest for metha- done. Here, the number of individuals also includes those who have had this drug dispensed as an analgesic, espe - cially cancer patients. According to the report from the drug assisted rehabilita- tion program, 4542 patients were included in this treat - ment in 2007(6). Referanser/References 1. Mellings\u00e6ter T, Furu K. Antidepressants among children and adolescents - did the warnings lead to fewer prescriptions? Tidsskr Nor L\u00e6geforen 2007; 127. K. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int. J. Geriatr. Psychiatry 2007; 22: 843-9. 6. Rapport fra SERAF: http://www.seraf.uio.no/publikasjoner/rapporter/2008/seraf-rapport1.html 38 Rapport 2008 Folkehelseinstituttet3. The Norwegian Prescription Database 2004 -2007- Main tables 3.1 Description of the tables The tables in Section 3 provide an overview of the number of individuals who have had prescriptions dispensed from pharmacies in Norway. Anyone who has had at least one prescription dispensed is included and the data are given for individual medi- cinal substance and for groups of medicines. Even if an individual has been given the same medicine several times, he or she is counted as one user. Only dispen-sing data to individuals with a personal identification number are included in the tables. In NorPD the complete personal identification number is missing for about 2 % of the dispensed medicines (see also p 20-21). The tables contain figures for the period 2004-2007. In addition, the following information for 2007 includes: Share of women (%) of the total number of individuals who had at least one prescription dispensed The number of individuals who had at least one prescription dispensed in the following age groups: <15, 15-44, 45-69, 70 Sales in Norwegian kroner (NOK), i.e. prescrip - tions dispensed to individuals with personal identification number. The amount in NOK corresponds to the actual retail price from the pharmacy. The tables are arranged according to the ATC system (see further description in p 17). The majority of ATC groups containing drugs on the Norwegian market are included. Medicine use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of medicine users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or institutions. We have excluded some ATC 3. Reseptregisteret 2004 - 2007 - Hovedtabeller 3.1 Beskrivelse av tabellene i del inkludert i tabellene i boken. I legemidler, og spesielt for lege - midler som 2008 Folkehelseinstituttet 39groups in this book that are mainly used in hospitals or institutions. The following ATC groups are omitted: - B05 Blood substitutes and perfusion solutions - B06 Other hematological agents - J06 and M03A relaxants, peripherally acting agents - N01 Anesthetics - S01H Local anesthetics - S01J Diagnostic agents - S01L Ocular vascular disorder agents - V Various (only ATC group V01 Allergens is included in the table) Non-prescription medicines are sometimes prescribed, but the majority of the OTC medicine sales will not be included in the tables in this book. Sales of OTC medi- cines are, however, included in the Norwegian Drug Wholesales Statistics database and the figures are published in \"Drug Consumption in Norway\" (see also page p 16). A footnote is used in the tables in part 3 of this book in the various ATC codes where OTC medi-cines are available in Norway. In 2007, OTC medicines had a share of 18 % of total sales measured in DDDs and about 12 % of total costs in Norway. These shares have remained almost unchanged over time. Most prescribed medicines have an approved marke - ting authorisation in Norway. However, physicians can prescribe drugs without approved marketing autho - risation. They must then apply for a licence from the Norwegian Medicines Agency. There are also some medicines that are part of a so-called \"negative list\" which can only be prescribed by special permission from the Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these medicines is often low. If the number of individuals is less than five, <5 is used in the tables. Many individuals use more than one medicine. Please be aware that the number of users of various drugs or drug groups in the tables cannot be added together to find the total number of users of two or more drugs. Statistics on the aggregate level in the tables will, however, include the use of at least one of the drugs in the included drug groups. For example, the figures in the tables show that the total number of users of hypnotics (ATC group N05C) is less than the sum of the number of users of the individual medicines classified in N05C. Some individuals have been given more than one type of hypnotic during a year, either through use of more than one simultaneous or by switching from one agent to another. F\u00f8lgende ATC grupper er (se ogs\u00e5 s 16). I tabellene i del 3 i denne er l\u00f8pet av et \u00e5r, enten ved bruk av 40 Rapport 2008 FolkehelseinstituttetNorPD website and access to data Information about the number of users of a particular drug or drug category split by sex, age and geography are accessible online. The website is: www.norpd.no (English version) or www.reseptregisteret.no (Norwe - gian version). Data are currently available from 2004 with an annual update in March for the preceding year. The figures in this book may differ slightly from the numbers found on the website www.norpd.no. This is because the data extraction for the book was made at a later date in 2008 than the data on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from 2007 can arrive in 2008. It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no ) and all applications for access to data from NIPH should be sent to Datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required. Calculation of prevalence by 1000 inhabitants Prevalence is often defined as the number of indi- viduals per 1000 inhabitants who was dispenced at least one prescription in a pharmacy in a specific time period. The number of individuals listed in the tables can be used to calculate the prevalence of drug users in the population. Please read the following example: The population in Norway for the years 2004-2007 is shown on p 97. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1 st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year).flere sovemidler samtidig eller i Rapporteringen av fra apotek s\u00f8ke Reseptregisteret som \u00e5ret (utleverings\u00e5r minus f\u00f8dsels\u00e5r). The number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2007: 882 923 The number of inhabitants in Norway as of 1st July 2007: 4 709 155Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2007: The number of individuals x 1000 882 923 x 1000 187.5 individuals The number of inhabitants 4 709 155 per individer som fikk minst ett Norge i 2007: 882 923 Antall innbyggere i Norge 709 Beregning av prevalens (per 1000) av hjerte/kar midler i Norge i 2007: Antall flest (tabeller) / Drugs with the highest number of users in Norway (tables) Table 1: The 10 most commonly prescribed drugs (defined as ATC 5th level) dispensed to individuals regardless of age in Norway in 2007 ATC code Active ingredient Number of individualsProportion (%) of the population J01CE02 B01AC06 Acetylsalicylic acid 947 7 C10AA01 Simvastatin N05CF01 Zopiclone Metoprolol 235 281 5 N02BE01 Paracetamol 224 742 5 Table 2: The 10 most commonly prescribed drugs (defined as ATC 5th level) dispensed to individuals aged 70 years in Norway in 2007 ATC code Active ingredient Number of individualsProportion (%) of the population B01AC06 Acetylsalicylic acid 463 C10AA01 112 N02BE01 53 197 10 Levothyroxine sodium 47 910 9 42 Rapport 2008 FolkehelseinstituttetTable 3: The 10 most commonly prescribed drugs (defined as ATC 5th level) dispensed toindividuals aged 15-69 years in Norway in 2007 ATC code Active ingredient Number of individualsProportion (%) of the population M01AB05 Ibuprofen 169 acid 165 334 5 N02BE01 Paracetamol 146 836 4 Table 4: The 10 most commonly prescribed drugs (defined as ATC 5th level) dispensed to individuals aged <15 years in Norway in 2007 ATC code Active ingredient Number of individualsProportion (%) of the population J01CE02 Phenoxymethylpenicillin 81 118 9 R03AC02 Salbutamol 47 774 5 S01AA01 Chloramphenicol 43 883 5 R06AE07 Cetirizine 41 848 5 R03CA02 Ephedrine 41 170 5 J01FA01 Erythromycin 37 656 4 R03BA05 Fluticasone 32 227 4 Fucidic acid Amoxicillin Folkehelseinstituttet 43A ALIMENTARY TRACT AND METABOLISM 510 517 545 884 570 912 610 570 58 13 767 146 396 265 671 184 736 1 338 638 B BLOOD AND BLOOD FORMING ORGANS 458 343 482 347 501 239 522 863 50 2 223 42 986 220 447 257 207 608 778 C CARDIOVASCULAR SYSTEM 785 454 815 355 849 656 882 924 52 3 511 81 908 448 329 349 176 2 165 510 D DERMATOLOGICALS 569 414 577 674 585 088 582 612 55 68 336 222 918 195 664 95 694 208 044 G GENITO URINARY SYSTEM AND SEX HORMONES 654 379 660 711 668 707 678 836 84 2 891 392 718 204 846 78 381 778 218 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 289 462 306 832 323 866 342 396 68 15 314 92 731 143 444 90 907 358 333 J ANTIINFECTIVES FOR SYSTEMIC USE 1 087 489 1 179 319 1 201 040 1 236 036 59 159 127 508 350 385 587 182 972 539 951 L ANTINEOPLASTIC AND IMMU- NOMODULATING AGENTS 50 823 55 517 59 802 65 259 54 1 058 13 632 30 011 20 558 1 854 470 M MUSCULO-SKELETAL SYSTEM 923 010 889 384 906 476 915 101 58 11 844 342 637 404 383 156 237 345 147 N NERVOUS SYSTEM 1 071 508 1 115 535 1 143 287 1 181 319 60 36 900 372 072 495 563 276 784 2 621 651 P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 80 656 82 270 83 430 87 940 65 2 822 43 429 33 040 8 649 31 586 R RESPIRATORY SYSTEM 1 008 945 1 088 589 1 120 184 1 152 808 56 184 311 428 435 386 128 153 934 1 424 134 S SENSORY ORGANS 538 623 563 989 575 529 585 773 57 111 891 187 073 167 356 119 453 284 754 V VARIOUS 6 753 7 981 9 022 10 013 47 2 434 3 489 2 613 1 477 37 8352004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-443.3 T able - ATC main groups2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group A 44 Rapport 2008 Folkehelseinstituttet1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.A01 STOMATOLOGICAL PREPARATIONS 18 589 18 520 17 449 18 361 62 1 577 6 152 6 854 3 778 1 994 A01A STOMATOLOGICAL PREPARATIONS 18 589 18 520 17 449 18 361 62 1 577 6 152 6 854 3 778 1 994 A01AA Caries prophylactic agents 436 538 557 601 71 11 208 115 A01AA01 Sodium fluoride 1) 436 538 557 601 71 11 146 236 208 115 A01AB Antiinfectives and antiseptics for local oral treatment 9 564 9 210 9 383 8 912 62 251 2 446 3 917 2 298 1 162 A01AB02 Hydrogen peroxide1) 425 473 287 53 51 0 36 16 <5 8 A01AB03 Chlorhexidine1)2 416 2 398 2 359 2 282 52 187 792 822 481 147 A01AB04 Amphotericin B 6 618 6 235 6 667 6 514 65 63 1 611 3 023 1 817 929 A01AB09 Miconazole 16 <5 <5 <5 1 A01AB17 Metronidazole 142 132 109 106 60 0 9 78 19 54 A01AC Corticosteroids for local oral treatment 8 223 8 866 7 496 8 815 62 1 308 3 376 2 789 1 342 629 A01AC01 Triamcinolone 8 223 8 866 7 496 8 815 62 1 308 3 376 2 789 1 342 629 A01AD Other agents for local oral treatment 827 315 359 402 53 33 288 68 13 90 A01AD01 Epinephrine <5 <5 10 6 33 0 0 5 <5 9 A01AD02 Benzydamine 761 258 314 368 53 25 275 59 9 78 A01AD11 Various 1)62 56 35 28 68 8 13 <5 <5 2 A02 DRUGS FOR ACID RELATED DISORDERS 222 770 236 537 255 203 277 321 54 3 883 60 630 131 440 81 368 420 566 A02A ANTACIDS 4 147 4 474 4 587 4 495 45 75 1 048 1 610 1 762 4 631 A02AC Calcium compounds 1 233 1 284 1 395 1 410 35 9 220 529 652 912 A02AC01 Calcium carbonate 1)1 233 1 284 1 395 1 410 35 9 220 529 652 912 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 1 963 2 001 1 859 1 547 60 48 629 508 362 190 A02AD01 Ordinary salt combinations 1)1 963 2 001 1 859 1 547 60 48 629 508 362 190 A02AH Antacids with sodium bicarbonate 1)1 466 1 714 1 935 2 106 36 21 275 794 1 016 3 530 A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) 220 359 233 983 252 573 274 806 54 3 822 60 050 130 610 80 324 415 934 A02BA H 2-receptor antagonists 59 242 57 961 59 042 60 197 58 808 15 831 27 456 16 102 26 132 A02BA01 Cimetidine 11 683 10 177 8 509 6 274 58 35 1 344 2 962 1 933 3 510 A02BA02 Ranitidine1)40 683 41 382 44 649 50 333 58 753 13 780 22 808 12 992 15 489 A02BA03 Famotidine1)5 380 4 804 4 459 3 919 57 15 696 1 852 1 356 7 008 A02BA07 Ranitidine bismuth citrate 2 271 2 183 2 202 247 59 0 60 137 50 47 A02BA53 Famotidine, combinations1) 260 280 264 307 59 5 96 134 72 79 A02BB Prostaglandins 258 295 250 237 68 0 46 128 63 251 A02BB01 Misoprostol 258 295 250 237 68 0 46 128 63 251 A02BC Proton pump inhibitors 173 099 187 790 205 934 227 534 53 3 078 47 577 109 536 67 343 389 058 A02BC01 Omeprazole1)26 167 26 143 27 011 40 013 54 2 312 7 166 17 950 12 585 55 812 A02BC02 Pantoprazole 4 496 6 104 12 691 56 974 53 146 13 143 27 134 16 551 62 950 A02BC03 Lansoprazole 39 724 42 747 37 106 48 531 51 519 9 330 24 064 14 618 31 000 A02BC05 Esomeprazole 112 430 122 965 139 209 117 297 54 275 24 962 58 319 33 741 239 2963.4 T able - ATC group A - Alimentary tract and metabolism2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group A Rapport 2008 Folkehelseinstituttet 451 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.A02BX Other drugs for peptic ulcer and gastro-oesopha-geal reflux disease (GORD) 1 730 1 820 1 674 1 684 62 150 482 555 497 493 A02BX02 Sucralfate 499 456 439 378 57 7 77 164 130 286 A02BX13 Alginic acid 1)1 238 1 372 1 243 1 311 63 143 406 394 368 207 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 46 283 49 269 52 586 54 553 70 1 620 18 013 19 996 14 924 10 792 A03A DRUGS FOR FUNCTIONAL BOWEL DISORDERS 3 134 3 314 3 522 3 419 60 114 768 1 125 1 412 1 358 A03AA Synthetic anticholinergics, esters with tertiary amino group 7 6 10 34 79 0 18 10 6 25 A03AA04 Mebeverine 7 6 10 34 79 0 18 10 6 25 A03AB Synthetic anticholinergics, quaternary ammonium compounds 25 21 36 41 34 <5 12 18 10 103 A03AB02 Glycopyrronium 10 11 22 28 39 <5 <5 14 10 95 A03AB05 Propantheline 15 10 14 13 23 0 9 <5 0 8 A03AD Papaverine and derivatives 39 53 36 41 71 0 10 17 14 18 A03AD01 Papaverine 39 53 36 41 71 0 10 17 14 18 A03AE Drugs acting on serotonin receptors 7 9 21 19 89 <5 10 7 <5 69 A03AE02 Tegaserod 7 9 21 19 89 <5 10 7 <5 69 A03AX Other drugs for functional bowel disorders 3 056 3 229 3 426 3 289 59 112 720 1 074 1 383 1 143 A03AX13 Silicones 1)3 056 3 229 3 426 3 289 59 112 720 1 074 1 383 1 143 A03B BELLADONNA AND DERIVATIVES, PLAIN 3 143 3 159 2 489 1 305 58 7 489 590 219 938 A03BA Belladonna alkaloids, tertiary amines 2 999 2 995 2 269 1 050 56 5 402 464 179 764 A03BA01 Atropine 21 22 31 33 39 0 12 18 <5 22 A03BA03 Hyoscyamine 2 978 2 973 2 242 1 017 56 5 390 446 176 742 A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds 151 167 259 70 <5 88 128 41 174 A03BB01 Butylscopolamine 133 152 210 238 70 <5 77 120 39 148 A03BB02 Methylatropine 9 <5 0 0 - 0 0 0 0 0 A03BB03 Methylscopolamine 10 12 21 21 67 0 11 8 <5 26 A03C ANTISPASMODICS IN COMBINATION WITH PSYC-HOLEPTICS 29 15 19 30 57 0 <5 16 11 31 A03CA Synthetic anticholinergic agents in combination with psycholeptics 29 15 19 30 57 0 <5 16 11 31 A03CA02 Clidinium and psycholeptics 29 15 19 30 57 0 <5 16 11 31 A03F PROPULSIVES 40 709 43 526 47 356 50 464 71 1 500 16 902 18 548 13 514 8 466 A03FA Propulsives 40 709 43 526 47 356 50 464 71 1 500 16 902 18 548 13 514 8 466 A03FA01 Metoclopramide 40 553 43 388 47 212 50 329 71 1 455 16 883 18 502 13 489 7 764 A03FA02 Cisapride 167 151 146 133 65 46 24 44 19 633 A03FA03 Domperidone 16 16 24 35 60 <5 6 15 11 69 A04 ANTIEMETICS AND ANTINAUSEANTS 9 793 10 647 10 837 12 159 60 239 2 160 6 928 2 832 46 937 46 Rapport 2008 Folkehelseinstituttet1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age groupSales in 1000 NOK45-69 70 <15 15-44ATC group A A04A ANTIEMETICS AND ANTINAUSEANTS 9 793 10 647 10 837 12 159 60 239 2 160 6 928 2 832 46 937 A04AA Serotonin (5HT3) antagonists 7 733 8 505 9 243 9 709 59 159 1 218 5 800 2 532 44 622 A04AA01 Ondansetron 6 792 7 551 8 328 8 989 59 159 1 156 5 329 2 345 40 661 A04AA02 Granisetron <5 10 10 A04AA03 Tropisetron 1 267 1 345 1 241 1 041 58 0 99 698 244 3 592 A04AA05 Palonosetron 0 0 0 82 68 0 13 58 11 360 A04AD Other antiemetics 2 158 2 302 1 952 3 096 66 81 1 102 1 539 374 2 315 A04AD01 Scopolamine 2 115 2 217 1 596 2 444 63 80 930 1 112 322 578 A04AD05 Metopimazine 24 18 43 23 74 <5 12 A04AD12 Aprepitant 17 64 324 635 79 0 167 419 49 1 721 A05 BILE AND LIVER THERAPY 899 1 064 1 254 1 456 73 71 465 698 222 7 180 A05A BILE THERAPY 899 1 064 1 254 1 456 73 71 465 698 222 7 180 A05AA Bile acid preparations 886 1 051 1 247 1 444 73 71 462 695 216 7 173 A05AA02 Ursodeoxycholic acid 886 1 051 1 247 1 444 73 71 462 695 216 7 173 A05AX Other drugs for bile therapy 13 13 7 12 67 0 <5 <5 6 7 A06 LAXATIVES 25 874 23 457 23 662 26 295 54 1 597 3 566 8 612 12 520 12 262 A06A LAXATIVES 25 874 23 457 23 662 26 295 54 1 597 3 566 8 612 12 520 12 262 A06AA Softeners, emollients 82 103 79 88 51 35 6 21 26 32 A06AA01 Liquid paraffin 1)82 103 79 88 51 35 6 21 26 32 A06AB Contact laxatives 8 899 9 857 10 691 11 916 54 229 1 161 4 019 6 507 1 971 A06AB02 Bisacodyl1)3 342 3 443 3 612 3 829 55 45 434 1 112 2 238 511 A06AB06 Senna glycosides1)2 151 2 076 2 049 2 138 48 32 146 625 1 335 345 A06AB08 Sodium picosulfate1)4 178 5 189 5 965 7 071 54 155 660 2 723 3 533 1 105 A06AB20 Contact laxatives in combination 1)14 13 <5 11 73 0 0 1)17 10 80 0 <5 <5 5 2 A06AC Bulk producers 1 662 1 646 1 680 1 586 58 543 422 A06AC01 Ispaghula (psylla seeds)1)1 662 1 640 1 665 1 575 58 56 439 545 535 420 A06AC51 Ispaghula, combinations1)0 6 16 11 82 0 <5 <5 8 2 A06AD Osmotically acting laxatives 16 677 12 805 12 281 14 673 51 1 079 1 577 5 255 6 762 4 483 A06AD11 Lactulose 1)15 259 10 958 10 145 12 295 50 509 1 251 4 571 5 964 3 027 A06AD12 Lactitol 179 150 86 58 55 25 <5 14 15 42 A06AD17 Sodium phosphate1) 785 1 019 901 602 57 7 112 267 216 276 A06AD65 Macrogol, combinations1) 630 881 1 395 2 084 53 577 240 574 693 1 138 A06AG Enemas 4 143 4 272 4 309 4 451 49 435 991 1 436 1 589 5 354 A06AG02 Bisacodyl1)1 623 1 579 1 523 1 572 48 28 460 598 486 634 A06AG04 Glycerol1) 581 619 652 649 49 195 137 932 A06AG10 Docusate sodium, incl. combinations 1)1 052 1 111 1 154 1 137 48 75 214 386 462 1 525 A06AG11 Laurilsulfate, incl.combinations 1)1 209 1 307 1 324 1 475 50 160 266 435 614 1 263 A07 ANTIDIARRHEALS, INTESTINAL ANTIINFLAM - MATORY/ANTIINFECTIVE AGENTS 49 749 53 287 54 522 55 418 58 3 203 16 671 22 559 12 985 89 5802004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group A Rapport 2008 Folkehelseinstituttet 471 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. A07A INTESTINAL ANTIINFECTIVES 19 522 21 745 21 599 21 041 67 2 713 5 574 7 468 5 286 7 619 A07AA Antibiotics 19 522 21 745 21 599 21 041 67 2 713 5 574 7 468 5 286 7 619 A07AA02 Nystatin 19 450 21 635 21 448 20 886 67 2 711 5 523 7 423 5 229 7 157 A07AA06 Paromomycin <5 13 44 49 63 <5 32 14 <5 118 A07AA09 Vancomycin 78 106 113 122 63 <5 25 35 58 345 A07B INTESTINAL ADSORBENTS 103 103 121 133 53 25 48 37 23 14 A07BA Charcoal preparations 103 103 121 133 53 25 48 37 23 14 A07BA01 Medicinal charcoal1) 103 103 121 133 53 25 48 37 23 14 A07C ELECTROLYTES WITH CARBOHYDRATES 272 298 407 281 52 89 95 67 30 45 A07CA Oral rehydration salt formulations 1) 272 298 407 281 52 89 95 67 30 45 A07D ANTIPROPULSIVES 12 511 13 228 14 084 15 083 55 160 3 596 6 352 4 975 5 863 A07DA Antipropulsives 12 511 13 228 14 084 15 083 55 160 3 596 6 352 4 975 5 863 A07DA01 14 A07DA02 Opium 52 53 51 42 52 0 6 16 20 76 A07DA03 Loperamide1)12 472 13 197 14 056 15 014 55 160 3 577 6 327 4 950 5 761 A07DA53 Loperamide, combinations10 0 0 76 62 0 25 29 22 13 A07E INTESTINAL ANTI-INFLAM - MATORY AGENTS 18 811 19 472 19 924 20 613 51 233 7 859 9 440 3 081 75 998 A07EA Corticosteroids acting locally 3 857 3 873 4 093 4 408 57 36 1 817 1 908 647 12 042 A07EA01 Prednisolone 1 166 1 032 1 041 975 50 8 393 439 135 1 026 A07EA02 Hydrocortisone 1 049 1 066 1 078 1 160 56 <5 484 513 160 1 302 A07EA06 Budesonide 1 880 1 987 2 176 2 480 60 28 1 034 1 046 372 9 714 A07EB Antiallergic agents, excl. corticosteroids 94 72 26 14 29 <5 447 A07EB01 Cromoglicic acid 94 72 69 71 65 26 14 29 <5 447 A07EC Aminosalicylic acid and similar agents 17 258 17 822 18 078 18 437 50 199 7 085 8 478 2 675 63 509 A07EC01 Sulfasalazine 7 163 7 043 6 854 6 610 52 10 1 803 3 606 1 191 9 293 A07EC02 Mesalazine 9 757 10 378 10 754 11 299 48 190 5 025 4 676 1 408 48 366 A07EC03 Olsalazine 522 494 476 49 <5 179 213 67 1 814 A07EC04 Balsalazide 700 761 862 890 46 0 453 335 102 4 036 A07F ANTIDIARRHEAL MICROORGANISMS 0 17 66 63 63 0 5 21 37 42 A07FA Antidiarrheal microorganisms 0 17 66 63 63 0 5 21 37 42 A07FA02 Saccharomyces boulardii 0 17 66 63 63 0 5 21 37 42 A08 ANTIOBESITY PREPA-RATIONS, EXCL. DIET PRODUCTS 35 772 36 481 33 419 36 773 79 15 18 036 17 132 1 590 86 880 A08A ANTIOBESITY PREPA-RATIONS, EXCL. DIET PRODUCTS 35 772 36 481 33 419 36 773 79 15 18 036 17 132 1 590 86 880 A08AA Centrally acting antiobesity products 16 747 17 684 16 358 17 852 83 12 10 896 6 558 386 35 981 A08AA10 Sibutramine 16 747 17 684 16 358 17 852 83 12 10 896 6 558 386 35 981 A08AB Peripherally acting antiobesity products 21 398 20 920 18 083 16 707 78 <5 6 642 8 996 1 065 35 611 A08AB01 Orlistat 21 398 20 920 18 083 16 707 78 <5 6 642 8 996 1 065 35 611 A08AX Other antiobesity drugs 0 0 1 033 5 240 70 0 2 046 2 972 222 15 2882004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group A 48 Rapport 2008 Folkehelseinstituttet1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.A08AX01 Rimonabant 0 0 1 033 5 240 70 0 2 046 2 972 222 15 288 A09 DIGESTIVES, INCL. ENZYMES 5 074 5 136 5 173 5 026 57 138 727 2 383 1 778 31 438 A09A DIGESTIVES, INCL. ENZYMES 5 074 5 136 5 173 5 026 57 138 727 2 383 1 778 31 438 A09AA Enzyme preparations 4 976 5 058 5 120 4 961 57 123 722 2 367 1 749 31 374 A09AA02 Multienzymes (lipase, protease etc.) 1)4 976 5 058 5 120 4 961 57 123 722 2 367 1 749 31 374 A09AB Acid preparations 107 86 78 76 61 15 8 20 33 64 A09AB01 Glutamic acid hydrochloride1)102 74 71 58 64 0 7 19 32 24 A09AB03 Hydrochloric acid1)5 12 0 A09AB04 Citric acid 0 0 0 15 47 15 0 0 0 40 A10 DRUGS USED IN DIABETES 110 749 117 533 124 649 131 957 46 1 749 20 926 63 915 45 367 441 528 A10A INSULINS AND ANALOGUES 45 650 47 074 48 123 49 342 44 1 726 13 000 21 477 13 139 320 444 A10AB Insulins and analogues for injection, fast-acting 27 274 28 720 29 763 30 984 43 1 710 11 730 13 019 4 525 112 032 A10AB01 Insulin (human) 9 920 8 787 4 557 2 536 41 102 680 1 195 559 6 288 A10AB03 Insulin (pork) 35 28 16 <5 67 0 <5 <5 <5 5 A10AB04 Insulin lispro 8 903 8 779 8 749 8 628 43 229 4 505 3 299 595 36 702 A10AB05 Insulin aspart 11 042 13 379 19 281 21 078 44 1 512 7 102 8 977 3 487 69 036 A10AB06 Insulin glulisine 0 0 0 <5 100 0 <5 0 0 2 A10AC Insulins and analogues for injection, intermediate- acting 37 409 36 967 35 488 34 018 44 991 7 885 15 320 9 822 116 012 A10AC01 Insulin (human) 37 363 36 929 35 479 34 013 44 991 7 884 15 318 9 820 115 996 A10AC03 Insulin (pork) 50 44 19 7 57 0 <5 <5 <5 17 A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting 10 476 10 332 10 379 10 246 46 47 1 109 4 909 4 181 49 205 A10AD01 Insulin (human) 6 388 4 802 939 43 37 0 5 20 18 147 A10AD03 Insulin (pork) <5 <5 0 0 - 0 0 0 0 0 A10AD04 Insulin lispro 928 828 803 763 42 5 145 389 224 3 880 A10AD05 Insulin aspart 4 136 7 766 9 389 9 475 46 43 964 4 520 3 948 45 178 A10AE Insulins and analogues for injection, long-acting 1 561 3 625 6 221 8 139 47 528 3 848 3 114 649 43 194 A10AE01 Insulin (human) 113 69 0 0 - 0 0 0 0 0 A10AE04 Insulin glargine 1 306 2 418 4 025 5 134 48 251 2 505 1 968 410 26 249 A10AE05 Insulin detemir 158 1 206 2 300 3 100 47 283 1 383 1 185 249 16 946 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 78 676 85 016 91 934 98 907 47 28 9 267 51 801 37 811 121 084 A10BA Biguanides 59 585 66 683 74 120 81 197 47 17 8 500 44 732 27 948 45 954 A10BA02 Metformin 59 585 66 683 74 120 81 197 47 17 8 500 44 732 27 948 45 954 A10BB Sulfonamides, urea derivatives 43 445 44 293 45 392 46 452 43 10 2 489 22 554 21 399 27 622 A10BB01 Glibenclamide 9 063 2 924 2 377 2 127 45 7 72 856 1 192 1 185 A10BB02 Chlorpropamide <5 Glipizide 7 718 7 000 6 520 6 093 44 <5 193 2 539 3 360 3 500 A10BB12 Glimepiride 32 566 35 073 36 985 38 628 43 <5 2 244 19 347 17 034 22 934 A10BD Combinations of oral blood glucose lowering drugs0 399 1 940 2 680 40 <5 216 1 756 707 13 9602004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group A Rapport 2008 Folkehelseinstituttet 49A10BD03 Metformin and rosiglitazone 0 399 1 940 2 680 40 <5 216 1 756 707 13 960 A10BF Alpha glucosidase inhibitors1 641 1 379 1 232 1 101 47 0 65 534 502 1 847 A10BF01 Acarbose 1 641 1 379 1 232 1 101 47 0 65 534 502 1 847 A10BG Thiazolidinediones 2 449 5 229 6 436 6 461 43 <5 523 4 026 1 911 30 178 A10BG02 Rosiglitazone 1 981 4 263 5 053 5 007 43 <5 365 3 068 1 573 22 496 A10BG03 Pioglitazone 495 1 027 1 430 1 516 42 0 164 999 353 7 682 A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors0 0 0 143 43 0 14 107 22 212 A10BH01 Sitagliptin 0 0 0 143 43 0 14 107 22 212 A10BX Other blood glucose lowering drugs, excl. insulins 644 538 464 530 40 <5 59 310 160 1 311 A10BX02 Repaglinide 631 527 455 435 38 <5 33 248 153 929 A10BX03 Nateglinide 14 12 9 12 33 0 <5 7 <5 28 A10BX04 Exenatide 0 0 0 85 49 0 23 57 5 354 A11 VITAMINS 2)51 137 63 761 66 735 75 631 62 449 16 558 26 522 32 102 40 978 A11A MUL TIVITAMINS, COMBINATIONS24 13 0 0 - 0 0 0 0 0 A11AA Multivitamins with minerals 24 13 0 0 - 0 0 0 0 0 A11AA01 Multivitamins and iron 1)24 13 0 0 - 0 0 0 0 0 A11B MUL TIVITAMINS, PLAIN 32 31 25 31 61 19 12 0 0 56 A11BA Multivitamins, plain 32 31 25 31 61 19 12 0 0 56 A11C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO4 865 5 050 5 862 6 738 53 121 1 622 2 757 2 238 8 661 A11CA Vitamin A, plain 23 24 24 31 81 <5 12 15 <5 79 A11CA01 Retinol (vit A) 18 17 15 18 78 0 8 9 <5 7 A11CA02 Betacarotene 5 7 9 13 85 <5 <5 6 0 72 A11CC Vitamin D and analogues 4 845 5 028 5 840 6 710 53 118 1 611 2 744 2 237 8 582 A11CC01 Ergocalciferol 741 767 1 098 1 482 73 11 722 600 149 1 137 A11CC02 Dihydrotachysterol <5 <5 0 0 - 0 0 0 0 0 A11CC03 Alfacalcidol 2 748 2 848 3 033 3 186 47 100 494 1 269 1 323 4 729 A11CC04 Calcitriol 1 398 1 511 1 657 1 907 44 6 298 828 775 2 667 A11CC05 Colecalciferol 0 0 93 220 80 <5 116 93 10 50 A11D VITAMIN B 1, PLAIN AND IN COMBINATION WITH VITAMIN B 6 AND B12 482 555 573 624 31 <5 73 404 145 368 A11DA Vitamin B1, plain 482 555 573 624 31 <5 73 404 145 368 B1)1) 482 555 573 624 145 368 A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS42 967 55 571 57 802 65 838 62 228 14 496 23 072 28 042 30 535 A11EA Vitamin B-complex, plain1)42 577 55 060 57 208 65 072 63 196 14 399 22 776 27 701 29 928 A11EX Vitamin B-complex, other combinations 393 521 610 787 36 32 98 300 357 607 A11G ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS3 021 2 984 3 043 3 306 70 <5 261 647 2 394 694 A11GA Ascorbic acid (vitamin C), plain3 021 2 984 3 043 3 306 70 <5 261 647 2 394 694 A11GA01 Ascorbic acid (vit C) 1)3 021 2 984 3 043 3 306 70 <5 261 647 2 394 694 A11H OTHER PLAIN VITAMIN PREPARATIONS1 241 1 144 1 262 1 246 65 82 371 444 349 581 A11HA Other plain vitamin preparations 1 241 1 144 1 262 1 246 65 82 371 444 349 581 A11HA01 Nicotinamide 1)11 14 21 14 79 <5 <5 7 <5 8 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2 Includes prescription sales only for medicinal products with an approved marketing authorisation. A lot of products belonging to the vitamins are also sold outside pharmacies. 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group A 50 Rapport 2008 Folkehelseinstituttet1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. A11HA02 Pyridoxine (vit B6)1) 399 466 554 571 73 24 219 230 98 275 A11HA03 Tocopherol (vit E)1) 843 672 695 650 58 56 142 203 249 295 A11HA04 Riboflavin (vit B2) 0 0 0 14 100 0 7 6 <5 4 A11J OTHER VITAMIN PRODUCTS, COMBINATIONS 46 44 37 50 48 38 11 <5 0 83 A11JA Combinations of vitamins 42 41 37 50 48 38 11 <5 0 83 A11JB Vitamins with minerals <5 <5 0 0 - 0 0 0 0 0 A12 MINERAL SUPPLEMENTS 52 536 62 480 69 316 76 549 79 305 4 722 27 881 43 641 51 299 A12A CALCIUM 35 462 44 151 50 058 56 456 84 121 3 585 21 703 31 047 31 808 A12AA Calcium 1 402 1 482 1 499 1 449 73 48 183 513 705 947 A12AA02 Calcium glubionate 5 5 5 0 <5 A12AA04 Calcium carbonate1) 393 397 390 371 <5 29 86 252 112 A12AA06 Calcium lactate gluconate1) 990 1 087 1 100 1 078 70 42 156 425 455 818 A12AA12 Calcium acetate anhydrous 28 9 18 11 45 0 0 7 <5 16 A12AX Calcium, combinations with other drugs1)34 207 42 852 48 744 55 179 84 73 3 418 21 248 30 440 30 861 A12B POTASSIUM 16 299 17 530 18 545 19 731 67 85 893 5 767 12 986 17 778 A12BA Potassium 16 299 17 530 18 545 19 731 67 85 893 5 767 12 986 17 778 A12BA01 Potassium chloride1)15 164 16 241 17 132 18 208 67 26 746 5 314 12 122 15 405 A12BA02 Potassium citrate1)1 320 1 501 1 650 1 798 66 63 167 527 1 041 2 332 A12BA30 5 <5 41 A12C OTHER MINERAL SUPPLEMENTS 2 662 3 031 3 404 3 344 61 101 404 1 200 1 639 1 557 A12CA Sodium 144 210 283 379 68 11 22 123 223 178 A12CA01 Sodium chloride 1) 144 210 283 379 68 11 22 123 223 178 A12CB Zinc 764 799 878 904 66 50 176 259 419 277 A12CB01 Zinc sulfate 764 799 878 904 66 50 176 259 419 277 A12CC Magnesium 1 769 2 050 2 272 2 095 58 44 208 833 1 010 1 101 A12CC04 Magnesium citrate 25 19 17 24 54 <5 <5 21 A12CC30 Magnesium (different salts in combination) 1)1 748 2 036 2 262 2 076 58 43 207 824 1 002 1 081 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 949 883 803 710 78 <5 168 457 84 656 A14A ANABOLIC STEROIDS 949 883 803 710 78 <5 168 457 84 656 A14AA Androstan derivatives 503 A14AA04 Metenolone <5 0 0 0 - 0 0 0 0 0 A14AA07 Prasterone 842 763 684 593 85 13 A14AB Estren derivatives 108 119 119 117 40 0 36 37 44 153 A14AB01 Nandrolone 108 119 119 117 40 0 36 37 44 153 A16 OTHER ALIMENTARY TRACT AND METABOLISM PROD - UCTS 83 113 158 197 53 64 63 60 10 96 496 A16A OTHER ALIMENTARY TRACT AND METABOLISM PROD - UCTS 83 113 158 197 53 64 63 60 10 96 496 A16AA Amino acids and derivatives 46 48 63 73 52 49 15 6 <5 1 938 A16AA01 Levocarnitine 40 41 52 56 52 A16AA04 Mercaptamine 6 6 7 8 50 6 <5 0 0 848Rapport 2008 Folkehelseinstituttet 512004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group A 6 83 <5 <5 <5 0 329 A16AB Enzymes 25 33 40 44 36 <5 19 19 <5 85 989 A16AB02 Imiglucerase 7 10 8 9 44 0 7 <5 0 16 432 A16AB03 Agalsidase alfa 10 12 17 17 29 <5 8 7 <5 36 031 A16AB04 Agalsidase beta 8 11 16 19 42 <5 <5 10 <5 33 526 A16AX Various alimentary tract and metabolism products 12 32 56 80 63 12 29 35 <5 8 569 A16AX01 Tioctic acid 12 20 44 66 73 0 27 35 <5 57 A16AX03 Sodium phenylbutyrate 0 <5 0 0 0 163 A16AX04 Nitisinone 0 11 11 11 18 10 <5 0 0 8 344 A16AX05 Zinc acetate 0 0 0 <5 0 <5 <5 0 0 6 52 Rapport 2008 FolkehelseinstituttetB01 ANTITHROMBOTIC AGENTS 378 616 398 759 418 397 437 804 45 346 17 203 186 797 233 458 357 396 B01AANTITHROMBOTIC AGENTS 378 616 398 759 418 397 437 804 45 346 17 203 186 797 233 458 357 396 B01AA Vitamin K antagonists 72 848 76 021 79 146 82 041 40 72 3 364 25 374 53 231 68 238 B01AA01 Dicoumarol 54 62 67 69 46 0 9 42 18 304 B01AA02 Phenindione 52 47 43 45 62 0 6 21 18 207 B01AA03 Warfarin 72 755 75 920 79 044 81 939 40 72 3 354 25 316 53 197 67 728 B01AB Heparin group 18 478 20 141 21 801 25 295 60 135 5 518 10 810 8 832 51 710 B01AB01 Heparin 554 647 649 746 58 106 164 344 132 1 067 B01AB02 Antithrombin III <5 0 0 0 - 0 0 0 0 0 B01AB04 Dalteparin 9 847 10 261 10 753 13 308 62 19 2 883 5 797 4 609 29 772 B01AB05 Enoxaparin 8 309 9 505 10 699 11 568 58 12 2 542 4 832 4 182 20 871 B01AB10 Tinzaparin <5 0 <5 0 - 0 0 B01AC Platelet aggregation inhibitors excl. heparin 304 778 320 695 337 653 353 116 45 152 9 691 159 032 184 241 237 397 B01AC04 Clopidogrel 17 973 21 604 22 541 23 283 33 <5 867 12 068 10 345 94 818 B01AC05 Ticlopidine 520 465 454 432 42 0 10 201 221 1 317 B01AC06 Acetylsalicylic acid 297 454 312 787 329 595 344 947 45 150 9 570 155 764 179 463 103 378 B01AC07 Dipyridamole 10 971 11 701 12 867 15 539 43 0 276 5 687 9 576 18 074 B01AC09 Epoprostenol 8 11 9 7 57 <5 <5 <5 0 11 437 B01AC11 Iloprost 9 6 60 0 <5 <5 <5 1 853 B01AC21 Treprostinil 0 0 0 8 75 0 5 <5 0 4 723 B01AC30 Combinations 1 637 1 488 1 440 1 331 45 0 31 531 769 1 797 B01AE Direct thrombin inhibitors <5 758 166 0 - 0 0 0 0 0 B01AE05 Ximelagatran <5 758 166 0 - 0 0 0 0 0 B01AX Other antithrombotic agents<5 <5 <5 <5 <5 5 <5 51 B02 ANTIHEMORRHAGICS 11 656 12 012 11 795 12 222 93 230 5 969 5 491 532 105 285 B02A ANTIFIBRINOLYTICS 11 372 11 711 11 501 11 870 94 138 5 812 5 432 488 14 160 B02AA Amino acids 11 353 11 689 11 480 11 846 94 137 5 797 5 425 487 4 208 B02AA02 Tranexamic acid 11 353 11 689 11 480 11 846 94 137 5 797 5 425 487 4 208 B02AB Proteinase inhibitors 23 28 30 33 67 <5 22 27 29 32 66 <5 19 10 <5 9 257 B02B VITAMIN K AND OTHER HEMOSTATICS 308 330 348 396 38 99 176 76 45 91 125 B02BA Vitamin K 238 231 195 224 62 65 83 35 41 150 B02BA01 Phytomenadione 238 231 195 224 62 65 83 35 41 150 B02BD Blood coagulation factors70 99 153 172 8 34 93 41 <5 90 975 B02BD02 Coagulation factor VIII 55 71 115 122 2 22 68 31 <5 64 857 B02BD03 Factor VIII inhibitor 10 564 B02BD04 Coagulation factor IX 0 8 17 26 0 9 13 <5 <5 9 491 B02BD06 Von Willebrand factor and coagulation factor VIII in combination<5 9 7 8 75 0 5 <5 0 4 658 B02BD08 Eptacog alfa (activated) 6 7 6 9 44 <5 5 <5 0 1 405 B03 ANTIANEMIC PREPARATIONS 102 404 108 357 108 856 112 774 64 1 615 21 135 37 780 52 244 132 865 B03A IRON PREPARATIONS 15 952 16 709 17 565 18 675 67 1 117 4 344 3 788 9 424 4 2892004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group B 3.5 T able - ATC group B - Blood and bloodforming organsRapport 2008 Folkehelseinstituttet 532004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group B B03AA Iron bivalent, oral preparations 14 754 15 629 16 453 17 488 65 1 112 3 781 3 385 9 208 2 719 B03AA01 Ferrous glycine sulfate1) 674 1 260 1 412 1 708 70 41 519 439 709 560 B03AA02 Ferrous fumarate1)1 132 1 233 1 292 1 205 51 853 154 56 140 158 B03AA06 Ferrous succinate 0 <5 0 0 - 0 0 0 0 0 B03AA07 Ferrous sulfate1)13 034 13 222 13 825 14 687 66 224 3 123 2 912 8 428 2 001 B03AC Iron trivalent, parenteral preparations 1 266 1 143 1 181 1 255 83 6 581 425 243 1 570 B03AC02 Saccharated iron oxide 297 286 301 302 72 <5 133 106 61 503 B03AC03 Iron-sorbitol-citric acid complex <5 0 0 0 - 0 0 0 0 0 B03AC06 Ferric oxide dextran complex 981 864 886 963 87 <5 453 323 183 1 066 B03AD Iron in combination with folic acid <5 0 0 0 - 0 0 0 0 0 B03AD03 Ferrous sulfate <5 0 0 0 - 0 0 0 0 0 B03B VITAMIN B 12 AND FOLIC ACID 87 544 92 791 92 279 95 290 65 541 17 254 33 702 43 793 25 098 B03BA Vitamin B12 (cyanocoba- lamin and analogues) 65 811 68 075 65 996 66 966 66 72 11 252 21 340 34 302 15 988 B03BA01 Cyanocobalamin 5 494 5 743 5 819 5 378 68 16 1 478 1 817 2 067 1 209 B03BA02 Cyanocobalamin tannin complex 35 752 36 735 34 861 35 654 66 22 5 904 11 252 18 476 8 603 B03BA03 Hydroxocobalamin 26 572 27 479 27 325 27 724 66 38 4 276 8 845 14 565 6 078 B03BA05 Mecobalamin 7 19 19 26 85 0 13 10 <5 98 B03BB Folic acid and derivatives 27 549 30 968 31 750 33 575 62 480 6 670 13 771 12 654 9 109 B03BB01 Folic acid1)27 549 30 968 31 750 33 575 62 480 6 670 13 771 12 654 9 109 B03X OTHER ANTIANEMIC PREPARATIONS 2 655 2 957 3 318 3 498 41 14 397 1 267 1 820 103 478 B03XA Other antianemic preparations 2 655 2 957 3 318 3 498 41 14 397 1 267 1 820 103 478 B03XA01 Erythropoietin 1 306 1 011 902 867 42 5 83 294 485 25 681 B03XA02 Darbepoetin alfa 1 449 2 013 2 473 2 670 41 10 320 988 1 352 77 743 B03XA03 Methoxy polyethylene glycol-epoetin beta 0 0 0 7 43 0 <5 0 5 54 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 54 Rapport 2008 FolkehelseinstituttetC01 CARDIAC THERAPY 140 813 136 852 134 588 130 266 49 2 051 5 638 40 369 82 208 80 538 C01A CARDIAC GLYCOSIDES 31 381 30 391 29 457 28 116 50 43 226 4 753 23 094 4 802 C01AA Digitalis glycosides 31 381 30 391 29 457 28 116 50 43 226 4 753 23 094 4 802 C01AA04 Digitoxin 29 883 28 973 28 140 26 912 50 <5 190 4 497 22 224 4 577 C01AA05 Digoxin 1 522 1 442 1 342 1 223 47 42 36 260 885 226 C01B ANTIARRHYTHMICS, CLASS I AND III 7 381 8 020 8 536 9 187 36 32 484 4 778 3 893 18 683 C01BA Antiarrhythmics, class Ia 276 253 228 202 49 <5 <5 81 116 516 C01BA01 Quinidine 23 20 18 9 67 0 0 <5 8 25 C01BA03 Disopyramide 254 233 210 193 <5 80 108 491 C01BB Antiarrhythmics, class Ib 36 46 31 33 45 0 10 16 7 108 C01BB02 Mexiletine 36 46 31 33 45 0 10 16 7 108 C01BC Antiarrhythmics, class Ic 3 950 4 412 4 708 5 112 40 27 377 3 191 1 517 13 948 C01BC03 Propafenone <5 <5 3 C01BC04 Flecainide 3 946 4 408 4 707 5 111 40 27 377 3 190 1 517 13 945 C01BD Antiarrhythmics, class III 3 223 3 433 3 696 3 964 30 <5 102 1 577 2 281 4 111 C01BD01 Amiodarone 3 223 3 433 3 696 3 964 30 <5 102 1 577 2 281 4 111 C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES 7 622 7 936 9 679 9 468 59 1 977 3 520 3 326 645 6 101 C01CA Adrenergic and dopaminergic agents 7 622 7 936 9 679 9 468 59 1 977 3 520 3 326 645 6 101 C01CA01 Etilefrine 381 185 148 131 64 0 33 49 49 224 C01CA17 Midodrine 0 7 10 18 61 0 12 <5 <5 99 C01CA24 Epinephrine 7 243 7 745 9 524 9 321 59 1 977 3 475 3 275 594 5 778 C01D VASODILATORS USED IN CARDIAC DISEASES 104 396 99 900 95 762 91 750 49 0 1 418 28 887 61 445 50 689 C01DA Organic nitrates 104 396 99 900 95 762 91 750 49 0 1 418 28 887 61 445 50 689 C01DA02 Glyceryl trinitrate 79 759 76 664 73 614 70 657 48 0 1 346 24 878 44 433 13 860 C01DA08 Isosorbide dinitrate 6 592 5 482 4 591 3 818 56 0 10 536 3 272 3 314 C01DA14 Isosorbide mononitrate 47 598 44 899 42 496 40 167 51 0 166 8 194 31 807 33 515 C01E OTHER CARDIAC PREPARATIONS 56 49 99 146 66 <5 42 80 23 262 C01EB Other cardiac preparations 56 49 99 146 66 <5 42 80 23 262 C01EB09 Ubidecarenone 48 43 92 133 67 <5 38 72 22 245 C01EB15 Trimetazidine 8 6 7 13 62 0 <5 8 <5 16 C02 ANTIHYPERTENSIVES 26 570 19 125 17 921 17 294 30 12 922 7 915 8 445 55 517 C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING 6 310 6 264 6 563 6 876 47 <5 696 3 668 2 509 9 874 C02AB Methyldopa 1 284 1 166 1 154 1 131 70 0 364 309 458 816 C02AB01 Methyldopa (levorotatory) 1 284 1 166 1 154 1 131 70 0 364 309 458 816 C02AC Imidazoline receptor agonists 5 089 5 155 5 465 5 813 43 <5 338 3 398 2 074 9 058 C02AC01 Clonidine 50 68 74 73 41 <5 34 33 <5 132 C02AC05 Moxonidine 5 039 5 087 5 393 5 741 43 0 304 3 366 2 071 8 926 C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING 20 560 13 002 11 497 10 575 18 0 227 4 393 5 955 26 349 C02CA Alpha-adrenoreceptor antagonists 20 560 13 002 11 497 10 575 18 0 227 4 393 5 955 26 349 C02CA04 Doxazosin 20 560 13 002 11 497 10 575 18 0 227 4 393 5 955 26 3492004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group C3.6 T able - group C - Cardiovascular systemRapport 2008 Folkehelseinstituttet 55C02D ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON 264 298 320 339 36 0 20 154 165 441 C02DB Hydrazinophthalazine derivatives 235 263 283 302 38 0 13 127 162 213 C02DB02 Hydralazine 235 263 283 302 38 0 13 127 162 213 C02DC Pyrimidine derivatives 30 36 37 40 23 0 9 28 <5 229 C02DC01 Minoxidil 30 36 37 40 23 0 9 28 <5 229 C02K OTHER ANTIHYPER- TENSIVES 89 98 94 89 70 9 21 48 11 18 852 C02KD Serotonin antagonists 43 37 24 21 90 0 5 15 <5 531 C02KD01 Ketanserin 43 37 24 21 90 0 5 15 <5 531 C02KX Other antihypertensives 47 64 72 69 64 9 17 33 10 18 322 C02KX01 Bosentan 47 64 72 69 64 9 17 33 10 18 322 C03 DIURETICS 193 506 204 734 218 208 225 126 62 197 11 315 85 310 128 304 82 593 C03A LOW-CEILING DIURETICS, THIAZIDES 33 463 43 334 53 817 61 857 60 11 4 074 32 423 25 349 22 267 C03AA Thiazides, plain 20 657 26 234 33 181 38 189 58 6 2 716 20 606 14 861 11 218 C03AA01 Bendroflumethiazide 13 001 17 022 22 562 26 164 58 <5 1 957 14 125 10 081 6 921 C03AA03 Hydrochlorothiazide 7 719 9 283 10 701 12 096 58 5 766 6 516 4 809 4 297 C03AB Thiazides and potassium in combination 13 426 17 922 21 623 24 862 63 5 1 433 12 431 10 993 11 049 C03AB01 Bendroflumethiazide and potassium 13 426 17 922 21 623 24 862 63 5 1 433 12 431 10 993 11 049 C03B LOW-CEILING DIURETICS, <5 <5 19 C03BA Sulfonamides, plain 7 <5 19 0 C03C HIGH-CEILING DIURETICS 128 119 128 289 129 779 128 564 62 174 5 627 36 354 86 409 42 739 C03CA Sulfonamides, plain 127 700 127 859 129 605 128 564 62 174 5 627 36 354 86 409 42 739 C03CA01 Furosemide 115 698 112 574 110 773 106 945 63 173 5 075 31 256 70 441 24 840 C03CA02 Bumetanide 15 898 19 808 23 649 26 363 53 <5 650 6 065 647 17 884 C03CA04 Torasemide <5 <5 Sulfonamides and potas-sium in combination 590 622 <5 33 0 0 <5 <5 0 C03CB02 Bumetanide and potassium 590 622 0 <5 <5 0 C03D POTASSIUM-SPARING AGENTS15 493 16 017 16 416 16 805 52 22 692 5 806 10 285 10 572 C03DA Aldosterone antagonists 15 469 15 995 16 401 16 792 52 22 692 5 797 10 281 10 495 C03DA01 Spironolactone 15 458 15 898 16 142 16 386 53 22 664 5 569 10 131 7 347 C03DA02 Potassium canrenoate 0 0 0 <5 100 0 0 0 <5 1 C03DA04 Eplerenone 24 167 321 453 14 0 29 260 164 3 148 C03DB Other potassium-sparing agents 28 28 17 16 6 0 0 11 5 77 C03DB01 Amiloride 28 28 17 16 6 0 0 11 5 77 C03E DIURETICS AND POTAS - SIUM-SPARING AGENTS IN COMBINATION 33 740 34 745 36 325 36 308 67 8 1 424 16 167 18 709 6 996 C03EA Low-ceiling diuretics and potassium-sparing agents 33 740 34 745 36 325 36 308 67 8 1 424 16 167 18 709 6 996 C03EA01 Hydrochlorothiazide and potassium-sparing agents 33 740 34 745 36 325 36 308 67 8 1 424 16 167 18 709 6 9962004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group C 56 Rapport 2008 Folkehelseinstituttet1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.C04 PERIPHERAL VASODILATORS 2 378 2 100 1 825 1 718 49 0 38 411 1 269 1 825 C04A PERIPHERAL VASODILATORS 2 378 2 100 1 825 1 718 49 0 38 411 1 269 1 825 C04AC Nicotinic acid and derivatives <5 <5 0 0 - 0 0 0 0 0 C04AC01 Nicotinic acid <5 <5 0 0 - 0 0 0 0 0 C04AD Purine derivatives 2 371 2 088 1 819 1 715 49 0 37 409 1 269 1 804 C04AD03 Pentoxifylline 2 371 2 088 1 819 1 715 49 0 37 409 1 269 1 804 C04AX Other peripheral vasodilators6 11 0 22 C04AX01 Cyclandelate 0 <5 <5 0 - 0 0 0 0 0 C04AX02 Phenoxybenzamine 6 10 <5 <5 67 0 <5 <5 0 22 C05 VASOPROTECTIVES 52 342 52 760 54 943 54 296 57 706 20 996 22 115 10 479 8 019 C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE 46 454 47 032 48 900 48 807 56 658 20 010 19 879 8 260 6 789 C05AA Corticosteroids 46 008 46 518 48 225 48 009 56 641 19 676 19 581 8 111 6 242 C05AA01 Hydrocortisone 1)14 729 14 399 14 664 11 922 53 271 4 517 5 088 2 046 2 198 C05AA04 Prednisolone1)33 166 33 617 35 196 38 314 57 389 16 050 15 432 6 443 4 043 C05AE Muscle relaxants 243 291 440 662 52 8 303 276 75 374 C05AE01 Glyceryl trinitrate 243 291 440 662 52 8 303 276 75 374 C05AX Other agents for treat-ment of hemorrhoids and anal fissures for topical use 480 565 805 993 38 11 384 414 184 173 C05AX03 Other preparations, combinations 1) 480 559 783 974 38 11 375 405 183 134 C05B ANTIVARICOSE THERAPY 6 117 5 948 6 255 5 655 70 48 1 025 2 295 2 287 1 231 C05BA Heparins or heparinoids for topical use 6 112 5 946 6 249 5 646 70 48 1 021 2 290 2 287 1 222 C05BA01 Organo-heparinoid 1)6 085 5 922 6 225 5 619 70 48 1 017 2 276 2 278 582 C05BA04 Pentosan polysulfate sodium27 24 25 27 96 0 <5 14 9 640 C05BB Sclerosing agents for local injection 5 <5 6 9 78 0 <5 5 0 9 C05BB02 Polidocanol 5 <5 6 9 78 0 <5 5 0 9 C07 BETA BLOCKING AGENTS 309 758 322 256 334 495 343 715 50 365 18 759 158 441 166 150 238 026 C07A BETA BLOCKING AGENTS 307 736 318 880 329 971 338 374 50 365 18 306 155 137 164 566 233 701 C07AA Beta blocking agents, non-selective 33 164 30 743 29 263 28 163 57 203 4 033 12 061 11 866 17 302 C07AA03 Pindolol 46 40 38 35 63 0 <5 14 17 83 C07AA05 Propranolol 17 428 16 069 15 955 15 986 64 198 3 627 7 550 4 611 8 266 C07AA06 Timolol 2 134 1 847 1 625 1 463 55 <5 152 602 706 1 134 C07AA07 Sotalol 14 003 12 908 11 730 10 744 46 <5 253 3 926 6 563 7 799 C07AA12 Nadolol 6 6 5 8 63 <5 5 <5 0 20 C07AB Beta blocking agents, selective 256 105 268 068 280 610 290 437 50 153 12 551 132 982 144 751 193 308 C07AB02 Metoprolol 189 286 209 280 224 281 235 281 49 122 10 165 108 285 116 709 171 113 C07AB03 Atenolol 67 324 57 960 51 204 46 630 57 28 1 950 20 708 23 944 14 160 C07AB07 Bisoprolol 3 459 5 913 8 799 12 009 47 <5 576 5 539 5 890 8 034 C07AG Alpha and beta blocking agents 25 536 25 594 25 222 24 755 46 20 2 004 12 318 10 413 23 0912004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group CRapport 2008 Folkehelseinstituttet 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group C C07AG01 Labetalol 1 944 1 973 2 033 2 157 74 <5 1 070 602 483 2 247 C07AG02 Carvedilol 23 629 23 650 23 215 22 633 43 18 942 11 733 9 940 20 844 C07B BETA BLOCKING AGENTS AND THIAZIDES2 520 4 035 5 092 5 873 54 0 481 3 618 1 774 4 324 C07BB Beta blocking agents, selective, and thiazides2 520 4 035 5 092 5 873 54 0 481 3 618 1 774 4 324 C07BB07 Bisoprolol and thiazides 2 520 4 035 5 092 5 873 54 0 481 3 618 1 774 4 324 C08 CALCIUM CHANNEL BLOCKERS 180 338 186 466 193 563 200 853 50 48 7 580 93 716 99 509 191 238 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS 150 318 158 110 166 923 175 988 49 39 6 778 84 671 84 500 162 645 C08CA Dihydropyridine derivatives 150 318 158 110 166 923 175 988 49 39 6 778 84 671 84 500 162 645 C08CA01 Amlodipine 103 523 106 736 109 210 111 161 47 5 3 568 53 125 54 463 70 016 C08CA02 Felodipine 19 311 18 854 18 312 17 747 52 <5 435 7 963 9 348 15 764 C08CA03 Isradipine 765 766 742 693 54 0 28 313 352 1 360 C08CA05 Nifedipine 22 208 23 414 24 842 26 438 49 34 1 890 12 604 11 910 40 876 C08CA06 Nimodipine 33 41 30 35 57 0 7 22 6 31 C08CA13 Lercanidipine 6 690 10 966 16 904 23 451 52 0 1 014 12 376 10 061 34 598 C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS 31 536 29 773 28 026 26 221 55 9 821 9 577 15 814 28 592 C08DA Phenylalkylamine derivatives 22 155 21 250 20 246 19 130 56 8 733 6 626 11 763 13 873 C08DA01 Verapamil 22 155 21 250 20 246 19 130 56 8 733 6 626 11 763 13 873 C08DB Benzothiazepine derivatives 9 447 8 597 7 858 7 159 54 <5 89 2 981 4 088 14 720 C08DB01 Diltiazem 9 447 8 597 7 858 7 159 54 <5 89 2 981 4 088 14 720 C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 364 356 384 732 406 861 430 060 50 240 23 915 226 907 178 998 903 778 C09A ACE INHIBITORS, PLAIN 118 442 117 975 118 902 120 667 44 200 5 863 52 299 62 305 77 968 C09AA ACE inhibitors, plain 118 442 117 975 118 902 120 667 44 200 5 863 52 299 62 305 77 968 C09AA01 Captopril 5 838 5 167 4 456 3 987 45 35 131 1 443 2 378 4 711 C09AA02 Enalapril 42 951 42 011 41 744 41 789 48 160 2 160 17 991 21 478 19 094 C09AA03 Lisinopril 32 598 30 722 29 322 28 411 48 5 1 593 13 012 13 801 20 991 C09AA05 Ramipril 37 776 40 725 43 993 47 128 37 <5 2 007 20 077 25 042 32 914 C09AA10 Trandolapril 71 103 117 117 32 0 8 67 42 256 C09B ACE INHIBITORS, COMBINATIONS 36 677 36 424 36 040 35 744 51 <5 1 122 17 777 16 843 33 200 C09BA ACE inhibitors and diuretics 36 677 36 424 36 040 35 744 51 <5 1 122 17 777 16 843 33 200 C09BA02 Enalapril and diuretics 19 656 19 737 19 795 19 810 51 <5 653 9 882 9 274 diuretics 17 054 16 718 16 265 15 960 51 <5 470 7 905 7 584 14 991 C09C ANGIOTENSIN II ANTAGONISTS, PLAIN 129 219 135 375 143 695 153 211 52 54 11 871 85 265 56 021 357 069 C09CA Angiotensin II antagonists, plain 129 219 135 375 143 695 153 211 52 54 11 871 85 265 56 021 357 069 C09CA01 Losartan 44 499 43 733 43 822 44 601 52 17 2 354 23 175 19 055 110 799 C09CA02 Eprosartan 1 467 1 567 1 755 2 210 56 0 132 1 025 1 053 4 000 C09CA03 Valsartan 17 952 18 476 19 186 19 497 49 0 1 268 11 450 6 779 46 282 58 Rapport 2008 Folkehelseinstituttet2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group C C09CA04 Irbesartan 24 469 24 463 24 321 23 784 50 5 1 550 13 986 8 243 61 641 C09CA06 Candesartan 41 042 46 908 53 496 60 228 54 32 6 277 33 804 20 115 125 185 C09CA07 Telmisartan 1 531 1 794 2 476 3 809 45 0 325 2 286 1 198 7 575 C09CA08 Olmesartan medoxomil 0 87 399 1 094 53 0 136 654 304 1 587 C09D ANGIOTENSIN II ANTAGONISTS, COMBINATIONS 115 043 130 058 144 645 158 602 52 0 7 246 92 515 58 841 435 541 C09DA Angiotensin II antago - nists and diuretics 115 043 130 058 144 645 157 754 52 0 7 199 92 029 58 526 433 702 C09DA01 Losartan and diuretics 55 676 58 516 61 122 63 360 54 0 2 319 35 076 25 965 176 316 C09DA02 Eprosartan and diuretics 26 421 889 1 427 51 0 81 801 545 2 878 C09DA03 Valsartan and diuretics 14 873 17 944 21 180 23 363 50 0 1 166 14 120 8 077 62 528 C09DA04 Irbesartan and diuretics 22 959 25 798 27 936 29 855 50 0 1 313 17 835 10 707 92 618 C09DA06 Candesartan and diuretics 22 842 28 492 34 108 39 094 51 0 2 242 23 759 13 093 93 532 C09DA07 Telmisartan and diuretics 580 913 1 461 2 415 42 0 171 1 499 745 5 466 C09DA08 Olmesartan medoxomil and diuretics 0 0 0 349 50 0 25 223 101 364 C09DB Angiotensin II antago - nists and calcium channel blockers 0 0 0 1 350 42 0 85 807 458 1 839 C09DB01 Valsartan and amlodipine 0 0 0 1 350 42 0 85 807 458 1 839 C10 LIPID MODIFYING AGENTS 306 138 331 972 363 051 398 152 47 61 18 728 220 791 158 572 603 977 C10A LIPID MODIFYING AGENTS, PLAIN 306 138 331 972 363 050 397 792 47 61 18 710 220 530 158 491 603 306 C10AA HMG CoA reductase inhibitors 304 365 329 952 360 893 395 238 47 50 18 207 219 090 157 891 555 072 C10AA01 Simvastatin 122 206 181 256 254 951 320 903 47 27 14 149 175 315 131 412 186 069 C10AA02 Lovastatin 3 000 2 688 2 107 1 884 56 0 37 789 1 058 6 568 C10AA03 Pravastatin 43 391 39 366 28 113 24 223 46 6 616 12 218 11 383 32 552 C10AA04 Fluvastatin 9 231 8 790 7 173 7 092 48 0 558 4 233 2 301 13 206 C10AA05 Atorvastatin 136 588 140 856 103 381 85 840 44 20 4 565 52 168 29 087 315 581 C10AA07 Rosuvastatin 0 0 22 234 44 0 40 180 14 1 096 C10AB Fibrates 269 298 322 320 31 0 66 234 20 1 626 C10AB02 Bezafibrate 107 95 80 76 32 0 6 67 <5 279 C10AB04 Gemfibrozil 96 92 93 102 27 0 21 71 10 867 C10AB05 Fenofibrate 71 119 151 143 32 0 39 97 7 480 C10AC Bile acid sequestrants 2 112 2 132 2 153 2 086 53 11 390 1 138 547 7 231 C10AC01 Colestyramine 1 461 1 505 1 535 1 486 56 7 327 751 401 2 455 C10AC02 Colestipol 552 479 439 430 44 <5 38 255 134 1 193 C10AC04 Colesevelam 108 166 197 183 45 <5 27 141 14 3 583 C10AD Nicotinic acid and derivatives 73 100 175 230 30 0 38 167 25 617 C10AD02 Nicotinic acid 42 76 154 211 30 0 37 151 23 480 C10AD06 Acipimox 32 24 22 19 26 0 <5 16 <5 137 C10AX Other lipid modifying agents 2 578 3 543 4 534 7 990 42 <5 1 031 5 597 1 358 38 760 C10AX06 Omega-3-triglycerides incl. other esters and acids1 666 1 949 2 039 2 192 28 <5 362 1 594 235 20 069 C10AX09 Ezetimibe 945 1 653 2 586 5 962 46 <5 694 4 127 1 138 18 690 C10B LIPID MODIFYING AGENTS, COMBINATIONS 0 0 <5 <5 0 0 <5 0 0 3Rapport 2008 Folkehelseinstituttet 592004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group C C10BA agents0 0 <5 <5 ezetimibe 0 0 <5 <5 0 0 <5 0 0 3 60 Rapport 2008 FolkehelseinstituttetD01 ANTIFUNGALS FOR DERMATOLOGICAL USE 103 159 103 625 106 211 109 774 49 8 440 43 332 39 416 18 586 30 495 D01A ANTIFUNGALS FOR TOPICAL USE 89 365 89 767 92 861 95 463 50 8 233 37 489 32 635 17 106 14 329 D01AA Antibiotics 2 166 2 429 2 786 3 197 89 171 2 503 314 209 247 D01AA01 Nystatin 2 166 2 429 786 3 197 89 171 2 503 314 209 247 D01AC Imidazole and triazole derivatives 64 455 65 360 68 170 70 646 50 6 483 26 173 24 240 13 750 8 493 D01AC01 Clotrimazole 1)7 474 7 383 7 979 8 182 53 815 2 850 2 383 2 134 1 009 D01AC02 Miconazole1)2 377 2 316 2 247 2 082 48 210 832 693 347 317 D01AC03 Econazole1)2 186 2 232 2 326 2 226 54 170 838 727 491 290 D01AC08 Ketoconazole1)15 844 15 499 15 122 15 362 41 749 6 639 5 799 2 175 2 312 D01AC20 Combinations1)39 684 41 229 44 008 46 252 51 4 806 16 253 15 791 9 402 4 565 D01AC60 Bifonazole, combinations 16 7 <5 0 - 0 0 0 0 0 D01AE Other antifungals for topical use 25 546 24 626 24 777 24 528 46 1 793 10 013 9 049 3 673 5 589 D01AE02 Methylrosaniline 1) 776 694 645 661 56 155 156 179 171 50 D01AE14 Ciclopirox1)34 27 33 52 62 7 23 14 8 10 D01AE15 Terbinafine1)16 692 16 312 17 149 17 204 43 1 426 7 435 5 723 2 620 2 747 D01AE16 Amorolfine 8 434 7 947 7 351 6 978 54 224 2 543 3 279 932 2 782 D01AE20 Combinations1)<5 0 0 0 - 0 0 0 0 0 D01B ANTIFUNGALS FOR SYSTEMIC USE 16 867 16 880 16 706 17 536 38 300 7 266 8 134 1 836 16 166 D01BA Antifungals for systemic use 16 867 16 880 16 706 17 536 38 300 7 266 8 134 1 836 16 166 D01BA01 Griseofulvin 21 23 26 14 29 11 0 <5 <5 9 D01BA02 Terbinafine 16 853 16 859 16 686 17 527 38 293 7 266 8 133 1 835 16 156 D02 EMOLLIENTS AND PROTECTIVES 1 425 1 448 1 361 1 572 51 179 512 559 322 268 D02A EMOLLIENTS AND PROTECTIVES 1 425 1 448 1 361 1 572 51 179 512 559 322 268 D02AB Zinc products 1)10 18 16 8 75 0 <5 <5 5 1 D02AE Carbamide products 38 68 44 222 53 34 76 62 50 53 D02AE01 Carbamide1)38 68 44 222 53 34 76 62 50 53 D02AF Salicylic acid preparations 1)1 371 1 360 1 298 1 274 50 121 412 482 259 175 D02AX Other emollients and protectives 1)8 <5 <5 76 62 27 26 15 8 39 D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 262 228 172 121 48 7 27 41 46 28 D03A CICATRIZANTS 262 228 172 121 48 7 27 41 46 28 D03AA Cod-liver oil ointments 1) 144 146 91 39 51 7 7 9 16 4 D03AX Other cicatrizants 118 82 81 82 46 0 20 32 30 24 D03AX03 Dexpanthenol 118 82 81 82 46 0 20 32 30 24 D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 2 316 2 907 2 978 2 993 64 384 972 813 824 436 D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 2 316 2 907 2 978 2 993 64 384 972 813 824 436 D04AA Antihistamines for topical use 8 5 6 5 60 0 <5 <5 <5 32004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group D 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 3.7 T able - ATC group D - Dermatologicals Rapport 2008 Folkehelseinstituttet 61D04AA02 Mepyramine <5 0 <5 0 - 0 0 0 0 0 D04AA13 Dimetindene 7 5 5 5 60 0 <5 <5 <5 3 D04AB Anesthetics for topical use 1 307 1 892 1 878 1 936 67 216 711 576 433 341 D04AB01 Lidocaine1)1 306 1 892 1 878 1 935 67 216 711 575 433 340 D04AB06 Tetracaine <5 0 0 <5 100 0 0 <5 0 2 D04AX Other antipruritics1)1 023 1 035 1 105 1 077 58 173 264 242 398 92 D05 ANTIPSORIATICS 24 667 24 776 24 547 25 463 45 405 7 947 13 040 4 071 42 551 D05A ANTIPSORIATICS FOR TOPICAL USE 23 582 23 723 23 414 24 285 45 398 7 711 12 286 3 890 36 463 D05AA Tars 1) 900 944 933 956 58 67 322 363 204 248 D05AC Antracen derivatives 231 206 167 109 55 <5 36 56 14 56 D05AC01 Dithranol 231 206 167 109 55 <5 36 56 14 56 D05AD Psoralens for topical use 22 <5 10 11 64 0 <5 6 <5 14 D05AD01 Trioxysalen 22 <5 10 0 <5 6 <5 14 D05AX Other antipsoriatics for topical use 22 736 22 858 22 573 23 425 45 333 7 430 11 969 3 693 36 145 D05AX02 Calcipotriol 14 635 14 482 13 491 11 689 46 196 3 556 5 986 1 951 11 855 D05AX03 Calcitriol 1 091 1 054 872 927 52 22 301 465 139 650 D05AX52 Calcipotriol, combinations 11 612 12 505 13 187 15 365 43 158 5 130 7 848 2 229 23 640 D05B ANTIPSORIATICS FOR SYSTEMIC USE 1 625 1 585 1 637 1 669 44 9 389 1 032 239 6 088 D05BA Psoralens for systemic use 179 79 68 59 53 0 18 37 <5 50 D05BA02 Methoxsalen 179 68 58 55 51 0 18 33 <5 42 D05BA03 Bergapten <5 11 10 <5 75 0 <5 0 8 D05BB Retinoids for treatment of psoriasis 1 467 1 516 1 568 1 603 44 9 366 995 233 5 605 D05BB02 Acitretin 1 467 1 516 1 568 1 603 44 9 366 995 233 5 605 D05BX Other antipsoriatics for systemic use <5 5 12 15 47 0 5 8 <5 433 D05BX51 Fumaric acid derivatives, combinations <5 5 12 15 47 0 5 8 <5 433 D06 ANTIBIOTICS AND CHEMO-THERAPEUTICS FOR DERMATOLOGICAL USE 126 729 117 793 118 079 110 265 60 13 991 48 988 33 118 14 168 16 235 D06A ANTIBIOTICS FOR TOPICAL USE 67 019 57 648 57 846 55 448 56 11 275 17 628 16 689 9 856 4 436 D06AA Tetracycline and derivatives 2 669 3 130 3 025 3 003 54 500 918 1 013 572 181 D06AA02 Chlortetracycline 45 36 33 26 54 0 10 12 <5 6 D06AA03 Oxytetracycline 2 625 3 096 2 992 2 977 54 500 908 1 001 568 175 D06AX Other antibiotics for topical use 64 536 54 722 54 992 52 600 56 10 801 16 753 15 738 9 308 4 255 D06AX01 Fusidic acid 62 534 52 807 53 086 50 915 56 10 261 16 208 15 421 9 025 4 068 D06AX05 Bacitracin1)2 172 2 058 2 044 1 819 51 580 585 344 310 184 D06AX07 Gentamicin <5 <5 0 <5 0 0 0 <5 21 <5 <5 <5 2 D06AX13 Retapamulin 0 5 <5 <5 0 1 D06B CHEMOTHERAPEUTICS FOR TOPICAL USE 62 339 62 386 62 469 56 889 65 2 882 32 316 17 087 4 604 11 799 D06BA Sulfonamides 2 445 3 462 3 447 3 463 54 585 1 221 1 027 630 435 D06BA01 Silver sulfadiazine 2 445 3 462 3 447 3 463 54 585 1 221 1 027 630 435 D06BB Antivirals 52 434 51 733 52 220 46 085 66 2 198 28 695 12 404 2 788 10 169 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group D 62 Rapport 2008 Folkehelseinstituttet1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. D06BB03 Aciclovir1)27 965 27 670 28 218 24 058 72 1 618 12 709 7 969 1 762 3 085 D06BB04 Podophyllotoxin 10 116 10 894 11 403 12 243 52 114 11 188 904 37 2 733 D06BB06 Penciclovir1)13 794 12 468 11 808 8 464 72 339 4 268 3 205 652 1 580 D06BB10 Imiquimod 1 565 1 728 1 853 2 224 57 141 1 289 440 354 2 771 D06BX Other chemotherapeutics 7 736 7 447 7 061 7 574 69 102 2 509 3 742 1 221 1 195 D06BX01 Metronidazole 7 736 7 447 7 061 7 574 69 102 2 509 3 742 1 221 1 195 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 335 013 344 291 347 421 345 358 54 44 562 108 815 124 397 67 584 80 854 D07A CORTICOSTEROIDS, PLAIN 255 748 264 714 270 398 275 446 55 37 169 86 900 97 727 53 650 58 461 D07AA Corticosteroids, weak (group I) 28 348 29 169 28 270 26 994 56 10 877 7 528 4 959 3 630 2 923 D07AA02 Hydrocortisone 1)28 348 29 169 28 270 26 994 56 10 877 7 528 4 959 3 630 2 923 D07AB Corticosteroids, mode-rately potent (group II) 84 619 86 994 88 545 91 251 56 18 398 28 370 27 741 16 742 13 606 D07AB02 Hydrocortisone butyrate 57 309 59 055 59 835 62 153 56 13 539 19 313 18 028 11 273 9 723 D07AB08 Desonide 28 476 29 186 29 907 30 370 56 5 180 9 435 10 031 5 724 3 882 D07AC Corticosteroids, potent (group III) 140 549 145 538 148 924 151 128 55 14 422 49 971 55 931 30 804 31 233 D07AC01 Betamethasone 45 440 47 521 48 812 50 712 54 2 692 16 600 20 321 11 099 7 802 D07AC03 Desoximetasone 14 746 14 431 14 160 13 764 53 532 4 118 5 797 3 317 3 585 D07AC04 Fluocinolone acetonide 8 312 7 826 7 548 7 292 55 201 1 525 3 326 2 240 1 307 D07AC08 Fluocinonide 1 428 1 172 1 173 998 56 14 234 472 278 177 D07AC13 Mometasone 59 460 64 373 66 960 69 055 55 9 041 23 866 23 441 12 707 14 994 D07AC17 Fluticasone 18 448 17 879 17 853 16 867 56 2 537 6 097 5 313 2 920 3 369 D07AD Corticosteroids, very potent (group IV) 40 099 42 244 43 658 45 616 56 1 287 14 241 21 288 8 800 10 699 D07AD01 Clobetasol 40 099 42 244 43 658 45 616 56 1 287 14 241 21 288 8 800 10 699 D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS 60 264 60 666 57 670 48 588 51 6 154 15 246 17 586 9 602 6 687 D07BB Corticosteroids, mode-rately potent, combi-nations with antiseptics 43 231 42 781 38 420 28 416 51 4 516 8 738 9 768 5 394 4 011 D07BB01 Flumetasone and antiseptics 0 <5 0 0 - 0 0 0 0 0 D07BB02 Desonide and antiseptics 8 793 9 257 10 643 14 104 51 2 210 3 997 4 979 2 918 2 381 D07BB03 Triamcinolone and antiseptics 29 583 28 375 19 574 351 48 40 96 144 71 38 D07BB04 Hydrocortisone butyrate and antiseptics 5 359 5 994 9 295 14 433 51 2 334 4 776 4 814 2 509 1 593 D07BC Corticosteroids, potent, combinations with antiseptics 18 681 19 618 20 868 21 606 50 1 901 6 936 8 298 4 471 2 675 D07BC01 Betamethasone and antiseptics 16 157 17 146 18 661 18 720 50 1 719 6 145 7 009 3 847 2 367 D07BC02 Fluocinolone acetonide and antiseptics 2 588 2 547 2 274 3 212 49 209 873 1 423 707 308 D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS 23 705 24 762 24 256 23 929 55 4 467 7 070 7 697 4 695 2 832 D07CA Corticosteroids, weak, combinations with antibiotics 23 705 24 762 24 256 23 929 55 4 467 7 070 7 697 4 695 2 8322004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group DRapport 2008 Folkehelseinstituttet 631 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. D07CA01 Hydrocortisone and antibiotics 23 705 24 762 24 256 23 929 55 4 467 7 070 7 697 4 695 2 832 D07X CORTICOSTEROIDS, OTHER COMBINATIONS 31 777 30 539 30 420 30 461 49 932 9 877 13 519 6 133 12 874 D07XA Corticosteroids, weak, other combinations 1 173 6 0 <5 100 0 <5 0 0 0 D07XA01 Hydrocortisone 1 173 6 0 <5 100 0 <5 0 0 0 D07XB Corticosteroids, mode- rately potent, other combinations 4 049 4 398 4 007 3 998 51 113 965 1 951 969 802 D07XB02 Triamcinolone 4 049 4 398 4 007 3 998 51 113 965 1 951 969 802 D07XC Corticosteroids, potent, other combinations 26 885 26 332 26 596 26 623 49 821 8 957 11 654 5 191 12 072 D07XC01 Betamethasone 25 153 26 329 26 596 26 623 49 821 8 957 11 654 5 191 12 072 D07XC02 Desoximetasone 2 204 <5 0 0 - 0 0 0 0 0 D08 ANTISEPTICS AND DISINFECTANTS 14 532 17 519 17 934 17 765 57 3 083 6 923 5 656 2 103 2 039 D08A ANTISEPTICS AND DISINFECTANTS 14 532 17 519 17 934 17 765 57 3 083 6 923 5 656 2 103 2 039 D08AB Aluminium agents 1) 146 194 211 267 52 103 70 64 30 37 D08AC Biguanides and amidines 12 799 13 786 13 980 13 928 59 1 993 5 765 4 716 1 454 1 463 D08AC01 Dibrompropamidine1)5 959 5 865 5 781 5 251 51 1 548 1 755 1 020 928 450 D08AC02 Chlorhexidine1)7 078 8 202 8 445 8 930 63 543 4 111 3 724 552 1 013 D08AG Iodine products 60 69 54 56 55 9 19 14 14 8 D08AG01 Iodine/octylphenoxy-polyglycolether 1)14 12 16 12 42 Povidone-iodine 0 <5 0 0 0 D08AG03 Iodine1)46 56 37 44 59 8 9 13 14 5 D08AJ Quaternary ammonium compounds 125 133 109 136 46 14 38 38 46 88 D08AJ03 Cetylpyridinium 1) 125 133 109 136 46 14 38 38 46 88 D08AX Other antiseptics and disinfectants 1 523 3 544 3 798 3 559 54 1 014 1 084 868 593 443 D08AX01 Hydrogen peroxide 1) 158 2 295 2 646 2 457 54 776 758 547 376 282 D08AX06 Potassium permanganate1)1 368 1 278 1 179 1 123 52 240 336 327 220 161 D09 MEDICATED DRESSINGS 2 697 2 375 2 203 2 199 57 183 509 703 804 303 D09A MEDICATED DRESSINGS 2 697 2 375 2 203 2 199 57 183 509 703 804 303 D09AA Medicated dressings with antiinfectives 2 697 2 375 2 203 2 199 57 183 509 703 804 303 D09AA01 Framycetin 11 0 0 0 - 0 0 0 0 0 D09AA02 Fusidic acid 2 686 2 375 2 203 2 199 57 183 509 703 804 303 D10 ANTI-ACNE PREPARATIONS 38 187 43 087 44 308 47 762 64 2 824 34 875 8 021 2 042 24 323 D10A ANTI-ACNE PREPARA - TIONS FOR TOPICAL USE 36 619 41 399 42 396 45 430 66 2 787 32 687 7 916 2 040 10 663 D10AD Retinoids for topical use in acne 16 035 18 028 18 652 21 387 67 1 359 15 201 3 594 1 233 3 640 D10AD01 Tretinoin 7 345 7 753 7 855 9 764 77 364 5 237 3 108 1 055 1 050 D10AD02 Retinol <5 15 57 44 64 <5 11 D10AD03 Adapalene 9 017 10 653 11 165 12 032 59 1 031 10 323 495 183 2 579 D10AE Peroxides 1 394 1 729 2 052 2 359 52 229 2 042 76 12 339 D10AE01 Benzoyl peroxide 1 394 1 729 2 052 2 359 52 229 2 042 76 12 339 D10AF Antiinfectives for treatment of acne 16 421 17 102 16 977 17 357 63 1 248 13 581 2 236 292 3 9052004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group D 64 Rapport 2008 FolkehelseinstituttetD10AF01 Clindamycin 16 368 17 064 16 932 17 309 63 1 247 13 536 2 234 292 3 883 D10AF02 Erythromycin 55 46 46 54 63 <5 51 <5 0 21 D10AX Other anti-acne prepa- rations for topical use 9 289 12 348 13 135 13 444 67 792 9 779 2 344 529 2 779 D10AX03 Azelaic acid 9 283 12 333 13 122 13 430 67 792 9 772 2 339 527 2 777 D10AX30 Various combinations 7 18 15 14 71 0 7 5 <5 2 D10B ANTI-ACNE PREPARA - TIONS FOR SYSTEMIC USE 2 226 2 462 2 744 3 422 40 87 3 198 135 <5 13 659 D10BA Retinoids for treatment of acne 2 226 2 462 2 744 3 422 40 87 3 198 135 <5 13 659 D10BA01 Isotretinoin 2 226 2 462 2 744 3 422 40 87 3 198 135 <5 13 659 D11 OTHER DERMATOLOGICAL PREPARATIONS 14 006 13 688 13 351 13 633 53 2 091 5 819 3 726 1 997 10 513 D11A OTHER DERMATOLOGICAL PREPARATIONS 14 006 13 688 13 351 13 633 53 2 091 5 819 3 726 1 997 10 513 D11AC Medicated shampoos 964 1 025 1 127 1 017 51 68 641 222 86 93 D11AC03 Selenium compounds 964 1 025 1 127 1 017 51 68 641 222 86 93 D11AF Wart and anti-corn preparations 1 264 1 328 1 468 1 416 51 563 555 196 102 146 D11AX Other dermatologicals 11 789 11 347 10 775 11 215 54 1 463 4 632 3 309 1 811 10 274 D11AX01 Minoxidil 1 082 367 196 172 20 109 D11AX10 Finasteride 790 831 810 767 1 0 613 149 5 3 955 D11AX14 Tacrolimus 5 537 4 551 3 949 4 344 56 657 2 061 1 328 298 3 149 D11AX15 Pimecrolimus 4 352 4 219 3 697 3 905 60 820 1 808 1 027 250 2 107 D11AX18 Diclofenac 269 1 422 2 120 2 070 54 0 47 776 1 247 9062004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group DRapport 2008 Folkehelseinstituttet 651 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.G01 GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 30 462 30 670 29 768 30 239 100 84 22 026 6 771 1 358 5 985 G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS 30 462 30 670 29 768 30 239 100 84 22 026 6 771 1 358 5 985 G01AA Antibiotics 16 149 15 889 14 683 14 366 100 47 10 409 3 417 493 3 306 G01AA10 Clindamycin 16 149 15 889 14 683 14 366 100 47 10 409 3 417 493 3 306 G01AF Imidazole derivatives 15 489 16 011 16 164 17 089 100 37 12 563 3 587 902 2 674 G01AF01 Metronidazole 7 429 8 275 8 843 9 950 100 8 7 564 2 126 252 1 430 G01AF02 Clotrimazole 1)5 731 5 511 5 229 5 254 99 23 3 628 1 090 513 902 G01AF04 Miconazole1) 890 949 823 788 100 G01AF05 1 624 1 646 1 492 99 <5 1 115 274 100 220 G01AX Other antiinfectives and antiseptics 5 18 12 12 58 0 7 <5 <5 5 G01AX03 Policresulen 5 18 12 12 58 0 7 <5 <5 5 G02 OTHER GYNECOLOGICALS 36 647 36 708 38 156 41 311 99 5 37 063 4 095 148 46 191 G02A OXYTOCICS 43 43 35 31 100 0 30 0 <5 3 G02AB Ergot alkaloids 43 43 34 31 100 0 30 0 <5 3 G02AB01 Methylergometrine 43 43 34 31 100 0 30 0 <5 3 G02AD Prostaglandins 0 0 <5 0 - 0 0 0 0 0 G02AD02 Dinoprostone 0 0 <5 0 - 0 0 0 0 0 G02B CONTRACEPTIVES FOR TOPICAL USE 34 319 34 307 35 776 39 027 100 <5 35 558 3 460 6 41 330 G02BA Intrauterine contraceptives 21 839 22 596 23 092 24 818 100 0 21 629 3 184 5 30 005 G02BA03 Plastic IUD with progestogen 21 839 22 596 23 092 24 818 100 0 21 629 3 184 5 30 005 G02BB Intravaginal contraceptives 12 626 11 823 12 805 14 334 100 <5 14 052 278 <5 11 325 G02BB01 Vaginal ring with progestogen and estrogen 12 626 11 823 12 805 14 334 100 <5 14 052 278 <5 11 325 G02C OTHER GYNECOLOGICALS 2 395 2 463 2 428 2 339 82 <5 1 561 635 141 4 858 G02CB Prolactine inhibitors 2 395 2 463 2 428 2 339 82 <5 1 561 635 141 4 858 G02CB01 Bromocriptine 1 540 1 475 1 360 1 259 90 <5 921 256 80 1 340 G02CB03 Cabergoline 682 820 904 913 70 0 542 318 53 2 790 G02CB04 Quinagolide 224 219 211 214 89 0 136 70 8 728 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 509 467 509 369 511 137 510 086 99 2 202 341 258 133 112 33 514 382 463 G03A HORMONAL CONTRACEP - TIVES FOR SYSTEMIC USE 283 225 295 013 300 970 301 396 100 1 011 291 607 8 759 19 162 263 G03AA Progestogens and estro - gens, fixed combinations 117 866 125 718 145 430 211 548 100 862 207 388 3 292 6 124 786 G03AA06 Norgestrel and estrogen 13 <5 <5 0 0 0 0 0 G03AA07 Levonorgestrel and estrogen 30 427 37 514 47 622 83 625 100 330 81 870 1 423 <5 37 641 G03AA09 Desogestrel and estrogen 9 122 8 225 10 862 40 375 100 334 39 274 766 <5 11 407 G03AA12 Drospirenone and estrogen 68 789 73 567 84 140 97 503 100 248 96 206 1 046 <5 69 002 G03AA13 Norelgestromin and estrogen 16 421 13 103 9 260 9 016 100 12 8 844 160 0 6 736 G03AB Progestogens and estrogens, sequential preparations 126 954 123 178 112 813 29 232 100 84 28 426 721 <5 6 3012004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group G 3.8 T able - ATC group G - Genito urinary system and sex hormones 66 Rapport 2008 FolkehelseinstituttetG03AB03 Levonorgestrel and estrogen 115 297 112 651 102 582 5 340 100 <5 5 147 191 0 905 G03AB04 Norethisterone and estrogen 12 169 10 990 12 073 24 611 100 82 23 967 561 <5 5 396 G03AC Progestogens 61 140 71 563 77 911 85 653 100 114 80 455 5 072 12 31 176 G03AC01 Norethisterone 20 314 16 278 12 892 10 485 100 5 9 359 1 121 0 2 289 G03AC02 Lynestrenol 4 336 1 555 0 0 - 0 0 0 0 0 G03AC03 Levonorgestrel 1)3 228 1 829 424 408 99 <5 388 17 0 376 G03AC06 Medroxyprogesterone 28 395 25 383 23 401 22 506 100 32 19 943 2 525 6 4 832 G03AC08 Etonogestrel 1 427 1 805 2 063 2 598 100 <5 2 548 46 0 3 362 G03AC09 Desogestrel 5 021 29 057 41 479 51 988 100 73 50 475 1 434 6 20 318 G03B ANDROGENS 3 922 3 941 3 999 4 291 5 56 1 356 2 313 566 17 938 G03BA 3-oxoandrosten (4) derivatives 3 922 3 941 3 999 4 291 5 56 1 356 2 313 566 17 938 G03BA01 Fluoxymesterone 8 <5 0 0 - 0 0 0 0 0 G03BA03 Testosterone 3 915 3 939 3 999 4 291 5 56 1 356 2 313 566 17 938 G03BB 5-androstanon (3) derivatives <5 0 0 0 - 0 0 0 0 0 G03BB01 Mesterolone <5 0 0 0 - 0 0 0 0 0 G03C ESTROGENS 96 512 97 380 101 558 105 539 100 173 4 559 71 844 28 963 67 294 G03CA Natural and semisynthetic estrogens, plain 81 335 84 359 90 029 95 287 100 173 4 296 62 351 28 467 49 558 G03CA01 Ethinylestradiol 162 165 165 159 81 71 66 21 <5 718 G03CA03 Estradiol 53 926 60 519 68 864 76 470 100 25 3 993 57 008 15 444 39 568 G03CA04 Estriol 1)29 012 25 429 22 779 20 429 100 77 265 6 160 13 927 9 271 G03CA53 Estradiol, combinations <5 0 0 0 - 0 0 G03CA57 Conjugated estrogens <5 1 G03CX Other estrogens 16 256 14 166 12 560 11 192 100 0 299 10 348 545 17 736 G03CX01 Tibolone 16 256 14 166 12 560 11 192 100 0 299 10 348 545 17 736 G03D PROGESTOGENS 39 474 40 356 39 386 39 335 100 1 003 28 892 9 272 168 14 444 G03DA Pregnen (4) derivatives 12 419 12 430 12 156 12 447 100 81 8 799 3 418 149 11 404 G03DA02 Medroxyprogesterone 8 386 8 030 7 539 7 330 100 81 3 737 3 364 148 1 356 G03DA04 Progesterone 4 072 4 483 4 703 5 201 100 0 5 146 54 <5 10 048 G03DC Estren derivatives 27 828 28 696 27 931 27 599 100 928 20 632 6 020 19 3 040 G03DC02 Norethisterone 27 828 28 696 27 931 27 599 100 928 20 632 6 020 19 3 040 G03F PROGESTOGENS AND ESTROGENS IN COMBINATION 78 166 65 110 56 823 50 988 100 6 2 599 45 147 3 236 36 222 G03FA Progestogens and estro - gens, fixed combinations 58 690 49 812 44 108 40 063 100 <5 687 36 285 3 088 29 009 G03FA01 Norethisterone and estrogen 57 686 48 944 43 324 39 328 100 <5 663 35 591 3 071 28 234 G03FA12 Medroxyprogesterone and estrogen 635 549 521 500 100 0 16 472 12 501 G03FA15 Dienogest and estrogen 530 422 and estrogens, sequential preparations 22 222 17 492 14 549 12 440 100 <5 1 999 10 276 162 7 213 G03FB01 Norgestrel and estrogen 1 302 1 057 820 5 0 <5 <5 <5 1 G03FB05 Norethisterone and estrogen 21 002 16 526 13 910 12 436 100 <5 1 998 10 274 161 7 213 G03FB11 Trimegestone and estrogen 16 <5 0 0 - 0 0 0 0 0 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group GRapport 2008 Folkehelseinstituttet 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group G STIMULANTS 9 514 9 693 9 748 10 111 96 0 9 952 159 0 68 024 G03GA Gonadotropins 5 064 5 293 5 263 5 551 99 0 5 487 64 0 66 383 G03GA01 Chorionic gonadotrophin 1 173 1 464 1 299 1 391 95 0 1 356 35 0 458 G03GA02 Human menopausal gonadotrophin <5 625 864 1 092 100 0 1 080 12 0 8 921 G03GA05 Follitropin alfa 1 853 1 738 1 595 1 624 99 0 1 609 15 0 21 873 G03GA06 Follitropin beta 2 709 2 826 2 787 2 877 100 0 2 847 30 0 32 627 G03GA07 Lutropin alfa 145 135 81 82 100 0 78 <5 0 270 G03GA08 Choriogonadotropin alfa 3 713 3 640 3 717 4 039 100 0 4 009 30 0 2 233 G03GB Ovulation stimulants, synthetic 5 665 5 652 5 647 5 843 94 0 5 722 121 0 1 641 G03GB02 Clomifene 5 665 5 652 5 647 5 843 94 0 5 722 121 0 1 641 G03H ANTIANDROGENS 18 095 18 297 19 127 19 572 99 67 19 028 348 129 10 447 G03HA Antiandrogens, plain 217 221 236 232 8 0 23 82 127 597 G03HA01 Cyproterone 217 221 236 232 8 0 23 82 127 597 G03HB Antiandrogens and estrogens 17 887 18 084 18 899 19 345 100 67 19 010 266 <5 9 851 G03HB01 Cyproterone and estrogen 17 887 18 084 18 899 19 345 100 67 19 010 266 <5 9 851 G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 2 616 2 255 1 958 1 719 98 <5 25 745 948 5 831 G03XA Antigonadotropins and similar agents 37 40 43 52 40 <5 20 23 8 192 G03XA01 Danazol 37 40 43 52 40 <5 20 23 8 192 G03XB Antiprogestogens <5 <5 <5 0 2 G03XC Selective estrogen receptor modulators 2 578 2 213 1 915 1 665 100 0 <5 722 940 5 637 G03XC01 Raloxifene 2 578 2 213 1 915 1 665 100 0 <5 722 940 5 637 G04 UROLOGICALS 110 697 116 315 122 740 131 435 22 608 13 530 69 352 47 945 343 578 G04B OTHER UROLOGICALS, INCL. ANTISPASMODICS 89 982 91 793 95 652 100 694 28 607 12 485 57 147 30 455 283 046 G04BA <5 Urinary antispasmodics 34 249 36 378 39 288 40 918 68 597 3 178 17 154 19 989 147 327 G04BD01 Emepronium 9 0 0 0 - 0 0 0 0 0 G04BD04 Oxybutynin 410 882 2 060 2 054 75 178 266 880 730 10 790 G04BD07 Tolterodine 33 858 31 502 27 131 23 740 70 380 1 526 9 251 12 583 86 437 G04BD08 Solifenacin 102 6 013 11 236 13 974 65 45 1 270 6 467 6 192 39 278 G04BD10 Darifenacin 0 0 2 185 4 336 70 9 398 1 959 1 970 10 822 G04BE Drugs used in erectile dysfunction 56 700 56 388 57 442 60 998 0 9 9 381 40 744 10 864 135 683 G04BE01 Alprostadil 1 974 1 906 1 941 2 038 0 0 128 1 347 563 3 751 G04BE02 Papaverine 24 32 30 30 0 0 <5 17 10 57 G04BE03 Sildenafil 35 463 32 480 32 054 33 253 1 9 5 055 21 641 6 548 70 029 G04BE04 Yohimbin 28 26 23 20 20 0 <5 13 <5 8 G04BE07 Apomorphine 760 319 160 6 0 0 0 <5 <5 2 G04BE08 Tadalafil 16 146 16 750 18 471 21 262 0 0 3 646 14 653 2 963 41 797 G04BE09 Vardenafil 11 009 12 268 11 727 11 619 0 0 1 688 7 987 1 944 19 110 G04BE30 Combinations 515 516 573 598 0 0 40 452 106 928 G04BX Other urologicals 12 10 13 10 40 <5 7 <5 <5 14 68 Rapport 2008 FolkehelseinstituttetG04BX01 Magnesium 12 13 10 40 <5 7 <5 14 G04C DRUGS USED IN BENIGN PROSTATIC HYPER- TROPHY 23 850 28 289 31 538 35 859 1 <5 1 164 14 746 19 947 60 532 G04CA Alpha-adrenoreceptor antagonists 17 934 21 301 23 708 27 126 1 <5 690 12 138 14 296 34 040 G04CA01 Alfuzosin 827 914 972 937 1 0 25 397 515 1 507 G04CA02 Tamsulosin 16 206 19 538 21 924 25 393 1 <5 609 11 407 13 375 31 631 G04CA03 Terazosin 1 052 992 984 986 1 0 60 431 495 902 G04CB Testosterone-5-alpha reductase inhibitors 7 162 8 867 10 299 11 658 0 0 485 3 776 7 397 26 493 G04CB01 Finasteride 5 998 5 961 5 913 5 805 0 0 428 1 505 3 872 12 041 G04CB02 Dutasteride 1 263 2 998 4 492 5 943 0 0 62 2 296 3 585 14 4512004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 70 HORMONES AND ANALOGUES 22 484 22 793 22 932 23 653 65 9 374 11 689 1 534 1 056 246 702 H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES 1 174 1 316 1 395 1 442 45 751 460 225 6 and somatropin agonists 1 168 1 304 1 383 1 430 45 750 454 220 6 137 248 H01AC01 Somatropin 1 168 1 304 1 383 1 430 45 750 454 220 6 137 248 H01AX Other anterior pituitary lobe hormones and analogues 5 8 10 10 40 0 5 5 0 3 053 H01AX01 Pegvisomant 5 8 10 10 40 0 5 5 0 3 053 H01B POSTERIOR PITUITARY LOBE HORMONES 18 297 18 368 18 267 18 536 60 8 650 7 914 1 077 895 40 282 H01BA Vasopressin and analogues 12 378 11 938 11 606 11 701 36 8 641 1 110 1 055 895 39 013 H01BA02 Desmopressin 12 378 11 938 11 606 11 701 36 8 641 1 110 1 055 895 39 013 H01BB Oxytocin and analogues 5 921 6 433 6 661 6 837 100 9 6 806 22 0 1 269 H01BB02 Oxytocin 5 921 6 433 6 661 6 837 100 9 6 806 22 0 1 269 H01C HYPOTHALAMIC HORMONES 3 174 3 272 3 444 3 845 94 5 3 408 276 156 66 117 H01CA Gonadotropin-releasing hormones 2 705 2 717 2 748 3 021 100 0 2 986 35 0 9 529 H01CA02 Nafarelin 2 705 2 717 2 748 3 021 100 0 2 986 35 0 9 529 H01CB Antigrowth hormones 363 377 415 458 52 5 62 235 156 55 245 H01CB02 Octreotide 334 333 358 383 52 <5 59 191 129 44 582 H01CB03 Lanreotide 38 56 67 89 51 <5 6 49 33 10 663 H01CC Anti-gonadotropin-releasing hormones 148 227 344 459 100 0 452 7 0 1 344 H01CC01 Ganirelix 79 142 261 351 100 0 347 <5 0 994 H01CC02 Cetrorelix 71 96 93 120 100 0 117 <5 0 350 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 134 018 145 047 156 724 169 602 56 4 088 51 338 67 546 46 630 43 772 H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN 133 875 144 892 156 588 169 475 56 4 087 51 306 67 472 46 610 43 691 H02AA Mineralocorticoids 1 019 1 087 1 121 1 144 57 86 363 477 218 320 H02AA02 Fludrocortisone 1 019 1 087 1 121 1 144 57 86 363 477 218 320 H02AB Glucocorticoids 133 770 144 763 156 447 169 332 56 4 073 51 274 67 428 46 557 43 370 H02AB01 Betamethasone 2 881 2 895 2 867 1 906 50 350 560 737 259 444 H02AB02 Dexamethasone 3 069 1 915 1 716 1 796 50 98 242 987 469 1 863 H02AB04 Methylprednisolone 5 752 7 192 9 139 9 567 52 79 3 101 4 548 1 839 3 716 H02AB06 Prednisolone 106 575 113 902 121 161 128 917 59 2 681 29 340 53 738 43 158 28 625 H02AB07 Prednisone 6 H02AB08 Triamcinolone 16 285 19 910 23 347 29 137 49 773 18 536 8 485 1 343 3 521 H02AB09 Hydrocortisone 447 430 447 429 61 34 174 179 42 194 H02AB10 Cortisone 2 253 2 344 2 375 2 452 52 134 631 1 138 549 4 947 H02AB13 Deflazacort 7 10 13 18 78 <5 <5 9 <5 56 H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS 302 358 344 359 66 <5 65 204 89 81 H02BX Corticosteroids for systemic use, combinations 302 358 344 359 66 <5 65 204 89 812004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 >=70 <15 15-44ATC group H 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-443.9 T able - ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins 70 Rapport 2008 Folkehelseinstituttet2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 >=70 <15 15-44ATC group H 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 66 <5 65 204 89 81 H03 THYROID THERAPY 141 006 148 122 154 293 160 905 83 1 103 30 341 80 506 48 955 52 395 H03A THYROID PREPARATIONS 137 408 144 601 150 748 157 347 83 1 084 29 328 78 994 47 941 50 235 H03AA Thyroid hormones 137 408 144 601 150 748 157 347 83 1 084 29 328 78 994 47 941 50 235 H03AA01 Levothyroxine sodium 137 235 144 428 150 511 157 090 83 1 081 29 240 78 859 47 910 46 617 H03AA02 Liothyronine sodium 3 459 3 461 3 643 3 867 90 11 1 348 2 243 265 3 196 H03AA03 Combinations of levo- thyroxine and liothyronine 180 91 <5 125 160 9 422 H03B ANTITHYROID PREPARATIONS 4 792 4 816 4 951 4 981 81 40 1 560 2 237 1 144 2 160 H03BA Thiouracils 448 450 453 470 88 <5 261 156 398 H03BA02 Propylthiouracil 448 450 398 H03BB Sulfur-containing imidazole derivatives 4 436 4 456 4 621 4 620 80 37 1 366 2 115 1 102 1 762 H03BB01 Carbimazole 4 436 4 456 4 621 4 620 80 37 1 366 2 115 1 102 1 762 H04 PANCREATIC HORMONES 4 997 5 142 5 018 4 767 46 1 026 2 402 1 108 231 2 458 H04A GLYCOGENOLYTIC HORMONES 4 997 5 142 5 018 4 767 46 1 026 2 402 1 108 231 2 458 H04AA Glycogenolytic hormones 4 997 5 142 5 018 4 767 46 1 026 2 402 1 108 231 2 458 H04AA01 Glucagon 4 997 5 142 5 018 4 767 46 1 026 2 402 1 108 231 2 458 H05 CALCIUM HOMEOSTASIS 348 457 532 602 68 0 69 216 317 13 005 H05A PARATHYROID HORMONES AND ANALOGUES 73 125 152 194 87 0 5 71 118 5 511 H05AA Parathyroid hormones and analogues 73 125 152 194 87 0 5 71 118 5 511 H05AA02 Teriparatide 73 125 152 174 87 0 <5 65 105 5 060 H05AA03 Parathyroid hormone 0 0 0 22 91 0 <5 8 13 451 H05B ANTI-PARATHYROID AGENTS 278 336 383 410 59 0 64 145 201 7 494 H05BA Calcitonin preparations 277 251 194 156 83 0 5 27 124 822 H05BA01 Calcitonin (salmon synthetic) 277 251 194 156 83 0 5 27 124 822 H05BX Other anti-parathyroid agents <5 85 189 254 44 0 59 118 77 6 672 H05BX01 Cinacalcet <5 85 189 254 44 0 59 118 77 6 672Rapport 2008 Folkehelseinstituttet 71J01 ANTIBACTERIALS FOR SYSTEMIC USE 1 034 011 1 101 329 1 136 873 1 167 977 59 154 806 477 226 361 924 174 021 277 739 J01A TETRACYCLINES 168 556 179 255 176 509 180 323 56 1 534 71 644 74 220 32 925 29 575 J01AA Tetracyclines 168 556 179 255 176 509 180 323 56 1 534 71 644 74 220 32 925 29 575 J01AA02 Doxycycline 135 542 144 704 141 389 144 442 57 691 47 408 65 342 31 001 17 818 J01AA04 Lymecycline 9 353 10 513 11 473 12 322 53 264 8 454 3 038 566 6 487 J01AA06 Oxytetracycline 6 573 6 463 6 065 5 785 52 105 3 422 1 721 537 1 143 J01AA07 Tetracycline 19 456 20 173 20 131 20 337 53 500 13 921 4 894 1 022 4 025 J01AA08 Minocycline 5 5 5 <5 67 0 0 <5 0 8 J01AA12 Tigecycline 0 0 <5 <5 0 0 95 J01B AMPHENICOLS <5 0 0 0 - 0 0 0 0 0 J01BA Amphenicols <5 0 0 0 - 0 0 0 0 0 J01BA01 Chloramphenicol <5 0 0 0 - 0 0 0 0 0 J01C BETA-LACTAM ANTIBAC-TERIALS, PENICILLINS 621 190 665 295 701 462 730 743 60 110 529 296 887 215 248 108 079 110 837 J01CA Penicillins with extended spectrum 209 454 226 201 245 166 262 239 74 31 772 88 680 79 598 62 189 49 309 J01CA01 Ampicillin 24 35 33 32 38 <5 6 <5 23 18 J01CA02 Pivampicillin 5 626 5 147 4 101 1 288 65 9 446 461 372 334 J01CA04 Amoxicillin 89 668 99 410 104 505 114 529 56 28 196 30 939 34 302 21 092 14 710 J01CA08 Pivmecillinam 122 534 130 617 146 361 156 795 87 3 852 60 434 48 099 44 410 34 223 J01CA11 Mecillinam 5 <5 11 12 26 J01CE Beta-lactamase sensitive penicillins 401 075 438 854 450 078 460 608 54 81 119 201 751 131 029 46 709 43 165 J01CE01 Benzylpenicillin 56 57 63 53 43 <5 12 16 23 36 J01CE02 Phenoxymethylpenicillin 401 006 438 772 449 987 460 529 54 81 118 201 715 131 005 46 691 43 016 J01CE08 Benzathine benzylpeni-cillin 39 48 61 50 <5 29 15 <5 113 J01CF Beta-lactamase resistant penicillins 59 115 53 033 65 515 73 672 48 6 019 31 803 23 992 11 858 18 180 J01CF01 Dicloxacillin 55 683 46 428 62 586 71 444 48 5 934 30 944 23 180 11 386 15 947 J01CF02 Cloxacillin 3 949 7 757 3 496 2 685 48 103 1 012 982 588 2 219 J01CF05 of penicil-lins, incl. beta-lactamase inhibitors 397 21 48 31 68 <5 <5 182 J01CR02 Amoxicillin and enzyme inhibitor 392 8 30 15 87 15 0 0 0 6 J01CR05 Piperacillin and enzyme inhibitor 5 13 18 <5 <5 176 J01D OTHER BETA-LACTAM ANTIBACTERIALS 35 909 33 484 29 319 28 933 57 2 892 10 628 9 989 5 424 7 865 J01DB First-generation cephalosporins 35 775 33 323 29 102 28 696 57 2 834 10 563 9 929 5 370 4 254 J01DB01 Cefalexin 35 762 33 318 29 090 28 672 57 2 833 10 557 9 919 5 363 4 215 J01DB03 Cefalotin 13 6 14 24 33 <5 6 10 7 39 J01DC Second-generation cephalosporins 33 41 46 57 60 0 6 16 35 51 J01DC02 Cefuroxime 33 41 46 57 60 0 6 16 35 51 J01DD Third-generation cephalosporins 105 125 173 197 47 62 50 57 28 2 063 J01DD01 Cefotaxime 9 14 16 16 44 <5 <5 5 6 40 J01DD02 Ceftazidime 52 45 54 66 44 13 28 17 8 1 468 J01DD04 Ceftriaxone 47 68 103 115 50 46 20 35 14 555 J01DF Monobactams 16 17 12 12 58 0 10 <5 0 452 J01DF01 Aztreonam 16 17 12 12 58 0 10 <5 0 452 J01DH Carbapenems 32 37 34 29 52 6 17 5 <5 1 0452004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 >=70 <15 15-44ATC group J 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-443.10 T able - ATC group J - Antiinfectives for systemic use 72 Rapport 2008 FolkehelseinstituttetJ01DH02 Meropenem 29 35 34 27 52 6 15 5 <5 1 038 J01DH03 Ertapenem 0 0 0 <5 2 J01E SULFONAMIDES AND TRIMETHOPRIM 132 720 134 733 131 635 125 901 79 12 649 37 227 38 979 37 046 14 262 J01EA Trimethoprim and derivatives 104 287 105 775 102 063 96 484 86 7 844 29 314 29 220 30 106 10 302 J01EA01 Trimethoprim 104 287 105 775 102 063 96 484 86 7 844 29 314 29 220 30 106 10 302 J01EE Combinations of sulfon- amides and trimetho - prim, incl. derivatives 32 823 33 489 33 886 33 468 57 5 279 8 693 10 924 8 572 3 960 J01EE01 Sulfamethoxazole and trimethoprim 32 823 33 489 33 886 33 468 57 5 279 8 693 10 924 8 572 3 960 J01F MACROLIDES, LINCOSA - MIDES AND STREPTO - GRAMINS 270 274 301 998 317 040 326 009 57 49 948 151 830 95 179 29 052 59 708 J01FA Macrolides 244 540 271 007 285 956 292 005 58 46 807 136 684 83 989 24 525 48 661 J01FA01 Erythromycin 134 119 150 319 161 938 158 247 58 37 656 63 764 42 951 13 876 21 283 J01FA02 Spiramycin 4 413 4 181 4 149 4 371 61 94 1 952 1 866 459 699 J01FA09 Clarithromycin 49 638 50 739 50 845 51 571 57 6 049 19 082 19 405 7 035 8 693 J01FA10 Azithromycin 66 207 76 886 81 225 90 864 59 4 464 58 631 23 721 4 048 17 986 J01FA15 Telithromycin 18 0 0 0 - 0 0 0 0 0 J01FF Lincosamides 31 188 37 647 37 933 41 651 53 3 987 18 955 13 441 5 268 11 048 J01FF01 Clindamycin 31 188 37 647 37 933 41 651 53 3 987 18 955 13 441 5 268 11 048 J01G AMINOGLYCOSIDE ANTIBACTERIALS 214 248 257 282 48 16 11 931 J01GA Streptomycins <5 <5 <5 0 J01GA01 Streptomycin <5 <5 <5 0 - 0 0 0 0 0 J01GB Other aminoglycosides 213 246 256 282 48 126 101 39 16 11 931 J01GB01 Tobramycin 187 226 229 253 48 115 95 30 13 11 636 J01GB03 Gentamicin 25 19 23 25 J01GB07 Netilmicin 0 0 <5 0 - 0 0 0 0 0 J01M QUINOLONE ANTIBACTERIALS 42 639 46 990 51 286 55 835 51 393 14 296 22 486 18 660 16 127 J01MA Fluoroquinolones 42 638 46 989 51 285 55 835 51 393 14 296 22 486 18 660 16 127 J01MA01 Ofloxacin 3 766 3 422 3 199 3 001 49 6 882 1 176 937 1 290 J01MA02 Ciprofloxacin 39 322 44 042 48 526 53 220 51 387 13 472 21 475 17 886 14 710 J01MA12 Levofloxacin <5 0 0 70 J01MA14 Moxifloxacin 0 0 0 36 36 0 30 6 0 58 J01MB Other quinolones <5 <5 <5 0 - J01MB02 Nalidixic acid <5 <5 <5 0 - 0 0 0 0 0 J01X OTHER ANTIBACTERIALS 42 672 44 071 45 040 46 595 84 1 483 10 423 14 430 20 259 27 434 J01XA Glycopeptide antibacterials 14 16 14 23 26 5 6 <5 8 196 J01XA01 Vancomycin 9 11 11 21 24 5 <5 <5 8 170 J01XA02 Teicoplanin 5 5 0 <5 0 0 26 J01XB Polymyxins 67 73 79 66 50 12 36 13 5 2 164 J01XB01 Colistin 47 39 47 37 43 6 23 6 <5 363 J01XC Steroid antibacterials 1 420 1 097 868 865 51 43 284 317 221 488 J01XC01 Fusidic acid 1 420 1 097 868 865 51 43 284 317 221 488 J01XD Imidazole derivatives 12 8 12 16 56 <5 <5 6 7 47 J01XD01 Metronidazole 12 8 12 16 56 <5 <5 6 7 47 J01XE Nitrofuran derivatives 28 436 29 002 29 180 29 366 87 1 344 8 109 9 082 10 831 3 3692004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 >=70 <15 15-44ATC group J 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44Rapport 2008 Folkehelseinstituttet 73J01XE01 Nitrofurantoin 28 436 29 002 29 180 29 366 87 1 344 8 109 9 082 10 831 3 369 J01XX Other antibacterials 15 622 17 030 18 199 19 846 82 109 2 528 6 104 11 105 21 170 J01XX04 Spectinomycin <5 0 0 0 - 0 0 0 0 0 J01XX05 Methenamine 15 500 16 900 18 074 19 703 82 107 2 497 6 041 11 058 15 378 J01XX08 Linezolid 123 134 128 146 42 <5 32 65 47 5 791 J02 ANTIMYCOTICS FOR SYSTEMIC USE 32 887 34 157 36 874 39 033 87 345 25 492 10 586 2 610 14 778 J02A ANTIMYCOTICS FOR SYSTEMIC USE 32 887 34 157 36 874 39 033 87 345 25 492 10 586 2 610 14 778 J02AA Antibiotics <5 0 7 <5 100 0 0 <5 0 0 J02AA01 Amphotericin B <5 0 7 <5 100 0 0 <5 0 0 J02AB Imidazole derivatives 2 182 2 239 2 317 2 325 45 28 1 525 672 100 724 J02AB02 Ketoconazole 2 182 2 239 2 317 2 325 45 28 1 525 672 100 724 J02AC Triazole derivatives 30 791 32 009 34 664 36 782 89 319 24 018 9 930 2 515 13 754 J02AC01 Fluconazole 30 560 31 747 34 357 36 534 90 310 23 893 9 838 2 493 8 539 J02AC02 Itraconazole 314 330 403 317 79 9 198 98 12 493 J02AC03 Voriconazole 29 45 62 59 41 <5 12 33 11 4 672 J02AC04 Posaconazole 0 0 0 <5 100 0 0 <5 0 50 J02AX Other antimycotics for systemic use 0 776 801 887 907 44 19 231 352 305 1 709 J04A DRUGS FOR TREATMENT OF TUBERCULOSIS 332 352 448 474 48 15 161 153 145 1 571 J04AB Antibiotics 191 217 267 314 49 8 68 121 117 1 044 J04AB02 Rifampicin 172 197 245 296 50 7 62 112 115 698 J04AB04 Rifabutin 19 23 24 17 47 <5 6 8 <5 310 J04AB30 Capreomycin 0 0 0 <5 0 0 0 <5 0 37 J04AC Hydrazides 72 62 55 43 65 <5 17 15 9 62 J04AC01 Isoniazid 72 62 55 43 65 <5 17 15 9 62 J04AD Thiocarbamide derivatives <5 0 0 <5 0 0 0 20 J04AD01 Protionamide <5 0 0 <5 0 0 0 <5 0 20 J04AK Other drugs for treat-ment of tuberculosis 119 124 155 125 52 5 61 39 20 365 J04AK01 Pyrazinamide 36 25 40 25 64 <5 15 <5 <5 25 J04AK02 Ethambutol 99 114 139 121 52 5 59 38 19 340 J04AM Combinations of drugs for treatment of tuberculosis 88 88 115 92 43 <5 59 15 16 80 J04AM02 Rifampicin and isoniazid 53 66 82 67 45 <5 44 13 8 52 J04AM05 Rifampicin, pyrazinamide and isoniazid 46 36 50 32 41 0 17 5 10 27 J04AM06 Rifampicin, pyrazinamide, ethambutol and isoniazid 0 0 0 <5 100 0 <5 0 0 1 J04B DRUGS FOR TREATMENT OF LEPRA 445 449 439 436 39 <5 71 200 161 137 J04BA Drugs for treatment of lepra 445 449 439 436 39 <5 71 200 161 137 J04BA02 Dapsone 445 449 439 436 39 <5 71 200 161 137 J05 ANTIVIRALS FOR SYSTEMIC USE 16 229 39 129 24 139 24 503 61 443 12 217 8 781 3 062 195 310 J05A DIRECT ACTING ANTIVIRALS 16 229 39 129 24 139 24 503 61 443 12 217 8 781 3 062 195 310 J05AB Nucleosides and nucle - otides excl. reverse transcriptase inhibitors 14 534 16 164 18 391 19 835 64 317 9 915 6 864 2 739 52 916 J05AB01 Aciclovir 6 402 7 596 8 359 8 781 67 174 4 177 3 011 1 419 4 8112004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 >=70 <15 15-44ATC group J 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44 74 Rapport 2008 FolkehelseinstituttetJ05AB04 521 J05AB06 Ganciclovir <5 0 0 - 0 0 0 0 0 J05AB11 Valaciclovir 7 605 8 093 9 532 10 462 64 146 5 442 3 553 1 321 19 474 J05AB12 Cidofovir 0 0 <5 0 - 0 0 0 0 0 J05AB14 Valganciclovir 182 181 191 196 42 <5 42 129 23 7 110 J05AD Phosphonic acid derivatives 0 0 <5 <5 100 0 0 0 38 J05AD01 Foscarnet 0 0 <5 <5 100 0 <5 0 0 38 J05AE Protease inhibitors 640 708 819 959 39 7 569 375 8 45 893 J05AE01 Saquinavir 24 20 16 19 42 0 9 10 0 720 J05AE02 Indinavir 54 46 30 20 35 0 9 11 0 476 J05AE03 Ritonavir 73 167 260 310 29 0 171 138 <5 1 404 J05AE04 Nelfinavir 102 79 68 51 65 0 35 15 <5 870 J05AE05 Amprenavir <5 <5 0 0 - 0 0 0 0 0 J05AE06 Lopinavir 425 386 410 523 45 7 340 173 <5 22 396 J05AE07 Fosamprenavir <5 5 6 5 40 0 <5 <5 0 159 J05AE08 Atazanavir 104 221 353 425 31 0 232 189 <5 18 344 J05AE09 Tipranavir 0 0 6 7 14 0 <5 <5 0 524 J05AE10 Darunavir 0 0 0 25 20 0 5 20 0 1 000 J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 479 539 450 400 34 14 192 187 7 16 457 J05AF01 Zidovudine 72 71 69 61 44 8 35 17 <5 1 308 J05AF02 Didanosine 193 182 131 102 38 <5 55 42 <5 1 854 J05AF04 Stavudine 153 99 69 47 45 <5 26 20 0 896 J05AF05 Lamivudine 279 261 209 174 36 7 82 80 5 2 270 J05AF06 Abacavir 71 82 51 52 31 0 24 25 <5 1 137 J05AF07 Tenofovir disoproxil 132 224 191 155 <5 76 76 0 5 797 J05AF08 Adefovir dipivoxil 14 26 32 36 19 0 17 19 0 1 843 J05AF09 Emtricitabine 8 90 47 20 30 0 6 14 0 390 J05AF10 Entecavir 0 0 <5 23 30 0 12 11 0 910 J05AF11 Telbivudine 0 0 0 <5 J05AG Non-nucleoside reverse transcriptase inhibitors 419 465 514 573 38 12 299 256 6 15 740 J05AG01 Nevirapine 178 180 176 179 35 10 83 83 <5 4 072 J05AG03 Efavirenz 250 298 342 398 220 173 <5 11 668 J05AH Neuraminidase inhibi-tors 740 22 151 4 584 3 270 52 106 1 507 1 347 310 929 J05AH01 Zanamivir 49 36 0 <5 0 0 <5 0 <5 1 J05AH02 Oseltamivir 692 22 120 4 584 3 268 53 106 1 506 1 347 309 928 J05AR Antivirals for treatment of HIV infections, combinations 688 800 1 054 1 297 38 8 744 535 10 62 489 J05AR01 Zidovudine and lamivu-dine 644 681 676 682 43 262 <5 23 516 J05AR02 Lamivudine and abacavir 0 87 125 161 35 0 78 <5 6 058 J05AR03 Tenofovir disoproxil and <5 30 896 J05AR04 Zidovudine, lamivudine and abacavir 49 44 38 39 38 <5 18 20 0 2 020 J05AX Other antivirals 11 7 7 8 50 0 J05AX07 Enfuvirtide 10 6 6 7 43 0 <5 6 0 8132004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 >=70 <15 15-44ATC group J 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44Rapport 2008 Folkehelseinstituttet 752004 2005 2006 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group L L02 ENDOCRINE THERAPY 20 238 21 608 22 455 23 650 51 168 2 263 8 402 12 817 352 146 L02A HORMONES AND RELATED AGENTS 9 516 10 025 10 194 10 625 21 166 1 742 1 946 6 771 114 583 L02AA Estrogens 111 99 79 74 9 0 <5 10 63 148 L02AA02 Polyestradiol phosphate 111 99 79 74 9 0 <5 10 63 148 L02AB Progestogens 389 358 313 294 70 0 10 132 152 1 123 L02AB01 Megestrol 285 257 227 216 63 0 9 103 104 866 L02AB02 Medroxyprogesterone 106 102 90 79 90 0 <5 29 49 257 L02AE Gonadotropin releasing hormone analogues 9 068 9 611 9 840 10 292 19 166 1 732 1 811 6 583 113 311 L02AE01 Buserelin 1 348 1 495 1 370 1 364 99 0 1 340 13 11 2 421 L02AE02 Leuprorelin 3 568 3 641 3 467 3 544 9 163 152 519 2 710 42 001 L02AE03 Goserelin 4 233 4 631 5 170 5 506 6 <5 252 1 316 3 935 68 884 L02AE04 Triptorelin <5 0 <5 <5 50 <5 <5 0 5 L02B HORMONE ANTAGONISTS AND RELATED AGENTS 13 047 14 101 14 904 16 018 62 <5 564 7 458 7 994 237 563 L02BA Anti-estrogens 6 508 6 635 5 841 5 566 99 <5 515 3 140 1 909 13 588 L02BA01 Tamoxifen 6 468 6 461 5 602 5 316 99 <5 508 3 004 1 802 6 141 L02BA03 Fulvestrant 52 182 257 271 99 0 7 145 119 7 447 L02BB Anti-androgens 4 868 5 215 5 512 6 003 0 0 <5 1 643 4 356 154 902 L02BB01 Flutamide 634 574 481 0 0 <5 319 2 056 L02BB03 Bicalutamide 4 266 4 676 5 058 5 595 0 0 <5 1 543 4 050 152 846 L02BG Enzyme inhibitors 2 226 3 676 4 610 5 518 100 0 78 3 329 2 111 69 073 L02BG03 Anastrozole 1 206 2 206 2 741 3 253 99 0 37 2 032 1 184 39 302 L02BG04 Letrozole 749 872 994 1 175 99 0 24 627 524 13 661 L02BG06 Exemestane 436 774 1 074 1 272 100 0 19 786 467 16 110 L03 IMMUNOSTIMULANTS 3 408 3 730 4 354 4 881 60 46 2 110 2 459 266 341 419 L03A IMMUNOSTIMULANTS 3 408 3 730 4 354 4 881 60 46 2 110 2 459 266 341 419 L03AA Colony stimulating factors 849 1 009 1 417 1 707 62 34 403 1 040 230 69 352 L03AA02 Filgrastim 553 315 366 378 52 33 100 204 41 9 528 L03AA13 Pegfilgrastim 378 763 1 137 1 424 65 <5 330 891 202 59 824 L03AB Interferons 2 203 2 335 2 486 2 601 56 11 1 405 1 152 33 215 871 L03AB03 Interferon gamma 10 8 10 11 45 7 <5 <5 0 1 816 L03AB04 Interferon alfa-2a 32 41 20 15 15 <5 1 041 L03AB05 Interferon alfa-2b 269 203 158 113 35 0 11 83 19 3 299 L03AB07 Interferon beta-1a 972 1 088 1 206 1 311 69 <5 751 555 <5 143 134 L03AB08 Interferon beta-1b 300 305 334 336 66 0 146 190 0 29 325 L03AB10 Peginterferon alfa-2b 359 443 446 503 37 0 291 205 7 23 658 L03AB11 Peginterferon alfa-2a 295 265 299 324 33 <5 13 597 L03AC Interleukins <5 398 425 506 72 <5 359 304 <5 56 182 L03AX03 BCG vaccine 13 12 8 5 40 0 0 <5 <5 55 L03AX13 Glatiramer <5 56 127 L04 IMMUNOSUPPRESSANTS 23 934 26 854 29 180 32 294 57 759 8 888 16 936 5 711 968 237 L04A IMMUNOSUPPRESSANTS 23 934 26 854 29 180 32 294 57 759 8 888 16 936 5 711 968 237 L04AA Selective immunos-uppressants 2 689 2 912 3 295 3 787 49 34 899 2 259 595 97 928 L04AA06 Mycophenolic acid 1 441 1 662 1 925 2 295 38 34 656 1 326 279 60 875 L04AA10 Sirolimus 66 59 76 68 34 <5 18 40 9 3 560 L04AA13 Leflunomide 1 221 1 158 1 214 1 260 71 0 173 788 299 6 936 L04AA18 Everolimus 7 62 147 228 25 0 50 154 24 12 904 L04AA21 Efalizumab 0 45 85 127 38 0 41 82 <5 13 2333.11 T able - ATC group L - Antineoplastic and immunomodulating agents 76 Rapport 2008 Folkehelseinstituttet2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group L L04AA24 Abatacept 13 69 0 <5 8 <5 421 L04AB Tumor necrosis factor alpha (TNF-) inhibitors 3 571 4 586 5 536 6 540 57 124 2 154 3 668 594 718 360 L04AB01 Etanercept 2 816 3 602 4 122 4 554 57 109 1 483 2 559 403 474 894 L04AB02 Infliximab <5 <5 20 405 45 7 170 192 36 35 849 L04AB04 Adalimumab 935 1 125 1 631 1 790 61 10 590 1 024 166 207 616 L04AC Interleukin inhibitors 72 62 55 61 66 9 18 28 6 5 337 L04AC03 Anakinra 72 62 55 61 66 9 18 28 6 5 337 L04AD Calcineurin inhibitors 3 905 4 054 4 166 4 327 39 138 1 310 2 346 533 125 062 L04AD01 Ciclosporin 3 399 3 442 3 445 3 424 39 73 959 1 903 489 84 826 L04AD02 Tacrolimus 563 675 769 975 40 72 376 479 48 40 236 L04AX Other immuno- suppressants 18 454 20 596 22 043 24 132 59 574 6 354 12 503 4 701 21 550 L04AX01 Azathioprine 5 028 5 464 5 661 5 951 52 172 2 762 2 394 623 7 841 L04AX02 Thalidomide 193 231 274 356 42 8 9 153 186 4 819 L04AX03 Methotrexate 13 320 15 004 16 203 17 919 62 397 3 618 10 001 3 903 8 821 L04AX04 Lenalidomide 0 0 0 <5 100 0 10 368 111 739 823 000 783 281 803 456 822 316 57 10 753 330 581 369 688 214 181 M01AA Butylpyrazolidines <5 M01AA01 Phenylbutazone <5 <5 <5 0 - 0 0 0 0 0 M01AB Acetic acid derivatives and related substances 256 230 352 480 389 169 436 287 55 5 943 186 551 193 666 50 127 63 519 M01AB01 Indometacin 12 211 12 801 13 002 12 711 53 46 4 009 6 410 2 246 3 213 M01AB02 Sulindac 741 854 750 Diclofenac 233 321 485 360 616 408 728 55 5 876 180 452 179 606 42 794 45 565 M01AB15 Ketorolac 5 <5 8 7 57 0 <5 5 0 6 M01AB16 Aceclofenac 1 381 1 658 360 0 - 0 0 0 0 0 M01AB55 Diclofenac, combinations 11 779 22 468 21 104 21 643 64 27 4 363 11 229 6 024 13 862 M01AC Oxicams 154 453 197 572 201 052 167 622 56 924 65 743 80 316 20 639 36 810 M01AC01 Piroxicam 134 864 164 983 172 204 140 361 55 853 59 637 66 394 13 477 28 360 M01AC06 Meloxicam 20 723 35 330 31 151 29 434 63 73 6 754 15 097 7 510 8 450 M01AE Propionic acid derivatives 229 176 250 484 251 798 262 454 61 4 098 109 623 114 182 34 551 57 561 M01AE01 Ibuprofen 1) 162 620 176 266 183 558 193 707 62 3 171 87 659 81 725 21 152 30 620 M01AE02 Naproxen1)63 880 71 216 64 988 64 431 59 939 21 446 29 978 12 068 23 026 M01AE03 Ketoprofen 6 817 8 222 8 279 8 789 61 26 2 241 4 620 1 902 3 513 M01AE14 Dexibuprofen 712 1 005 1 223 2 182 58 7 949 952 274 402 M01AG Fenamates 937 1 003 918 847 80 9 568 256 14 729 M01AG02 Tolfenamic acid 937 1 003 918 847 80 9 568 256 14 729 M01AH Coxibs 331 908 76 318 34 413 37 255 55 54 12 624 18 545 6 032 20 876 M01AH01 Celecoxib 104 979 31 909 11 194 9 397 59 13 2 742 4 768 1 874 9 475 M01AH02 Rofecoxib 160 920 8 0 <5 100 0 0 <5 <5 0 M01AH03 Valdecoxib 65 831 14 483 0 0 0 <5 0 M01AH04 Parecoxib <5 0 0 0 - 0 0 0 0 0 M01AH05 Etoricoxib 52 038 31 817 23 504 28 104 54 41 9 958 13 902 4 203 11 402 M01AX Other antiinflammatory and antirheumatic agents, non-steroids 19 316 66 335 71 115 64 408 68 29 6 434 36 941 21 004 34 686 M01AX01 Nabumetone 6 930 14 899 12 718 12 759 67 20 2 970 6 672 3 097 7 212 M01AX05 Glucosamine 11 795 52 185 58 707 51 510 69 9 3 440 30 222 17 839 25 485 M01C SPECIFIC ANTIRHEUMATIC AGENTS 612 498 444 360 68 0 35 213 112 1 807 M01CB Gold preparations 514 418 383 308 70 0 29 178 101 786 M01CB01 Sodium aurothiomalate 259 213 188 109 66 0 7 54 48 167 M01CB03 Auranofin 256 205 196 200 72 0 22 125 53 618 M01CC Penicillamine and similar agents 15 17 17 15 47 0 <5 12 <5 97 M01CC01 Penicillamine 15 17 17 15 47 0 <5 12 <5 97 M01CX Other specific antirheumatic agents 83 63 44 37 65 0 <5 23 10 924 M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 61 484 49 719 41 863 37 831 57 1 337 12 956 14 744 8 794 5 233 M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 61 484 49 719 41 863 37 831 57 1 337 12 956 14 744 8 794 5 2332004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group M 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 3.12 T able - ATC group M - Musculo-skeletal system 78 Rapport 2008 FolkehelseinstituttetM02AA Antiinflammatory prepa- rations, non-steroids for topical use 61 321 49 570 41 729 37 720 57 1 333 12 927 14 720 8 740 5 215 M02AA10 Ketoprofen 1)57 306 45 267 37 832 33 759 57 1 150 11 668 13 361 7 580 4 649 M02AA13 Ibuprofen1)4 121 4 390 3 934 3 956 59 182 1 247 1 342 1 185 540 M02AA15 Diclofenac 61 62 66 127 73 <5 40 47 36 26 M02AB Capsicum preparations and similar agents 12 16 14 13 62 0 <5 6 <5 6 M02AC Preparations with salicylic acid derivatives 153 142 129 106 69 <5 30 18 54 9 M02AX Other topical products for joint and muscular pain 18 11 10 21 86 0 <5 6 11 2 M02AX10 Various 18 11 10 21 86 0 <5 6 11 2 M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS 87 448 85 255 78 404 51 670 64 127 19 211 27 918 4 414 35 683 M03BA Carbamic acid esters 84 482 82 183 75 164 48 202 65 8 18 355 25 915 3 924 28 763 M03BA02 Carisoprodol 84 455 82 152 75 145 48 188 65 8 18 352 25 907 3 921 28 720 M03BA52 Carisoprodol, combinations excl. psycholeptics 56 48 33 25 80 8 14 <5 43 M03BB Oxazol, thiazine, and triazine derivatives 13 excl. psycholeptics 11 12 5 0 - 0 0 0 0 0 M03BC Ethers, chemically close to antihistamines <5 0 0 <5 0 3 M03BX Other centrally acting agents 3 235 3 344 3 500 3 834 52 119 1 013 2 195 507 6 914 M03BX01 Baclofen 3 212 3 317 3 469 3 802 52 119 1 001 2 175 507 6 547 M03BX02 Tizanidine 48 55 59 60 38 0 22 37 <5 367 M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS <5 <5 M04 ANTIGOUT PREPARATIONS 32 675 34 548 35 891 36 438 31 9 2 255 15 163 19 011 15 153 M04A ANTIGOUT PREPARATIONS 32 675 34 548 35 891 36 438 31 9 2 255 15 163 19 011 15 153 M04AA Preparations inhibiting uric acid production 30 443 32 065 33 319 33 742 31 <5 2 001 14 030 17 707 12 907 M04AA01 Allopurinol 30 443 32 065 33 319 33 742 31 <5 2 001 14 030 17 707 12 907 M04AB Preparations increasing uric acid excretion 1 973 2 083 2 063 2 061 32 0 168 868 1 025 1 494 M04AB01 Probenecid 1 973 2 083 2 063 2 061 32 0 168 868 1 025 1 494 M04AC Preparations with no effect on uric acid metabolism 1 394 1 713 1 906 2 064 24 5 187 927 945 752 M04AC01 Colchicine 1 394 1 713 1 906 2 064 24 5 187 927 945 752 M05 DRUGS FOR TREATMENT OF BONE DISEASES 49 559 54 063 56 095 56 735 90 <5 619 18 213 37 899 71 260 M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION 49 559 54 063 56 095 56 735 90 <5 619 18 213 37 899 71 260 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 70 <15 15-44ATC group MRapport 2008 Folkehelseinstituttet 79M05BA Bisphosphonates 44 762 50 056 52 810 53 886 90 <5 606 17 647 35 629 64 420 M05BA01 Etidronic acid 830 693 567 442 94 0 <5 63 378 486 M05BA02 Clodronic acid 66 44 40 44 61 0 0 22 22 650 M05BA03 Pamidronic acid <5 acid 40 486 43 650 48 332 51 581 90 <5 564 16 791 34 222 53 679 M05BA06 Ibandronic acid 19 74 1 424 719 93 0 16 336 367 4 004 M05BA07 Risedronic acid 3 955 6 277 6 033 1 971 91 0 35 723 1 213 4 858 M05BA08 Zoledronic acid 49 40 32 47 53 0 0 27 20 716 M05BB Bisphosphonates, combinations 5 666 4 675 3 865 3 236 94 0 16 645 2 575 6 840 M05BB01 Etidronic acid and calcium, sequential 5 666 4 674 3 860 3 235 94 0 16 645 2 574 6 840 M05BB03 Alendronic acid and colecalciferol 0 <5 5 <5 0 0 0 0 <5 0 M09 OTHER DRUGS FOR DIS-ORDERS OF THE MUSCULO-SKELETAL SYSTEM <5 5 <5 <5 50 0 0 0 <5 5 M09A OTHER DRUGS FOR DISOR-DERS OF THE MUSCULO- SKELETAL SYSTEM <5 5 <5 <5 50 0 0 0 <5 5 M09AX Other drugs for disorders of the musculo-skeletal system <5 5 <5 <5 50 0 Hyaluronic 5 <5 <5 50 0 0 0 <5 52004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group M 80 Rapport 2008 FolkehelseinstituttetN02 ANALGESICS 564 852 600 215 618 356 647 629 60 7 877 219 580 275 389 144 783 597 655 N02A OPIOIDS 431 645 451 368 456 177 470 638 57 4 346 158 074 201 995 106 223 318 452 N02AA Natural opium alkaloids 387 339 402 882 401 143 406 292 56 4 256 140 693 174 714 86 629 217 015 N02AA01 Morphine 7 540 7 080 6 607 6 754 48 11 1 263 3 034 2 446 21 242 N02AA03 Hydromorphone 0 121 90 65 52 0 16 26 23 911 N02AA05 Oxycodone 6 029 8 974 10 842 12 629 52 <5 1 772 5 659 5 194 53 029 N02AA08 Dihydrocodeine 51 40 35 38 68 0 7 26 5 150 N02AA59 Codeine, combinations excl. psycholeptics 380 786 394 958 392 189 396 222 56 4 245 139 142 170 316 82 519 141 682 N02AB Phenylpiperidine derivatives 9 326 9 334 9 737 10 084 56 11 1 888 4 232 3 953 40 313 N02AB01 Ketobemidone 3 980 3 863 3 753 3 744 53 <5 1 136 1 760 845 3 524 N02AB02 Pethidine 1 559 1 482 1 466 1 399 60 <5 443 687 267 1 839 N02AB03 Fentanyl 4 380 4 559 5 098 5 496 58 6 438 2 043 3 009 34 950 N02AC Diphenylpropylamine derivatives 11 786 11 356 10 161 9 268 62 <5 1 348 4 096 3 823 5 721 N02AC03 Piritramide <5 0 0 0 - 0 0 0 0 N02AC54 Dextropropoxyphene, comb. excl. psycholeptics 11 785 11 356 10 161 9 268 62 <5 1 348 4 096 3 823 5 721 N02AD Benzomorphan derivatives 1 591 162 79 52 54 0 6 36 10 554 N02AD01 Pentazocine 1 591 162 79 52 54 0 6 36 10 554 N02AE Oripavine derivatives 2 324 2 430 5 304 7 907 65 0 1 417 2 591 3 899 20 476 N02AE01 Buprenorphine 2 324 2 430 5 304 7 907 65 0 1 417 2 591 3 899 20 476 N02AG Opioids in combination with antispasmodics 1 904 1 946 1 866 1 854 57 <5 570 852 430 1 632 N02AG01 Morphine and antispasmodics 88 109 165 178 50 0 8 58 112 38 N02AG02 Ketobemidone and antispasmodics 1 820 1 839 1 708 1 684 57 <5 562 796 324 1 594 N02AX Other opioids 60 801 68 160 77 715 91 718 62 102 26 174 39 213 26 229 32 740 N02AX02 Tramadol 60 801 68 160 77 715 91 718 62 102 26 174 39 213 26 229 32 740 N02B OTHER ANALGESICS AND ANTIPYRETICS 146 649 176 813 198 085 226 047 65 2 246 54 904 92 802 76 095 39 968 N02BA Salicylic acid and derivatives 1 685 1 493 1 222 791 58 93 217 250 231 108 N02BA01 Acetylsalicylic acid 1) 885 788 705 779 57 93 216 242 228 96 N02BA11 Diflunisal 799 703 517 11 82 0 N02BB Pyrazolones 1 229 1 136 1 045 987 70 11 331 356 289 478 N02BB02 Metamizole sodium 0 <5 excl. Psycholeptics 1)1 229 1 135 1 981 70 11 328 353 289 475 N02BE Anilides 144 300 174 805 196 364 224 742 65 2 147 54 479 92 357 75 759 39 377 N02BE01 Paracetamol1) 144 299 174 805 196 364 224 742 65 2 147 54 479 92 357 75 759 39 376 N02BE05 Propacetamol <5 <5 0 0 - 0 0 0 0 N02BE51 Paracetamol, combinations excl. psycholeptics 0 0 0 <5 100 4 N02C ANTIMIGRAINE PREPARATIONS 78 276 81 304 83 837 86 656 79 1 647 42 445 39 585 2 979 239 235 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group N 3.13 T able - ATC group N - Nervous systemRapport 2008 Folkehelseinstituttet 81N02CA Ergot alkaloids 6 072 5 416 4 811 4 262 82 22 834 2 621 785 1 858 N02CA04 Methysergide 11 48 N02CA52 Ergotamine, combinations excl. psycholeptics 25 64 <5 9 <5 26 N02CA72 Ergotamine, combinations with psycholeptics 6 043 5 391 4 790 4 245 82 22 833 2 610 780 1 784 N02CC Selective serotonin (5HT 1) agonists 71 068 74 361 77 245 80 445 79 1 555 41 119 35 684 2 087 235 652 N02CC01 Sumatriptan 28 757 30 763 31 849 32 324 77 1 321 15 997 14 119 887 86 105 N02CC02 Naratriptan 1 692 1 584 1 563 1 527 85 5 637 828 57 4 783 N02CC03 Zolmitriptan 12 291 11 997 13 666 13 948 82 59 6 576 6 931 382 42 565 N02CC04 Rizatriptan 19 326 20 777 22 384 24 815 80 197 13 972 10 069 577 57 763 N02CC05 Almotriptan 4 078 4 879 5 124 4 684 82 18 2 869 1 706 91 8 102 N02CC06 Eletriptan 14 077 13 256 12 526 12 532 82 52 6 608 5 645 227 36 335 N02CX Other antimigraine preparations 2 754 2 949 3 093 3 154 78 76 901 1 999 178 1 725 N02CX01 Pizotifen 81 92 81 75 73 <5 25 38 8 161 N02CX02 Clonidine 2 674 2 858 3 013 3 081 72 876 1 963 170 1 564 N03 ANTIEPILEPTICS 67 532 76 515 83 661 90 853 55 3 562 30 852 39 666 16 773 351 984 N03A ANTIEPILEPTICS 67 532 76 515 83 661 90 853 55 3 562 30 852 39 666 16 773 351 984 N03AA Barbiturates and derivatives 3 725 3 554 3 340 3 111 51 13 410 1 646 1 042 2 146 N03AA02 Phenobarbital 3 506 3 310 3 110 2 885 52 13 378 1 533 961 1 760 N03AA03 Primidone 256 261 247 243 46 0 33 123 87 386 N03AB Hydantoin derivatives 2 986 2 861 2 661 2 485 42 27 355 1 329 774 1 194 N03AB02 Phenytoin 2 986 2 859 2 661 2 484 42 27 355 1 328 774 1 175 N03AB05 Fosphenytoin 0 <5 18 N03AD Succinimide derivatives 121 116 110 110 73 46 38 22 <5 418 N03AD01 Ethosuximide 121 116 110 110 73 46 38 22 <5 418 N03AE Benzodiazepine derivatives 13 353 13 894 13 950 13 983 56 191 4 431 6 770 2 591 7 937 N03AE01 Clonazepam 13 353 13 894 13 950 13 983 56 191 4 431 6 770 2 591 7 937 N03AF Carboxamide derivatives 24 026 23 144 22 315 21 518 47 853 6 544 9 946 4 175 27 087 N03AF01 Carbamazepine 22 458 21 431 20 410 19 475 47 578 5 710 9 244 3 943 18 000 N03AF02 Oxcarbazepine 1 701 1 833 2 009 2 104 45 277 855 729 243 8 890 N03AF03 Rufinamide 0 0 0 41 22 25 14 <5 0 198 N03AG Fatty acid derivatives 11 719 12 062 12 450 12 751 47 1 622 5 577 4 593 959 27 000 N03AG01 Valproic acid 11 554 11 919 12 334 12 651 47 1 596 5 540 4 559 956 25 851 N03AG04 Vigabatrin 180 164 142 119 49 39 44 32 <5 812 N03AG06 Tiagabine 40 31 29 19 53 0 10 9 0 338 N03AX Other antiepileptics 23 876 33 928 42 118 50 424 59 1 793 18 780 21 123 8 728 286 202 N03AX03 Sultiame 21 28 39 51 47 32 18 <5 0 166 N03AX09 Lamotrigine 11 367 14 009 16 504 18 792 59 1 132 9 919 6 272 1 469 113 956 N03AX10 Felbamate 20 22 25 23 35 <5 19 <5 0 529 N03AX11 Topiramate 2 106 2 582 2 926 2 975 67 352 1 648 898 77 21 969 N03AX12 Gabapentin 9 178 8 133 7 618 7 481 60 14 1 548 3 770 2 149 33 797 N03AX14 Levetiracetam 1 738 2 183 2 746 3 496 50 499 1 656 1 067 274 39 301 N03AX15 Zonisamide 130 137 180 297 51 62 175 56 <5 3 832 N03AX16 Pregabalin 1 512 10 043 15 405 21 037 60 17 5 468 10 386 5 166 72 652 N04 ANTI-PARKINSON DRUGS 12 620 12 853 14 219 17 098 52 19 1 668 7 276 8 135 112 777 N04A ANTICHOLINERGIC AGENTS 4 123 3 942 3 484 3 268 51 5 834 1 925 504 1 818 N04AA Tertiary amines 2 691 3 414 3 399 3 202 51 5 822 1 881 494 1 6912004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group N 82 Rapport 2008 FolkehelseinstituttetN04AA01 Trihexyphenidyl 14 15 18 19 63 <5 5 8 <5 96 N04AA02 Biperiden 2 670 3 393 3 375 3 179 51 <5 817 1 871 489 1 589 N04AA04 Procyclidine 8 7 7 <5 50 0 0 <5 <5 6 N04AB Ethers chemically close to antihistamines 1 520 1 263 132 81 62 0 17 52 12 127 N04AB02 Orphenadrine (chloride) 1 520 1 263 132 81 62 0 17 52 12 127 N04B DOPAMINERGIC AGENTS 8 631 9 045 10 828 13 906 53 17 838 5 380 7 671 110 959 N04BA Dopa and dopa derivatives 7 195 7 374 7 531 7 599 47 13 93 2 116 5 377 48 887 N04BA02 Levodopa and decarboxylase inhibitor 7 172 7 131 7 119 7 065 48 13 88 1 892 5 072 31 763 N04BA03 Levodopa, decarboxylase inhibitor and COMT inhibitor 375 803 969 1 132 40 0 8 490 634 17 124 N04BB Adamantane derivatives 100 104 104 116 55 0 31 78 7 408 N04BB01 Amantadine 100 104 104 116 55 0 31 78 7 408 N04BC Dopamine agonists 2 980 3 330 5 144 8 303 55 <5 737 4 224 3 338 50 383 N04BC01 Bromocriptine 46 21 9 <5 0 0 45 N04BC02 Pergolide 9 0 <5 0 23 N04BC04 Ropinirole 690 881 1 125 1 819 53 <5 160 1 017 641 13 026 N04BC05 Pramipexole 953 1 432 3 226 5 921 57 <5 578 3 001 2 339 25 474 N04BC06 Cabergoline 1 414 1 187 978 796 44 0 19 345 432 8 138 N04BC07 Apomorphine 10 6 11 13 38 0 0 7 6 1 649 N04BC09 Rotigotine 0 0 5 232 47 0 6 145 81 2 028 N04BD Monoamine oxidase B inhibitors 2 157 2 143 2 223 2 413 39 0 31 1 143 1 239 7 288 N04BD01 Selegiline 2 157 2 141 2 113 2 098 39 0 28 994 1 076 3 606 N04BD02 Rasagiline 0 <5 173 405 40 0 5 201 199 3 682 N04BX Other dopaminergic agents 734 565 424 341 45 0 <5 118 219 3 993 N04BX01 Tolcapone 38 25 20 15 33 0 0 10 5 251 N04BX02 Entacapone 701 540 404 327 46 0 <5 109 214 3 741 N05 PSYCHOLEPTICS 561 339 579 815 591 634 603 038 64 7 622 133 360 267 959 194 097 653 905 N05A ANTIPSYCHOTICS 104 551 106 183 106 268 105 699 57 747 33 888 45 465 25 599 400 198 N05AA Phenothiazines with aliphatic side-chain 32 465 32 191 31 414 29 867 57 32 8 805 14 742 6 288 10 669 N05AA01 Chlorpromazine 6 432 6 674 6 645 3 950 52 5 1 486 1 881 578 1 089 N05AA02 Levomepromazine 26 562 26 050 25 294 26 780 58 27 7 581 13 322 5 850 9 580 N05AB Phenothiazines with piperazine structure 26 671 26 501 25 162 23 005 68 16 4 902 9 245 8 842 10 784 N05AB01 Dixyrazine 1 979 1 926 1 815 620 61 <5 166 345 108 149 N05AB02 Fluphenazine 123 107 101 89 48 0 <5 59 29 119 N05AB03 Perphenazine 7 021 6 693 6 343 6 176 59 <5 1 597 3 418 1 159 7 208 N05AB04 Prochlorperazine 17 695 17 937 17 058 16 329 72 14 3 175 5 542 7 598 3 302 N05AB06 Trifluoperazine 8 <5 N05AC Phenothiazines with piperidine structure 744 504 111 85 53 0 12 50 23 423 N05AC01 Periciazine <5 <5 N05AC02 Thioridazine 733 492 102 77 52 0 12 44 21 368 N05AC04 Pipotiazine 8 9 7 6 50 0 0 <5 <5 53 N05AD Butyrophenone derivatives 4 659 4 904 4 796 4 818 55 19 525 1 573 2 701 1 814 N05AD01 Haloperidol 4 639 4 887 4 784 4 807 55 19 522 1 569 2 697 1 805 N05AD03 Melperone 21 19 12 11 36 0 <5 <5 <5 102004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 70 <15 15-44ATC group NRapport 2008 2 280 1 860 1 574 1 463 59 7 857 537 62 20 543 N05AE03 Sertindole 22 18 43 119 55 0 95 24 0 1 269 N05AE04 Ziprasidone 2 259 1 843 1 535 1 355 59 7 772 514 62 19 274 N05AF Thioxanthene derivatives 22 226 22 490 22 906 24 161 57 21 8 163 11 822 4 155 10 988 N05AF01 Flupentixol 6 054 5 950 5 595 5 521 69 <5 1 360 2 874 1 284 2 766 N05AF03 Chlorprothixene 13 320 13 807 14 611 16 170 53 18 6 264 7 614 2 274 5 627 N05AF05 Zuclopenthixol 3 433 3 352 3 333 3 196 53 0 818 1 716 662 2 596 N05AG Diphenylbutylpiperidine derivatives 194 200 179 172 30 20 91 49 12 417 N05AG02 Pimozide 157 165 148 138 33 14 74 39 11 355 N05AG03 Penfluridol 37 36 31 34 21 6 17 10 <5 62 N05AH Diazepines, oxazepines and thiazepines 18 925 20 724 22 530 24 910 51 116 11 980 9 789 3 025 251 646 N05AH02 Clozapine 1 769 1 869 1 989 2 098 38 0 1 146 892 60 14 327 N05AH03 Olanzapine 14 175 14 499 14 912 15 639 48 30 7 003 6 612 1 994 177 012 N05AH04 Quetiapine 3 758 5 183 6 622 8 312 58 88 4 486 2 723 1 015 60 308 N05AL Benzamides 648 821 725 664 46 N05AL01 N05AL05 Amisulpride 640 811 46 <5 400 229 23 4 881 N05AN Lithium 7 749 7 843 7 749 7 713 57 8 2 324 4 205 1 176 9 554 N05AN01 Lithium 7 749 7 843 7 749 7 713 57 8 2 324 4 205 1 176 9 554 N05AX Other antipsychotics 7 711 8 811 9 649 10 217 49 578 4 622 3 055 1 962 78 396 N05AX08 Risperidone 7 685 7 665 7 810 7 895 48 479 3 028 2 479 1 909 49 308 N05AX12 Aripiprazole 33 1 337 2 042 2 604 49 133 1 775 638 58 29 088 N05B ANXIOLYTICS 273 997 279 510 281 230 285 070 65 3 625 64 868 130 442 86 135 109 276 N05BA Benzodiazepine derivatives 256 577 261 101 261 607 264 604 66 3 137 57 162 122 814 81 491 96 892 N05BA01 Diazepam 150 341 149 404 146 677 145 978 64 2 999 30 247 68 623 44 109 48 634 N05BA02 Chlordiazepoxide 6 5 6 6 50 0 0 <5 <5 9 N05BA04 Oxazepam 116 955 122 797 126 384 130 630 68 71 29 998 59 464 41 097 39 896 N05BA06 Lorazepam 34 32 35 34 47 <5 15 9 7 72 N05BA08 Bromazepam 6 6 9 8 63 0 0 6 <5 17 N05BA09 Clobazam 519 520 507 532 52 185 251 90 6 1 535 N05BA12 Alprazolam 5 455 5 514 5 009 4 678 52 <5 2 008 2 137 531 6 729 N05BB Diphenylmethane derivatives 22 313 23 688 25 710 27 092 62 491 9 658 10 557 6 386 5 575 N05BB01 Hydroxyzine 22 313 23 688 25 710 27 092 62 491 9 658 10 557 6 386 5 575 N05BC Carbamates 18 14 14 10 70 0 0 <5 6 24 N05BC01 Meprobamate 18 14 14 10 70 0 0 <5 6 24 N05BE Azaspirodecanedione derivatives 3 454 3 124 2 965 3 019 58 <5 1 170 1 454 393 6 784 N05BE01 Buspirone 3 454 3 124 2 965 3 019 58 <5 1 170 1 454 393 6 784 N05C HYPNOTICS AND SEDATIVES 342 371 360 940 374 196 385 779 66 3 982 72 206 170 340 139 251 144 431 N05CA Barbiturates, plain 5 0 <5 <5 100 0 1 N05CA04 Barbital 5 0 <5 <5 100 0 0 <5 0 1 N05CD Benzodiazepine derivatives 58 782 56 018 52 547 49 513 63 591 8 022 18 421 22 479 18 754 N05CD01 Flurazepam 27 26 28 24 54 0 0 13 11 74 N05CD02 Nitrazepam 44 099 43 492 41 495 39 695 64 376 6 607 14 538 18 174 10 429 N05CD03 Flunitrazepam 16 316 13 589 11 740 10 179 58 8 1 532 4 140 4 499 6 763 N05CD04 Estazolam 6 0 0 <5 0 0 <5 0 0 62004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group N 84 Rapport 2008 FolkehelseinstituttetN05CD05 Triazolam 94 104 102 99 64 0 11 45 43 103 N05CD08 Midazolam 117 295 441 639 50 278 210 107 44 1 378 N05CF Benzodiazepine related drugs 295 155 314 282 328 939 341 129 67 109 63 739 156 101 121 180 117 518 N05CF01 Zopiclone 266 982 283 001 295 009 303 710 67 85 52 815 138 539 112 271 96 961 N05CF02 Zolpidem 37 769 41 381 44 380 48 400 67 25 14 077 22 535 11 763 20 555 N05CF03 Zaleplon 0 0 <5 5 <5 <5 0 2 N05CH Melatonin receptor agonists 6 021 7 847 9 481 12 418 52 3 456 4 844 3 395 723 6 676 N05CH01 Melatonin 6 021 7 847 9 481 12 418 52 3 456 4 844 3 395 723 6 676 N05CM Other hypnotics and sedatives 980 1 295 1 491 1 761 46 0 163 460 1 138 1 481 N05CM02 Clomethiazole 954 1 266 1 462 1 735 46 0 160 453 1 122 1 421 N05CM05 Scopolamine 26 28 28 24 54 0 16 37 N05CM11 Bromides 0 <5 0 N05CM18 Dexmedetomidine 0 0 0 <5 100 0 <5 0 0 22 N06 PSYCHOANALEPTICS 293 562 294 767 300 440 312 171 64 9 358 102 841 128 983 70 989 736 146 N06A ANTIDEPRESSANTS 273 435 270 003 273 505 283 093 66 476 92 789 127 436 62 392 466 696 N06AA Non-selective monoamine reuptake inhibitors 57 596 57 347 57 549 58 335 71 81 13 700 30 314 14 240 25 284 N06AA01 Desipramine <5 <5 0 0 - 0 0 0 0 0 N06AA02 Imipramine 67 53 41 40 53 12 8 13 7 126 N06AA04 Clomipramine 4 534 4 145 3 880 3 593 70 13 741 2 019 820 2 759 N06AA05 5 10 N06AA06 Trimipramine 14 205 13 733 13 449 13 341 69 8 2 824 6 738 3 771 7 740 N06AA07 Lofepramine 25 24 22 18 67 0 <5 15 <5 104 N06AA09 Amitriptyline 32 822 33 992 34 911 36 513 72 47 9 736 19 513 7 217 11 106 N06AA10 Nortriptyline 1 623 1 471 1 641 1 547 66 <5 319 694 533 668 N06AA12 Doxepin 5 248 4 768 4 424 4 063 71 0 296 1 737 030 2 765 Maprotiline <5 <5 Selective serotonin reuptake inhibitors 173 328 167 719 169 267 174 853 67 363 62 252 75 212 37 026 254 519 N06AB03 Fluoxetine 9 757 8 971 8 563 8 627 74 147 4 531 3 211 738 15 610 N06AB04 Citalopram 57 450 45 761 41 264 38 124 68 10 10 153 17 267 10 694 34 644 N06AB05 Paroxetine 28 060 23 917 21 309 19 823 70 <5 4 599 10 539 4 684 19 437 N06AB06 Sertraline 32 534 29 279 27 618 26 532 67 195 9 662 11 185 5 490 25 095 N06AB08 Fluvoxamine 807 766 725 662 60 5 258 304 95 1 393 N06AB10 Escitalopram 54 858 66 527 76 432 87 515 65 14 35 681 35 257 16 563 158 339 N06AF Monoamine oxidase inhibitors, non-selective 147 142 134 117 67 0 30 68 19 926 N06AF03 Phenelzine 137 131 120 108 64 0 27 64 17 719 N06AF04 Tranylcypromine 11 11 14 <5 207 N06AG Monoamine oxidase A inhibitors 1 622 1 411 1 292 1 204 62 0 276 689 239 2 702 N06AG02 Moclobemide 1 622 1 411 1 292 1 204 62 0 276 689 239 2 702 N06AX Other antidepressants 79 439 79 987 82 253 86 877 61 54 28 641 38 871 19 311 183 265 N06AX01 Oxitriptan 0 0 56 217 75 <5 116 83 16 148 N06AX02 Tryptophan <5 <5 50 0 <5 0 0 2 N06AX03 Mianserin 33 455 32 733 32 936 33 184 63 17 8 657 15 262 9 248 15 741 N06AX05 Trazodone <5 <5 <5 0 - 0 0 0 0 0 N06AX06 Nefazodone 151 68 64 55 49 0 14 38 <5 351 N06AX11 Mirtazapine 26 928 26 410 26 956 27 856 58 31 8 687 11 879 7 259 37 1202004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group NRapport 2008 Folkehelseinstituttet 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group N 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. N06AX14 Tianeptine 0 0 0 <5 0 0 <5 0 0 3 N06AX16 Venlafaxine 25 935 27 000 27 896 28 809 61 5 11 960 13 149 3 695 116 787 N06AX18 Reboxetine 566 631 639 587 64 0 324 237 26 1 089 N06AX21 Duloxetine 95 632 1 590 4 986 67 <5 1 994 2 386 605 12 024 N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS 12 353 17 200 19 567 22 513 32 8 996 12 088 1 316 113 158 881 N06BA Centrally acting sympathomimetics 12 083 16 850 19 160 22 149 31 8 993 11 865 1 210 81 158 563 N06BA01 Amfetamine 189 183 156 178 35 16 111 43 8 404 N06BA02 Dexamfetamine 545 595 633 722 37 125 454 123 20 5 594 N06BA04 Methylphenidate 10 866 14 528 16 273 19 195 31 8 163 10 092 895 45 114 910 N06BA07 Modafinil 228 295 275 272 63 <5 150 110 9 3 863 N06BA09 Atomoxetine 838 3 203 3 207 3 183 28 1 315 1 754 112 <5 33 791 N06BC Xanthine derivatives 228 319 364 327 52 <5 210 93 23 157 N06BC01 Caffeine 228 319 364 327 52 <5 210 93 23 157 N06BX Other psychostimulants and nootropics 48 37 48 43 53 <5 18 14 9 161 N06BX03 Piracetam 48 37 48 43 53 <5 18 14 9 161 N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION 0 <5 0 0 - 0 0 0 0 0 N06CA Antidepressants in combination with psycholeptics 0 <5 0 0 - 0 0 0 0 0 N06CA02 Melitracen and psycholeptics 0 <5 0 0 - 0 0 0 0 0 N06D ANTI-DEMENTIA DRUGS 13 103 13 705 13 958 13 482 62 0 10 1 096 12 376 110 569 N06DA Anticholinesterases 12 582 12 884 12 978 12 428 63 0 5 986 11 437 100 946 N06DA02 Donepezil 10 241 10 490 10 588 10 032 64 0 <5 738 9 291 81 526 N06DA03 Rivastigmine 1 316 1 466 1 681 1 773 54 0 <5 185 1 587 12 523 N06DA04 Galantamine 1 445 1 279 1 058 889 61 0 <5 95 793 6 897 N06DX Other anti-dementia drugs 1 044 1 363 1 589 1 616 58 0 5 212 1 399 9 623 N06DX01 Memantine 1 044 1 363 1 589 1 616 58 0 5 212 1 399 9 623 N07 OTHER NERVOUS SYSTEM DRUGS 15 949 15 995 17 913 38 261 48 7 14 464 21 821 1 969 164 694 N07A PARASYMPATHO- MIMETICS 783 737 054 N07AA Anticholinesterases 467 459 477 483 65 <5 89 209 184 1 064 N07AA01 Neostigmine 0 <5 0 0 - 0 0 0 0 0 N07AA02 Pyridostigmine 467 459 477 481 65 <5 88 209 1 064 N07AA51 Neostigmine, 0 <5 1 N07AB Choline esters 212 175 145 152 61 <5 19 69 63 112 N07AB01 Carbachol 212 175 145 152 61 <5 19 69 63 112 N07AX Other parasympatho- mimetics 126 122 106 122 91 0 16 81 25 877 N07AX01 Pilocarpine 126 122 106 122 91 0 16 81 25 877 N07B DRUGS USED IN ADDICTIVE DISORDERS 14 621 14 621 16 520 36 821 48 <5 14 246 21 070 1 504 152 342 N07BA Drugs used in nicotine dependence 8 236 7 049 8 025 27 358 54 0 9 386 16 679 1 293 35 417 N07BA01 Nicotine 1) 865 781 770 49 0 126 480 164 472 N07BA02 Bupropion 7 409 6 289 6 944 4 430 51 0 1 755 2 483 192 5 121 86 Rapport 2008 Folkehelseinstituttet2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group N N07BA03 Varenicline 0 0 250 22 637 55 0 7 656 14 017 964 29 824 N07BB Drugs used in alcohol dependence 3 770 3 972 4 287 4 868 29 <5 1 658 3 010 199 2 818 N07BB01 Disulfiram 3 277 3 549 3 773 4 066 28 0 1 394 2 509 163 1 579 N07BB03 Acamprosate 544 481 472 629 32 0 189 414 26 850 N07BB04 Naltrexone 60 54 154 362 49 <5 139 208 14 389 N07BC Drugs used in opioid dependence 2 696 3 684 4 300 4 853 30 0 3 300 1 536 17 114 107 N07BC01 Buprenorphine 1 062 1 443 1 787 1 907 29 0 1 458 448 <5 37 452 N07BC02 Methadone3)1 654 2 361 2 673 2 852 31 0 1 753 1 083 16 63 733 N07BC04 Lofexidine 0 <5 0 0 - 0 0 0 0 0 N07BC51 Buprenorphine, combinations 130 197 219 969 28 0 755 214 0 12 923 N07C ANTIVERTIGO PREPARATIONS 303 364 382 407 61 <5 64 241 99 1 072 N07CA Antivertigo preparations 303 364 382 407 61 <5 64 241 99 1 072 N07CA01 Betahistine 291 357 379 403 61 <5 62 241 99 1 061 N07CA03 Flunarizine 12 7 <5 <5 50 <5 <5 0 0 11 N07X OTHER NERVOUS SYSTEM DRUGS 249 279 304 310 46 <5 38 174 97 9 226 N07XX Other nervous system drugs 249 279 304 310 46 <5 38 174 97 9 226 N07XX02 Riluzole 219 236 246 252 43 0 15 150 87 7 256 N07XX04 Hydroxybutyric acid 0 12 23 26 50 <5 16 6 <5 1 405 N07XX06 Tetrabenazine 30 31 35 32 63 0 7 18 7 565 3 The figures only include methadone dispensed according to prescription from the pharmacies. Patients may also receive methadone dispensed according to special arrangements in the health regions. Rapport 2008 Folkehelseinstituttet 872004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group P 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.P01 ANTIPROTOZOALS 77 478 79 254 80 298 84 749 65 1 696 42 047 32 505 8 501 30 768 P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES 51 797 51 066 50 677 51 701 70 487 25 477 19 106 6 631 5 985 P01AB Nitroimidazole derivatives 51 796 51 065 50 675 51 699 70 487 25 476 19 105 6 631 5 922 P01AB01 Metronidazole 51 796 51 065 50 675 51 699 70 487 25 476 19 105 6 631 5 922 P01AC Dichloroacetamide derivatives 0 <5 7 9 <5 0 11 P01AC01 Diloxanide 0 <5 7 9 44 <5 5 <5 0 11 P01AX Other agents against amoebiasis and other protozoal diseases 0 0 0 <5 0 0 <5 0 0 52 P01AX11 Nitazoxanide 0 0 0 <5 0 0 <5 0 0 52 P01B ANTIMALARIALS 26 206 28 724 30 119 33 681 57 1 216 16 912 13 642 1 911 24 766 P01BA Aminoquinolines 9 187 9 120 8 430 8 701 72 196 3 670 3 978 857 3 505 P01BA01 Chloroquine 4 860 4 720 4 012 4 222 60 171 2 557 1 360 134 524 P01BA02 Hydroxychloroquine 4 328 4 405 4 410 4 485 84 25 1 114 2 622 724 2 979 P01BA03 Primaquine 13 10 26 8 13 0 6 <5 0 2 P01BB Biguanides 13 733 16 059 17 897 20 820 51 771 11 006 8 405 638 19 041 P01BB01 Proguanil 959 747 525 340 61 9 202 117 12 86 P01BB51 Proguanil, combinations 12 817 15 359 17 401 20 502 51 763 10 815 8 298 626 18 955 P01BC Methanolquinolines 4 566 4 663 4 748 5 014 56 267 2 803 1 503 441 2 208 P01BC01 Quinine 512 547 606 621 65 0 31 248 342 247 P01BC02 Mefloquine 4 056 4 116 4 143 4 393 55 267 2 772 1 255 99 1 961 P01BE Artemisinin and derivatives 14 0 0 0 - 0 0 0 0 0 P01BE52 Artemether, combinations 14 0 0 0 - 0 0 0 0 0 P01C AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS 0 17 P02 ANTHELMINTICS 2 060 1 911 2 061 2 024 58 955 674 308 87 360 P02B ANTITREMATODALS 22 21 10 11 55 0 6 5 0 11 P02BA Quinoline derivatives and related substances 22 21 10 11 55 0 6 5 0 11 P02BA01 Praziquantel 22 21 10 11 55 0 6 5 0 11 P02C ANTINEMATODAL AGENTS 2 024 1 880 2 036 1 996 58 950 659 300 87 339 P02CA Benzimidazole derivatives 1 882 1 780 1 888 1 859 58 912 588 276 83 302 P02CA01 Mebendazole 1)1 877 1 766 1 872 1 843 58 910 578 272 83 253 P02CA02 Tiabendazole <5 0 0 0 - 0 0 0 0 0 P02CA03 Albendazole <5 14 16 17 65 <5 10 5 0 49 P02CE Imidazothiazole derivatives 0 <5 0 0 - 0 0 0 0 0 P02CE01 Levamisole 0 <5 0 0 - 0 0 0 0 0 P02CF Avermectines 15 13 38 41 59 8 22 11 0 21 P02CF01 Ivermectin 15 13 38 41 59 8 22 11 0 21 P02CX Other antinematodals 137 102 124 118 68 42 56 16 <5 15 P02CX01 Pyrvinium 1) 137 102 124 118 68 42 56 16 <5 153.14 T able - ATC group P - Antiparasitic products, insecticides and repellents 88 Rapport 2008 Folkehelseinstituttet1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group P P02D ANTICESTODALS 15 13 16 20 55 6 10 <5 0 10 P02DA Salicylic acid derivatives 15 13 16 20 55 6 10 <5 0 10 P02DA01 Niclosamide 15 13 16 20 55 P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTI- CIDES AND REPELLENTS 1 215 1 218 1 192 1 283 47 179 781 256 67 458 P03A ECTOPARASITICIDES, INCL. SCABICIDES 1 215 1 218 1 192 1 283 47 179 781 256 67 458 P03AC Pyrethrines, incl. synthetic compounds 1 048 1 036 1 028 1 139 44 149 708 220 62 413 P03AC04 Permethrin 1)1 048 1 036 1 028 1 708 220 62 413 P03AX Other ectoparasiticides, incl. scabicides 174 197 178 152 33 76 38 5 45 P03AX01 Benzyl benzoate 1)39 36 41 38 50 7 20 8 <5 14 P03AX03 Malathion1) 136 161 138 114 80 26 56 30 <5 31Rapport 2008 Folkehelseinstituttet 891 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group R R01 NASAL PREPARATIONS 286 020 302 900 313 512 330 828 56 31 905 162 236 111 537 25 150 114 209 R01A DECONGESTANTS AND OTHER NASAL PREPARA - TIONS FOR TOPICAL USE 236 601 250 120 261 098 274 864 55 30 402 130 623 91 283 22 556 108 816 R01AA Sympathomimetics, plain 5 086 5 186 4 654 4 594 52 897 1 782 1 331 584 300 R01AA05 Oxymetazoline1)2 002 2 103 1 952 1 895 52 503 750 448 194 109 R01AA07 Xylometazoline1)3 113 3 094 2 726 2 721 53 396 1 038 892 395 192 R01AC Antiallergic agents, excl. corticosteroids 38 109 40 792 44 156 47 380 56 12 039 24 537 9 228 1 576 11 677 R01AC01 Cromoglicic acid1)11 132 11 356 11 797 11 769 60 2 257 6 476 2 625 411 3 053 R01AC02 Levocabastine1)26 726 29 261 32 419 35 673 55 9 847 18 070 6 595 1 161 8 564 R01AC03 Azelastine1) 604 531 276 303 48 62 175 57 9 60 R01AD Corticosteroids 199 442 210 111 218 295 229 598 55 18 797 107 837 82 377 20 587 96 624 R01AD01 Beclometasone 2 996 2 801 2 577 2 396 53 85 773 1 188 350 1 209 R01AD04 Flunisolide 5 223 4 988 4 811 4 529 51 132 1 336 2 312 749 1 688 R01AD05 Budesonide 50 750 48 831 48 122 46 625 55 3 160 21 094 17 975 4 396 20 619 R01AD08 Fluticasone 39 301 38 294 36 639 34 279 55 2 317 15 079 13 350 3 533 16 407 R01AD09 Mometasone 92 615 106 874 117 994 133 980 55 12 119 65 564 45 337 10 960 50 776 R01AD11 Triamcinolone 16 288 15 881 15 051 14 825 55 1 386 7 081 5 107 1 251 5 925 R01AX Other nasal preparations 102 333 431 438 51 13 104 124 197 214 R01AX03 Ipratropium bromide 38 201 272 265 49 0 28 74 163 162 R01AX06 Mupirocin 64 132 159 173 53 13 76 50 34 52 R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 64 184 68 736 69 851 75 585 65 1 862 42 541 27 693 3 489 5 393 R01BA Sympathomimetics 64 184 68 736 69 851 75 585 65 1 862 42 541 27 693 3 489 5 393 R01BA01 Phenylpropanolamine 64 184 68 736 69 851 75 585 65 1 862 42 541 27 693 3 489 5 393 R03 DRUGS FOR OBSTRUC-TIVE AIRWAY DISEASES 361 077 384 945 392 064 395 583 53 105 536 102 889 122 856 64 302 1 047 777 R03A ADRENERGICS, INHALANTS 281 161 295 903 303 707 309 302 54 55 966 92 052 107 175 54 109 708 410 R03AA Alpha-and beta-adrenore - ceptor agonists 300 275 240 196 39 167 19 10 0 304 R03AA01 Epinephrine 300 275 240 196 39 167 19 10 0 304 R03AC Selective beta-2-adreno - receptor agonists 204 389 212 498 222 359 230 889 54 51 513 70 449 73 097 35 830 158 595 R03AC02 Salbutamol 134 446 146 460 161 600 171 581 53 47 774 49 460 49 923 24 424 86 096 R03AC03 Terbutaline 54 087 52 012 46 582 43 398 57 3 541 17 438 15 698 6 721 20 267 R03AC04 Fenoterol 437 363 192 22 59 0 <5 12 8 90 R03AC12 Salmeterol 10 474 9 147 9 630 11 110 56 409 1 570 5 023 4 108 22 794 R03AC13 Formoterol 20 574 18 836 18 468 56 671 4 924 8 467 4 643 29 349 R03AK Adrenergics and other drugs for obstructive airway diseases 146 183 157 900 157 931 154 790 55 13 866 43 393 63 927 33 604 549 511 R03AK04 Salbutamol and other drugs for obstructive airway diseases 0 <5 <5 <5 100 0 0 0 <5 6 R03AK06 Salmeterol and other drugs for obstructive airway diseases 86 861 93 122 92 468 87 838 55 10 916 21 332 35 248 20 342 336 605 R03AK07 Formoterol and other drugs for obstructive airway diseases 62 980 68 469 68 289 69 882 56 3 106 22 942 29 995 13 839 212 899 R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS 124 486 126 212 129 993 132 625 51 37 655 20 210 42 687 32 073 223 0103.15 T able - ATC group R - Respiratory system 90 Rapport 2008 Folkehelseinstituttet1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.R03BA Glucocorticoids 89 835 87 949 88 344 87 558 51 37 395 17 604 21 655 10 904 102 938 R03BA01 Beclometasone 6 841 5 389 5 090 4 904 55 1 043 1 132 1 834 895 5 934 R03BA02 Budesonide 40 722 37 512 35 120 31 517 55 6 361 8 053 11 039 6 064 50 006 R03BA05 Fluticasone 44 079 46 996 49 821 53 821 47 32 227 8 576 8 969 4 049 46 992 R03BA07 Mometasone <5 093 44 739 47 831 50 686 52 569 2 944 23 502 23 671 119 641 R03BB01 Ipratropium bromide 35 464 36 811 39 147 41 577 53 565 2 758 18 784 19 470 63 918 R03BB04 Tiotropium bromide 10 052 11 165 11 795 12 510 47 5 246 6 413 5 846 55 723 R03BC Antiallergic agents, excl. corticosteroids 825 780 769 632 60 83 245 246 58 431 R03BC01 Cromoglicic acid 825 780 769 632 60 83 245 246 58 431 R03C ADRENERGICS FOR SYSTEMIC USE 62 820 71 340 69 005 65 061 49 51 186 5 776 5 649 2 450 8 239 R03CA Alpha-and beta- adrenoreceptor agonists 47 423 55 300 53 615 50 309 49 41 170 4 034 3 767 1 338 5 396 R03CA02 Ephedrine 47 423 55 300 53 615 50 309 49 41 170 4 034 3 767 1 338 5 396 R03CB Non-selective beta-adrenoreceptor agonists <5 <5 0 0 0 R03CB03 Orciprenaline <5 <5 0 0 - 0 0 0 0 0 R03CC Selective beta-2-adreno - receptor agonists 18 515 19 594 18 677 17 390 50 12 559 1 783 1 920 1 128 2 843 R03CC02 Salbutamol 6 520 6 855 6 242 5 887 50 4 340 493 652 402 1 037 R03CC03 Terbutaline 11 947 12 727 12 399 11 406 50 8 316 1 271 1 168 651 1 559 R03CC12 Bambuterol 226 205 215 222 63 0 28 111 83 248 R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 28 173 33 614 35 627 37 514 54 8 398 9 259 13 531 6 326 108 117 R03DA Xanthines 8 363 7 767 7 134 6 527 57 11 446 3 056 3 014 4 958 R03DA02 Choline theophyllinate 35 34 15 13 92 0 <5 8 <5 83 R03DA04 Theophylline 8 308 7 714 7 096 6 497 57 11 438 3 040 3 008 4 707 R03DA05 Aminophylline 52 44 44 37 68 0 9 21 7 168 R03DC Leukotriene receptor antagonists 21 109 27 142 29 700 32 099 54 8 392 8 955 11 137 3 615 99 815 R03DC01 Zafirlukast 46 40 37 32 59 0 6 20 6 237 R03DC03 Montelukast 21 067 27 105 29 667 32 068 54 8 392 8 949 11 118 3 609 99 578 R03DX Other systemic drugs for obstructive airway diseases <5 6 24 33 39 <5 14 16 0 3 344 R03DX05 Omalizumab <5 6 24 33 39 <5 14 16 0 3 344 R05 COUGH AND COLD PREPARATIONS 306 856 358 631 374 210 389 332 60 32 045 131 005 152 666 73 616 59 243 R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS 94 047 110 743 116 430 125 858 59 5 936 29 647 51 776 38 499 24 914 R05CA Expectorants 3 486 3 670 3 468 3 571 59 1 035 968 876 692 229 R05CA10 Combinations1)3 486 3 670 3 468 3 571 59 1 035 968 876 692 229 R05CB Mucolytics 91 067 107 640 113 569 122 911 59 4 944 28 817 51 131 38 019 24 685 R05CB01 Acetylcysteine 85 344 101 675 108 126 118 278 59 3 947 27 772 49 689 36 870 17 105 R05CB02 Bromhexine1)6 629 6 993 6 431 5 498 55 1 013 1 157 1 743 1 585 890 R05CB12 Tiopronin 0 0 R05CB13 Dornase alfa (desoxyribonuclease) 102 87 87 99 49 37 53 9 0 6 651 R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS 217 382 254 046 264 972 265 461 61 23 922 98 137 104 535 38 867 29 7602004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group RRapport 2008 Folkehelseinstituttet 911 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group R R05DA Opium alkaloids derivatives 209 634 245 083 256 854 262 662 61 22 832 97 417 103 830 38 583 29 590 R05DA01 Ethylmorphine 200 118 235 008 246 746 251 979 61 22 324 93 617 99 187 36 851 26 842 652 7 453 7 341 8 196 64 115 3 166 3 649 1 266 1 522 R05DA07 Noscapine1)1 396 1 497 1 590 1 844 61 322 578 618 326 119 R05DA08 Pholcodine1) 967 988 887 292 67 81 99 67 45 18 R05DA09 Dextromethorphan 0 0 <5 0 - 0 0 0 0 0 R05DA20 Combinations 3 348 3 344 3 439 3 976 62 73 1 324 1 896 683 863 R05DB Other cough suppressants 9 786 11 332 10 171 3 510 60 1 230 911 992 377 170 R05DB05 Pentoxyverine 9 786 11 332 10 171 3 510 60 1 230 911 992 377 170 R05F COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS 27 251 33 426 34 870 47 032 61 3 509 17 657 18 408 7 458 4 569 R05FA Opium derivatives and expectorants 27 251 33 426 34 870 47 032 61 3 509 17 657 18 408 7 458 4 569 R05FA02 Opium derivatives and expectorants 27 251 33 426 34 870 47 032 61 3 509 17 657 18 408 7 458 4 569 R06 ANTIHISTAMINES FOR SYSTEMIC USE 452 109 477 248 495 713 513 205 58 77 776 221 140 166 928 47 361 202 905 R06A ANTIHISTAMINES FOR SYSTEMIC USE 452 109 477 248 495 713 513 205 58 77 776 221 140 166 928 47 361 202 905 R06AA Aminoalkyl ethers 30 28 27 24 54 0 6 13 5 69 R06AA02 Diphenhydramine 7 9 5 <5 25 0 0 <5 0 44 R06AA04 Clemastine 23 19 22 20 60 0 6 9 5 25 R06AB Substituted alkylamines 35 082 35 397 37 627 38 563 64 15 185 12 655 7 427 3 296 8 191 R06AB02 Dexchlorpheniramine 35 082 35 397 37 627 38 563 64 15 185 12 655 7 427 3 296 8 191 R06AD Phenothiazine derivatives 52 930 56 599 59 277 61 370 62 5 014 21 600 25 246 9 510 32 895 R06AD01 Alimemazine 46 142 49 880 52 699 54 765 61 4 951 19 184 22 369 8 261 30 161 R06AD02 Promethazine 7 319 7 278 7 559 7 301 65 65 2 695 3 232 1 309 2 713 R06AD03 Thiethylperazine 10 9 9 8 63 0 <5 <5 5 21 R06AE Piperazine derivatives 183 507 178 730 224 618 260 098 58 42 021 111 695 82 861 23 521 54 150 R06AE03 Cyclizine 1) 709 813 801 11 155 252 189 226 R06AE04 Chlorcyclizine <5 0 0 0 - 0 0 0 0 0 R06AE05 Meclozine1)1 716 1 929 1 874 1 892 86 42 1 285 314 251 184 R06AE07 Cetirizine1) 141 123 171 636 220 190 256 534 57 41 848 109 722 81 960 23 004 52 851 R06AE09 Levocetirizine 50 833 5 799 2 297 1 518 57 143 750 482 143 889 R06AX Other antihistamines for systemic use 211 734 236 941 212 567 192 364 59 21 075 92 017 64 827 14 445 107 600 R06AX02 Cyproheptadine 54 54 35 57 63 12 19 19 7 47 R06AX13 Loratadine 1)44 390 37 023 56 304 72 051 59 6 930 35 034 24 209 5 878 19 793 Ebastine1)30 419 35 263 31 167 25 663 62 1 056 12 820 9 710 2 077 20 070 R06AX26 Fexofenadine 12 992 13 476 11 888 10 209 62 195 4 875 4 169 970 7 896 R06AX27 Desloratadine 129 973 159 117 124 719 93 903 58 13 491 43 935 30 310 6 167 59 780 92 Rapport 2008 FolkehelseinstituttetS01 OPHTHALMOLOGICALS 479 567 505 500 513 004 519 028 57 99 825 165 951 142 721 110 531 272 887 S01A ANTIINFECTIVES 241 912 255 624 255 406 250 557 56 68 559 77 266 67 064 37 668 34 427 S01AA Antibiotics 237 630 250 505 250 725 247 583 56 68 244 76 209 66 065 37 065 33 182 S01AA01 Chloramphenicol 173 797 195 558 187 144 184 767 56 43 883 59 741 52 378 28 765 26 815 S01AA11 Gentamicin 2 440 2 652 2 278 2 122 59 234 815 673 400 215 S01AA12 Tobramycin 326 343 480 2 210 56 315 742 674 479 202 S01AA13 Fusidic acid 75 023 66 302 76 128 72 936 58 29 075 18 842 15 433 9 586 5 617 S01AA30 Combinations of different antibiotics 4 793 5 068 4 516 4 584 59 325 1 226 1 675 1 358 333 S01AD Antivirals 3 092 3 242 3 157 3 091 58 139 998 1 164 790 760 S01AD02 Trifluridine 0 <5 0 <5 100 0 0 0 <5 1 S01AD03 Aciclovir 3 092 3 242 3 157 3 090 58 139 998 1 164 789 760 S01AX Other antiinfectives 3 151 4 204 3 857 2 111 51 309 796 638 368 485 S01AX05 Bibrocathol 0 <5 0 0 - 0 0 0 0 0 S01AX13 Ciprofloxacin 3 151 4 203 3 856 2 109 51 307 796 638 368 464 S01B ANTIINFLAMMATORY AGENTS 31 778 33 572 34 171 39 668 58 1 460 9 287 14 655 14 266 10 824 S01BA Corticosteroids, plain 24 829 26 425 26 543 29 707 57 1 383 8 103 11 543 8 678 8 666 S01BA01 Dexamethasone 14 317 15 014 14 828 16 999 54 450 4 499 6 952 5 098 6 086 S01BA02 Hydrocortisone 7 0 0 0 - 0 0 0 0 0 S01BA04 Prednisolone 12 841 13 558 13 776 14 720 59 970 4 289 5 627 3 834 1 797 S01BA07 Fluorometholone 17 63 0 <5 11 <5 15 S01BA09 Clobetasone 0 11 12 18 50 <5 7 7 <5 61 S01BA13 Rimexolone 1 363 1 587 1 754 2 096 51 66 967 760 303 707 S01BB Corticosteroids and mydriatics in combination <5 <5 2 S01BC Antiinflammatory agents, non-steroids 7 835 8 001 8 608 11 289 59 92 1 478 3 590 6 129 2 156 S01BC03 Diclofenac 7 835 8 001 8 608 11 289 59 92 1 478 3 590 6 129 2 156 S01C ANTIINFLAMMATORY AGENTS AND ANTIINFEC-TIVES IN COMBINATION 55 027 54 884 54 487 54 804 59 1 182 9 946 18 130 25 546 11 783 S01CA Corticosteroids and anti- infectives in combination 55 027 54 884 54 487 54 804 59 1 182 9 946 18 130 25 546 11 783 S01CA01 Dexamethasone and antiinfectives 55 027 54 884 54 487 54 804 59 1 182 9 946 18 130 25 546 11 783 S01E ANTIGLAUCOMA PREPA - RATIONS AND MIOTICS 64 382 65 485 66 581 67 445 58 140 1 858 18 891 46 556 162 431 S01EA Sympathomimetics in glaucoma therapy 3 096 3 410 3 583 3 654 55 11 145 939 2 559 4 447 S01EA01 Epinephrine <5 S01EA02 Dipivefrine 392 310 275 234 50 0 <5 51 181 239 S01EA03 Apraclonidine 56 66 70 69 54 <5 9 24 35 35 S01EA05 Brimonidine 2 693 3 073 3 275 3 399 55 11 138 877 2 373 4 173 S01EB Parasympathomimetics 2 244 2 044 1 802 1 637 60 7 65 340 1 225 995 S01EB01 Pilocarpine 2 243 2 040 1 799 1 634 60 7 65 338 1 224 989 S01EB02 Carbachol <5 5 S01EC Carbonic anhydrase inhibitors 9 055 9 206 9 383 9 559 58 65 581 2 430 6 483 12 702 S01EC01 Acetazolamide 1 442 1 497 1 580 1 694 52 39 432 606 617 1 140 S01EC02 Diclofenamide <5 0 0 0 - 0 0 0 0 0 S01EC03 Dorzolamide 3 955 3 468 3 242 2 974 57 <5 53 615 2 304 4 468 S01EC04 Brinzolamide 4 040 4 550 4 887 5 150 60 27 107 1 292 3 724 7 080 S01EC05 Methazolamide 8 5 8 6 67 0 <5 <5 <5 132004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group S 3.16 T able - ATC group S - Sensory organsRapport 2008 Folkehelseinstituttet 932004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group S 1 The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.S01ED Beta blocking agents 47 129 46 966 47 137 47 223 58 83 1 095 13 224 32 821 72 069 S01ED01 Timolol 24 421 24 292 23 957 23 424 58 64 596 7 453 15 311 20 416 S01ED02 Betaxolol 3 623 3 114 2 805 2 525 66 <5 19 530 1 975 1 756 S01ED51 Timolol, combinations 21 560 21 901 22 592 23 680 57 31 571 5 963 17 115 49 897 S01EE Prostaglandin analogues 31 263 33 213 34 371 35 228 59 21 651 9 260 25 296 72 218 S01EE01 Latanoprost 28 118 29 095 29 517 29 949 59 18 538 7 739 21 654 62 403 S01EE03 Bimatoprost 1 493 1 686 1 836 1 790 60 <5 46 512 1 229 3 000 S01EE04 Travoprost 2 304 3 026 3 607 4 046 58 <5 76 1 181 2 788 6 816 S01F MYDRIATICS AND CYCLOPLEGICS 5 042 5 324 5 233 4 586 46 606 1 264 1 814 902 845 S01FA Anticholinergics 5 036 5 316 5 225 4 568 46 605 1 260 1 807 896 836 S01FA01 Atropine 3 858 3 914 3 398 2 594 46 542 680 929 443 485 S01FA02 Scopolamine 8 9 5 <5 100 0 0 <5 0 5 S01FA04 Cyclopentolate 284 605 926 1 901 46 54 559 843 445 297 S01FA05 Homatropine 923 919 1 048 127 46 <5 40 61 22 13 S01FA06 Tropicamide 180 115 112 185 58 12 80 73 20 36 S01FB Sympathomimetics excl. antiglaucoma preparations 39 39 39 62 39 <5 17 29 14 10 S01FB01 Phenylephrine 39 39 39 62 39 <5 17 29 14 10 S01G DECONGESTANTS AND ANTIALLERGICS 147 499 159 735 167 390 175 204 58 32 661 84 098 46 270 12 175 49 392 S01GA Sympathomimetics used as decongestants 24 779 25 656 25 621 25 914 60 3 754 12 606 7 436 2 118 7 166 S01GA51 Naphazoline, combinations 8 7 9 11 82 0 5 5 <5 3 S01GA52 Tetryzoline, combinations 1)24 771 25 649 25 613 25 903 60 3 754 12 601 7 431 2 117 7 163 S01GX Other antiallergics 126 622 138 195 145 873 153 776 58 29 955 73 594 39 925 10 302 42 226 S01GX01 Cromoglicic acid1)27 087 27 759 27 758 27 703 61 4 190 13 576 7 974 1 963 7 467 S01GX02 Levocabastine1)66 791 70 654 74 462 78 424 57 15 829 37 823 19 912 4 860 17 886 S01GX04 Nedocromil 2 890 2 722 2 466 2 327 57 360 1 251 586 130 474 S01GX05 Lodoxamide1) 682 604 470 444 63 66 141 S01GX06 Emedastine 856 756 648 643 61 116 273 176 78 209 S01GX07 Azelastine 2 015 1 776 923 901 57 193 369 237 102 226 S01GX08 Ketotifen1)17 426 17 893 18 526 18 611 59 3 547 8 850 4 912 1 302 7 453 S01GX09 Olopatadine 14 083 21 652 25 832 30 544 56 7 153 13 675 7 493 2 223 8 372 S01H LOCAL ANESTHETICS 116 130 98 132 38 7 58 54 13 22 S01HA Local anesthetics 116 130 98 132 38 7 58 54 13 22 S01HA02 Oxybuprocaine 65 73 51 86 36 <5 43 35 6 15 S01HA03 Tetracaine 23 21 17 21 52 <5 10 6 <5 3 S01HA04 Proxymetacaine 29 39 31 26 35 <5 5 13 7 4 S01J DIAGNOSTIC AGENTS 5 5 <5 <5 33 0 0 <5 0 1 S01JA Colouring agents 5 5 <5 combinations <5 <5 <5 0 0 0 0 0 S01L OCULAR VASCULAR DISORDER AGENTS 0 0 0 9 78 0 0 <5 7 172 S01LA Antineovascularisation agents 0 0 0 9 78 0 0 <5 7 172 S01LA04 Ranibizumab 0 0 0 9 78 0 0 <5 7 172 S01X OTHER OPHTHALMOLO - GICALS 5 691 5 964 5 760 6 054 70 63 775 2 029 3 187 2 806 S01XA Other ophthalmologicals 5 691 5 964 5 760 6 054 70 63 775 2 029 3 187 2 806 94 Rapport 2008 Folkehelseinstituttet2004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group S S01XA03 Sodium chloride, hypertonic 27 29 19 18 78 0 0 5 13 13 S01XA20 Artificial tears and other indifferent preparations 1)5 668 5 940 5 744 6 038 70 63 775 2 025 3 175 2 792 S02 OTOLOGICALS 6 263 6 173 7 290 11 991 54 2 257 3 283 4 629 1 822 2 157 S02A ANTIINFECTIVES 446 441 2 346 5 578 48 2 132 1 532 1 377 537 1 074 S02AA Antiinfectives 446 441 2 346 5 578 48 2 132 1 532 1 377 537 1 074 S02AA01 Chloramphenicol 446 441 315 253 50 119 72 49 13 70 S02AA15 Ciprofloxacin 0 0 2 046 5 347 48 2 023 1 466 1 334 524 1 004 S02B CORTICOSTEROIDS 5 725 5 638 4 982 6 623 59 131 1 838 3 346 1 308 1 072 S02BA Corticosteroids 5 725 5 638 4 982 6 623 59 131 1 838 3 346 1 308 1 072 S02BA07 Betamethasone 5 725 5 638 4 982 6 623 59 131 1 838 3 346 1 308 1 072 S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 108 105 66 75 63 <5 18 36 18 12 S02CA Corticosteroids and anti- infectives in combination 108 105 66 75 63 <5 18 36 18 12 S02CA02 Flumetasone and antiinfectives 108 105 66 75 63 <5 18 36 18 12 S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 68 989 68 730 73 527 74 412 54 13 788 22 735 26 531 11 358 9 710 S03B CORTICOSTEROIDS 1 590 <5 0 0 - 0 0 0 0 0 S03BA Corticosteroids 1 590 <5 0 0 - 0 0 0 0 0 S03BA01 Dexamethasone 1 590 <5 0 0 - 0 0 0 0 0 S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 67 795 68 727 73 527 74 412 54 13 788 22 735 26 531 11 358 9 710 S03CA Corticosteroids and anti-infectives in combination 67 795 68 727 73 527 74 412 54 13 788 22 735 26 531 11 358 9 710 S03CA01 Dexamethasone and antiinfectives 18 162 23 473 21 089 16 096 56 2 049 4 804 6 331 2 912 2 021 S03CA04 Hydrocortisone and antiinfectives 53 047 49 329 55 887 61 041 54 12 048 18 853 21 282 8 858 7 689Rapport 2008 Folkehelseinstituttet 952004 2005 2006 2007 2007 ATC level Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 45-69 70 <15 15-44ATC group V V01 ALLERGENS 1 672 2 525 3 343 4 170 47 989 2 461 699 21 14 700 V01A ALLERGENS 1 672 2 525 3 343 4 170 47 989 2 461 699 21 14 700 V01AA Allergen extracts 1 672 2 525 3 343 4 170 47 989 2 461 699 21 14 700 V01AA02 Grass pollen 851 1 380 1 938 2 501 42 580 1 633 280 8 6 298 V01AA03 House dust 88 116 171 211 44 71 108 32 0 894 V01AA05 Tree pollen 1 074 1 581 2 139 2 691 50 624 1 585 472 10 5 765 V01AA07 Insects 182 246 215 192 53 14 56 114 8 730 V01AA10 Flowers 16 27 35 36 61 <5 26 7 0 124 V01AA11 Animals 86 129 140 178 53 53 88 37 0 8893.17 T able - ATC group V - Various 96 Rapport 2008 FolkehelseinstituttetADHD ATC BPH Benign prostatahyperplasi/Benign prostatic hyper Definert d\u00f8gndose/Defined Daily Doses European Economic Association Europeisk \u00f8konomisk samarbeid FolkehelseinstituttetGeneral Practitioner International Classification of Diseases version 10 International Classification of Primary Care Legemiddelassistert rehabilitering Markedsf\u00f8ringstillatelse/Marketing Authorisation Arbeids- og velferdsforvaltningen/Norwegian National Insurance Administration Norwegian Institute of Public Health Norsk Medisinaldepot/Norwegian Medicinal Depot (wholesaler) Norske kroner/Norwegian kroner Reseptregisteret/Norwegian Prescription Database Reseptfritt/Over The Counter, non prescription drugs Regular General PractitionerSummary of Product Characteristics Statistisk sentralbyr\u00e5/Statistics Norway tidligere, definert periode. Definitions PrevalenceA user (individual) is defined as a person who has had at least one prescription dispensed in a pharmacy during a specific time period. In NorPD, you can find the number of users of a particular drug/drug category per year in a defined popu- lation selection (e.g. sex, age, county). Prevalence is defined as the number of users per 1000 inhabitants in the selected populations. Incidence (new users)Incidence is the number of users of a particular drug/drug category in a defined time period who are not users in a previous, defined time period. Rapport 2008 Folkehelseinstituttet 97Folkemengde i Norge 2004-2007 (per 1 juli)/ Population in Norway 2004 -2007 (as of 1st July) Y ear 2004 2005 2006 2007 Population 4 591 996 4 623 474 4 661 041 4 709 155 Folkemengde etter alder i 2007 (per 1 juli)/ Population by age in 2007 (as of 1st July) Age groups <15 15-44 45-69 70 Population 874 990 1 917 103 1 395 605 521 457 Kilde: Statistisk sentralbyr\u00e5 "}